United States Patent	12394120
Kind Code	B2
Date of Patent	August 19, 2025
Inventor(s)	Kamath; Apurv Ullas et al.

Integrated medicament delivery device for use with continuous analyte sensor

Abstract

An integrated system for the monitoring and treating diabetes is provided, including an integrated receiver/hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor. In some embodiments, the receiver is configured to receive continuous glucose sensor data, to calculate a medicament therapy (e.g., via the integrated system electronics) and to automatically set a bolus dose of the integrated hand-held medicament injection pen, whereby the user can manually inject the bolus dose of medicament into the host. In some embodiments, the integrated receiver and hand-held medicament injection pen are integrally formed, while in other embodiments they are detachably connected and communicated via mutually engaging electrical contacts and/or via wireless communication.

Inventors: **Kamath; Apurv Ullas (San Diego, CA), Yang; Richard C. (Carlsbad, CA), Leach; Jacob S. (San Diego, CA), Quintana; Nelson (San Diego, CA)**

Applicant: **DexCom, Inc.** (San Diego, CA)

Family ID: **1000008764439**

Assignee: **Dexcom, Inc. (San Diego, CA)**

Appl. No.: **17/751020**

Filed: **May 23, 2022**

Prior Publication Data

Document Identifier	Publication Date
US 20220292746 A1	Sep. 15, 2022

Related U.S. Application Data

continuation parent-doc US 16513380 20190716 US 11373347 child-doc US 17751020
continuation parent-doc US 15653394 20170718 US 10403012 20190903 child-doc US 16513380
continuation parent-doc US 12133786 20080605 US 8562558 20131022 child-doc US 13963416
division parent-doc US 13963416 20130809 US 9741139 20170822 child-doc US 15653394
us-provisional-application US 60942787 20070608

Publication Classification

Int. Cl.: **G06T11/20** (20060101); **A61B5/00** (20060101); **A61B5/145** (20060101); **A61B5/1486** (20060101); **A61M5/142** (20060101); **A61M5/172** (20060101); **A61M5/24** (20060101); **A61M5/31** (20060101); **A61M5/315** (20060101); A61M5/00 (20060101)

U.S. Cl.:

CPC **G06T11/206** (20130101); **A61B5/0002** (20130101); **A61B5/14532** (20130101); **A61B5/14546** (20130101); **A61B5/14865** (20130101); **A61B5/4839** (20130101); **A61M5/24** (20130101); **A61M5/31525** (20130101); A61B2560/0406 (20130101); A61B2560/0431 (20130101); A61B2560/0443 (20130101); A61M5/003 (20130101); A61M5/14244 (20130101); A61M5/1723 (20130101); A61M5/3129 (20130101); A61M2205/3569 (20130101); A61M2205/505 (20130101); A61M2209/086 (20130101)

Field of Classification Search

CPC: A61B (2560/0406); A61B (2560/0431); A61B (2560/0443); A61B (5/0002); A61B (5/14532); A61B (5/14546); A61B (5/14865); A61B (5/4839); A61M (2205/3569); A61M (2205/505); A61M (2209/086); A61M (5/003); A61M (5/14244); A61M (5/1723); A61M (5/24); A61M (5/3129); A61M (5/31525); G06T (11/206)

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
52641	12/1865	Gates	N/A	N/A
62334	12/1866	Holmes	N/A	N/A
65604	12/1866	Reynolds	N/A	N/A
1954643	12/1933	Neuhaus	N/A	N/A
2719797	12/1954	Rosenblatt et al.	N/A	N/A
3210578	12/1964	Sherer	N/A	N/A
3219533	12/1964	Mullins	N/A	N/A
3381371	12/1967	Russell	N/A	N/A
3506032	12/1969	Eveleigh et al.	N/A	N/A
3556950	12/1970	Dahms et al.	N/A	N/A
3610226	12/1970	Albisser	N/A	N/A
3775182	12/1972	Patton et al.	N/A	N/A
3780727	12/1972	King	N/A	N/A
3826244	12/1973	Salcman et al.	N/A	N/A
3837339	12/1973	Aisenberg et al.	N/A	N/A
3838682	12/1973	Clark et al.	N/A	N/A

3874850	12/1974	Sorensen et al.	N/A	N/A
3898984	12/1974	Mandel et al.	N/A	N/A
3910256	12/1974	Clark et al.	N/A	N/A
3929971	12/1974	Roy	N/A	N/A
3933593	12/1975	Sternberg	N/A	N/A
3943918	12/1975	Lewis	N/A	N/A
3957613	12/1975	Macur	N/A	N/A
3964974	12/1975	Banauch et al.	N/A	N/A
3979274	12/1975	Newman	N/A	N/A
4008717	12/1976	Kowarski	N/A	N/A
4016866	12/1976	Lawton	N/A	N/A
4024312	12/1976	Korpman	N/A	N/A
4040908	12/1976	Clark, Jr.	N/A	N/A
4052754	12/1976	Homsy	N/A	N/A
4055175	12/1976	Clemens et al.	N/A	N/A
4073713	12/1977	Newman	N/A	N/A
4076656	12/1977	White et al.	N/A	N/A
4109505	12/1977	Clark et al.	N/A	N/A
4119406	12/1977	Clemens	N/A	N/A
4136250	12/1978	Mueller et al.	N/A	N/A
4151845	12/1978	Clemens	N/A	N/A
4172770	12/1978	Semersky et al.	N/A	N/A
4176659	12/1978	Rolfe	N/A	N/A
4197840	12/1979	Beck et al.	N/A	N/A
4197852	12/1979	Schindler et al.	N/A	N/A
4206755	12/1979	Klein	N/A	N/A
4215703	12/1979	Willson	N/A	N/A
4240438	12/1979	Updike et al.	N/A	N/A
4240889	12/1979	Yoda et al.	N/A	N/A
4245634	12/1980	Albisser et al.	N/A	N/A
4253469	12/1980	Aslan	N/A	N/A
4255500	12/1980	Hooke	N/A	N/A
4259540	12/1980	Sabia	N/A	N/A
4265249	12/1980	Schindler et al.	N/A	N/A
4319578	12/1981	Enger	N/A	N/A
4327725	12/1981	Cortese et al.	N/A	N/A
4366040	12/1981	Marsoner et al.	N/A	N/A
4369785	12/1982	Rehkopf et al.	N/A	N/A
4374013	12/1982	Enfors	N/A	N/A
4388166	12/1982	Suzuki et al.	N/A	N/A
4403984	12/1982	Ash et al.	N/A	N/A
4415666	12/1982	D'Orazio et al.	N/A	N/A
4431004	12/1983	Bessman et al.	N/A	N/A
4432366	12/1983	Margules	N/A	N/A
4436094	12/1983	Cerami	N/A	N/A
4442841	12/1983	Uehara et al.	N/A	N/A
4454295	12/1983	Wittmann et al.	N/A	N/A
4457339	12/1983	Juan et al.	N/A	N/A
4477314	12/1983	Richter et al.	N/A	N/A
4478222	12/1983	Koning et al.	N/A	N/A

4486290	12/1983	Cahalan et al.	N/A	N/A
4492575	12/1984	Mabille	N/A	N/A
4494950	12/1984	Fischell	N/A	N/A
4506680	12/1984	Stokes	N/A	N/A
4519973	12/1984	Cahalan et al.	N/A	N/A
RE31916	12/1984	Oswin et al.	N/A	N/A
4526569	12/1984	Bernardi	N/A	N/A
4534825	12/1984	Koning et al.	N/A	N/A
4535786	12/1984	Kater	N/A	N/A
4538616	12/1984	Rogoff	N/A	N/A
4545382	12/1984	Higgins et al.	N/A	N/A
4554927	12/1984	Fussell	N/A	N/A
4565665	12/1985	Fogt	N/A	N/A
4565666	12/1985	Cahalan et al.	N/A	N/A
4568444	12/1985	Nakamura et al.	N/A	N/A
4571292	12/1985	Liu et al.	N/A	N/A
4573968	12/1985	Parker	N/A	N/A
4577642	12/1985	Stokes	N/A	N/A
4583976	12/1985	Ferguson	N/A	N/A
4592824	12/1985	Smith et al.	N/A	N/A
4600495	12/1985	Fogt	N/A	N/A
4614514	12/1985	Carr et al.	N/A	N/A
4619793	12/1985	Lee	N/A	N/A
4625730	12/1985	Fountain et al.	N/A	N/A
4626104	12/1985	Pointon et al.	N/A	N/A
4632968	12/1985	Yokota et al.	N/A	N/A
RE32361	12/1986	Duggan	N/A	N/A
4655880	12/1986	Liu	N/A	N/A
4663824	12/1986	Kenmochi	N/A	N/A
4671288	12/1986	Gough	N/A	N/A
4672970	12/1986	Uchida et al.	N/A	N/A
4680268	12/1986	Clark, Jr.	N/A	N/A
4685463	12/1986	Williams	N/A	N/A
4685903	12/1986	Cable et al.	N/A	N/A
4694861	12/1986	Goodale et al.	N/A	N/A
4702732	12/1986	Powers et al.	N/A	N/A
4703756	12/1986	Gough et al.	N/A	N/A
4705503	12/1986	Dorman et al.	N/A	N/A
4711245	12/1986	Higgins et al.	N/A	N/A
4711251	12/1986	Stokes	N/A	N/A
4721677	12/1987	Clark, Jr.	N/A	N/A
4726381	12/1987	Jones	N/A	N/A
4731726	12/1987	Allen, III	N/A	N/A
4736748	12/1987	Nakamura et al.	N/A	N/A
4747822	12/1987	Peabody	N/A	N/A
4750496	12/1987	Reinhart et al.	N/A	N/A
4753652	12/1987	Langer et al.	N/A	N/A
4755168	12/1987	Romanelli et al.	N/A	N/A
4757022	12/1987	Shults et al.	N/A	N/A
4759828	12/1987	Young et al.	N/A	N/A

4763648	12/1987	Wyatt	N/A	N/A
4763658	12/1987	Jones	N/A	N/A
4777953	12/1987	Ash et al.	N/A	N/A
4781798	12/1987	Gough	N/A	N/A
4784157	12/1987	Halls et al.	N/A	N/A
4786394	12/1987	Enzer et al.	N/A	N/A
4787398	12/1987	Garcia et al.	N/A	N/A
4789467	12/1987	Lindsay et al.	N/A	N/A
4791932	12/1987	Margules	N/A	N/A
4803243	12/1988	Fujimoto et al.	N/A	N/A
4805624	12/1988	Yao et al.	N/A	N/A
4805625	12/1988	Wyler	N/A	N/A
4807632	12/1988	Liess et al.	N/A	N/A
4808089	12/1988	Buchholtz et al.	N/A	N/A
4808292	12/1988	Kessler et al.	N/A	N/A
4809704	12/1988	Sogawa et al.	N/A	N/A
4810243	12/1988	Howson	N/A	N/A
4810470	12/1988	Burkhardt et al.	N/A	N/A
4815471	12/1988	Stobie	N/A	N/A
4820281	12/1988	Lawler, Jr.	N/A	N/A
4822336	12/1988	DiTraglia	N/A	N/A
4823808	12/1988	Clegg et al.	N/A	N/A
4828544	12/1988	Lane et al.	N/A	N/A
4830013	12/1988	Maxwell	N/A	N/A
4831070	12/1988	McInally et al.	N/A	N/A
4832005	12/1988	Takamiya et al.	N/A	N/A
4832034	12/1988	Pizziconi et al.	N/A	N/A
4834101	12/1988	Collison et al.	N/A	N/A
4838281	12/1988	Rogers et al.	N/A	N/A
4841974	12/1988	Gumbrecht et al.	N/A	N/A
4849458	12/1988	Reed et al.	N/A	N/A
4852573	12/1988	Kennedy	N/A	N/A
4854322	12/1988	Ash et al.	N/A	N/A
4858615	12/1988	Meinema	N/A	N/A
4867741	12/1988	Portnoy	N/A	N/A
4871440	12/1988	Nagata et al.	N/A	N/A
4874363	12/1988	Abell	N/A	N/A
4883057	12/1988	Broderick	N/A	N/A
4883467	12/1988	Franetzki et al.	N/A	N/A
4889528	12/1988	Nadai et al.	N/A	N/A
4889744	12/1988	Quaid	N/A	N/A
4890620	12/1989	Gough	N/A	N/A
4890621	12/1989	Hakky	N/A	N/A
4900305	12/1989	Smith et al.	N/A	N/A
4902294	12/1989	Gosserez	N/A	N/A
4907857	12/1989	Giuliani et al.	N/A	N/A
4908208	12/1989	Lee et al.	N/A	N/A
4909786	12/1989	Gijselhart et al.	N/A	N/A
4919114	12/1989	Miyazaki	N/A	N/A
4919141	12/1989	Zier et al.	N/A	N/A

4919649	12/1989	Timothy et al.	N/A	N/A
4921477	12/1989	Davis	N/A	N/A
4921480	12/1989	Sealfon	N/A	N/A
4925444	12/1989	Orkin et al.	N/A	N/A
4927407	12/1989	Dorman	N/A	N/A
4927516	12/1989	Yamaguchi et al.	N/A	N/A
4928694	12/1989	Maxwell	N/A	N/A
4934369	12/1989	Maxwell	N/A	N/A
4934375	12/1989	Cole et al.	N/A	N/A
4944299	12/1989	Silvian	N/A	N/A
4946439	12/1989	Eggers	N/A	N/A
4950246	12/1989	Muller	N/A	N/A
4951657	12/1989	Pfister et al.	N/A	N/A
4951669	12/1989	Maxwell et al.	N/A	N/A
4953552	12/1989	DeMarzo	N/A	N/A
4957483	12/1989	Gonser et al.	N/A	N/A
4963595	12/1989	Ward et al.	N/A	N/A
4966579	12/1989	Polaschegg	N/A	N/A
4967940	12/1989	Blette et al.	N/A	N/A
4970145	12/1989	Bennetto et al.	N/A	N/A
4973320	12/1989	Brenner et al.	N/A	N/A
4974592	12/1989	Branco	N/A	N/A
4974929	12/1989	Curry	N/A	N/A
4975636	12/1989	Desautels	N/A	N/A
4976687	12/1989	Martin	N/A	N/A
4979509	12/1989	Hakky	N/A	N/A
4984929	12/1990	Rock et al.	N/A	N/A
4986671	12/1990	Sun et al.	N/A	N/A
4988341	12/1990	Columbus et al.	N/A	N/A
4989607	12/1990	Keusch et al.	N/A	N/A
4992794	12/1990	Brouwers	N/A	N/A
4994026	12/1990	Fecondini	N/A	N/A
4994167	12/1990	Shults et al.	N/A	N/A
4997627	12/1990	Bergkuist et al.	N/A	N/A
5002055	12/1990	Merki et al.	N/A	N/A
5002572	12/1990	Picha	N/A	N/A
5006050	12/1990	Cooke et al.	N/A	N/A
5006111	12/1990	Inokuchi et al.	N/A	N/A
5007929	12/1990	Quaid	N/A	N/A
5009251	12/1990	Pike et al.	N/A	N/A
5019974	12/1990	Beckers	N/A	N/A
5026348	12/1990	Venegas	N/A	N/A
5030199	12/1990	Barwick et al.	N/A	N/A
5030333	12/1990	Clark, Jr.	N/A	N/A
5034112	12/1990	Murase et al.	N/A	N/A
5035711	12/1990	Aoki et al.	N/A	N/A
5041092	12/1990	Barwick	N/A	N/A
5045057	12/1990	Van Driessche et al.	N/A	N/A
5046496	12/1990	Betts et al.	N/A	N/A
5048525	12/1990	Maxwell	N/A	N/A

5050612	12/1990	Matsumura	N/A	N/A
5055171	12/1990	Peck	N/A	N/A
5055198	12/1990	Shettigar	N/A	N/A
5059654	12/1990	Hou et al.	N/A	N/A
5067491	12/1990	Taylor et al.	N/A	N/A
5068536	12/1990	Rosenthal	N/A	N/A
5070169	12/1990	Robertson et al.	N/A	N/A
5077476	12/1990	Rosenthal	N/A	N/A
5088981	12/1991	Howson et al.	N/A	N/A
5089421	12/1991	Dieffenbach	N/A	N/A
5096669	12/1991	Lauks et al.	N/A	N/A
5097834	12/1991	Skrabal	N/A	N/A
5098377	12/1991	Borsanyi et al.	N/A	N/A
5101814	12/1991	Palti	N/A	N/A
5108819	12/1991	Heller et al.	N/A	N/A
5109850	12/1991	Blanco et al.	N/A	N/A
5112301	12/1991	Fenton, Jr. et al.	N/A	N/A
5116313	12/1991	McGregor	N/A	N/A
5127405	12/1991	Alcala et al.	N/A	N/A
5137028	12/1991	Nishimura	N/A	N/A
5140985	12/1991	Schroeder et al.	N/A	N/A
5145565	12/1991	Kater et al.	N/A	N/A
5152746	12/1991	Atkinson et al.	N/A	N/A
5153827	12/1991	Coutre et al.	N/A	N/A
5160418	12/1991	Mullen	N/A	N/A
5161532	12/1991	Joseph	N/A	N/A
5165406	12/1991	Wong	N/A	N/A
5165407	12/1991	Wilson et al.	N/A	N/A
5174291	12/1991	Schoonen et al.	N/A	N/A
5176632	12/1992	Bernardi	N/A	N/A
5176658	12/1992	Ranford	N/A	N/A
5178142	12/1992	Harjunmaa et al.	N/A	N/A
5182004	12/1992	Kohno	N/A	N/A
5188591	12/1992	Dorsey, III	N/A	N/A
5190041	12/1992	Palti	N/A	N/A
5195963	12/1992	Yafuso et al.	N/A	N/A
5198771	12/1992	Fidler et al.	N/A	N/A
5208147	12/1992	Kagenow et al.	N/A	N/A
5208313	12/1992	Krishnan	N/A	N/A
5220917	12/1992	Cammilli et al.	N/A	N/A
5220920	12/1992	Gharib	N/A	N/A
5224929	12/1992	Remiszewski	N/A	N/A
5225063	12/1992	Gumbrecht et al.	N/A	N/A
5232434	12/1992	Inagaki et al.	N/A	N/A
5235003	12/1992	Ward et al.	N/A	N/A
5243982	12/1992	Mostl et al.	N/A	N/A
5243983	12/1992	Tarr et al.	N/A	N/A
5249576	12/1992	Goldberger et al.	N/A	N/A
5251126	12/1992	Kahn et al.	N/A	N/A
5254102	12/1992	Ogawa	N/A	N/A

5262305	12/1992	Heller et al.	N/A	N/A
5265594	12/1992	Olsson et al.	N/A	N/A
5266179	12/1992	Nankai et al.	N/A	N/A
5269891	12/1992	Colin	N/A	N/A
5271736	12/1992	Picha	N/A	N/A
5271815	12/1992	Wong	N/A	N/A
5279294	12/1993	Anderson et al.	N/A	N/A
5281319	12/1993	Kaneko et al.	N/A	N/A
5282848	12/1993	Schmitt	N/A	N/A
5284140	12/1993	Allen et al.	N/A	N/A
5284570	12/1993	Savage et al.	N/A	N/A
5285513	12/1993	Kaufman et al.	N/A	N/A
5287753	12/1993	Routh et al.	N/A	N/A
5298022	12/1993	Bernardi	N/A	N/A
5299571	12/1993	Mastrototaro	N/A	N/A
5302093	12/1993	Owens et al.	N/A	N/A
5304468	12/1993	Phillips et al.	N/A	N/A
5307263	12/1993	Brown	N/A	N/A
5310469	12/1993	Cunningham et al.	N/A	N/A
5311908	12/1993	Barone et al.	N/A	N/A
5312361	12/1993	Zadini et al.	N/A	N/A
5314471	12/1993	Brauker et al.	N/A	N/A
5316008	12/1993	Suga et al.	N/A	N/A
5316452	12/1993	Bogen et al.	N/A	N/A
5318511	12/1993	Riquier et al.	N/A	N/A
5322063	12/1993	Allen et al.	N/A	N/A
5324322	12/1993	Grill, Jr. et al.	N/A	N/A
5326356	12/1993	Della Valle et al.	N/A	N/A
5326449	12/1993	Cunningham	N/A	N/A
5330521	12/1993	Cohen	N/A	N/A
5330634	12/1993	Wong et al.	N/A	N/A
5331555	12/1993	Hashimoto et al.	N/A	N/A
5335658	12/1993	Bedingham	N/A	N/A
5337747	12/1993	Neftel	N/A	N/A
5342409	12/1993	Mullett	N/A	N/A
5342789	12/1993	Chick et al.	N/A	N/A
5343869	12/1993	Pross et al.	N/A	N/A
5344454	12/1993	Clarke et al.	N/A	N/A
5345932	12/1993	Yafuso et al.	N/A	N/A
5348788	12/1993	White	N/A	N/A
5352348	12/1993	Young et al.	N/A	N/A
5352351	12/1993	White et al.	N/A	N/A
5354272	12/1993	Swendson et al.	N/A	N/A
5354449	12/1993	Band et al.	N/A	N/A
5356375	12/1993	Higley	N/A	N/A
5356378	12/1993	Doan	N/A	N/A
5356786	12/1993	Heller et al.	N/A	N/A
5368028	12/1993	Palti	N/A	N/A
5368224	12/1993	Richardson et al.	N/A	N/A
5368562	12/1993	Blomquist et al.	N/A	N/A

5372133	12/1993	Hogen Esch	N/A	N/A
5372135	12/1993	Mendelson et al.	N/A	N/A
5372709	12/1993	Hood	N/A	N/A
5376070	12/1993	Purvis et al.	N/A	N/A
5378229	12/1994	Layer et al.	N/A	N/A
5380268	12/1994	Wheeler	N/A	N/A
5380491	12/1994	Carver, Jr. et al.	N/A	N/A
5380536	12/1994	Hubbell et al.	N/A	N/A
5380665	12/1994	Cusack et al.	N/A	N/A
5384028	12/1994	Ito	N/A	N/A
5390671	12/1994	Lord et al.	N/A	N/A
5391250	12/1994	Cheney, II et al.	N/A	N/A
5397848	12/1994	Yang et al.	N/A	N/A
5405510	12/1994	Betts et al.	N/A	N/A
5411052	12/1994	Murray	N/A	N/A
5411647	12/1994	Johnson et al.	N/A	N/A
5411866	12/1994	Luong et al.	N/A	N/A
5417206	12/1994	Kaneyoshi	N/A	N/A
5421328	12/1994	Bedingham	N/A	N/A
5421923	12/1994	Clarke et al.	N/A	N/A
5423738	12/1994	Robinson et al.	N/A	N/A
5423749	12/1994	Merte et al.	N/A	N/A
5428123	12/1994	Ward et al.	N/A	N/A
5429485	12/1994	Dodge	N/A	N/A
5429602	12/1994	Hauser	N/A	N/A
5429735	12/1994	Johnson et al.	N/A	N/A
5431160	12/1994	Wilkins	N/A	N/A
5431174	12/1994	Knute	N/A	N/A
5431921	12/1994	Thombre	N/A	N/A
5434412	12/1994	Sodickson et al.	N/A	N/A
5437635	12/1994	Fields et al.	N/A	N/A
5438984	12/1994	Schoendorfer	N/A	N/A
5443508	12/1994	Giampapa	N/A	N/A
5445610	12/1994	Evert	N/A	N/A
5448992	12/1994	Kupershmidt	N/A	N/A
5451260	12/1994	Versteeg et al.	N/A	N/A
5453278	12/1994	Chan et al.	N/A	N/A
5458631	12/1994	Xavier	N/A	N/A
5462051	12/1994	Oka et al.	N/A	N/A
5462064	12/1994	D'Angelo et al.	N/A	N/A
5466356	12/1994	Schneider et al.	N/A	N/A
5469846	12/1994	Khan	N/A	N/A
5474552	12/1994	Palti	N/A	N/A
5476776	12/1994	Wilkins	N/A	N/A
5482008	12/1995	Stafford et al.	N/A	N/A
5482446	12/1995	Williamson et al.	N/A	N/A
5482473	12/1995	Lord et al.	N/A	N/A
5484404	12/1995	Schulman et al.	N/A	N/A
5491474	12/1995	Suni et al.	N/A	N/A
5494562	12/1995	Maley et al.	N/A	N/A

5496453	12/1995	Uenoyama et al.	N/A	N/A
5497772	12/1995	Schulman et al.	N/A	N/A
5502396	12/1995	Desarzens et al.	N/A	N/A
5505828	12/1995	Wong et al.	N/A	N/A
5507288	12/1995	Bocker et al.	N/A	N/A
5508203	12/1995	Fuller et al.	N/A	N/A
5509888	12/1995	Miller	N/A	N/A
5512046	12/1995	Pusinelli et al.	N/A	N/A
5512055	12/1995	Domb et al.	N/A	N/A
5512248	12/1995	Van	N/A	N/A
5513636	12/1995	Palti	N/A	N/A
5514253	12/1995	Davis et al.	N/A	N/A
5515851	12/1995	Goldstein	N/A	N/A
5518601	12/1995	Foos et al.	N/A	N/A
5527288	12/1995	Gross et al.	N/A	N/A
5531679	12/1995	Schulman et al.	N/A	N/A
5531878	12/1995	Vadgama et al.	N/A	N/A
5536249	12/1995	Castellano et al.	N/A	N/A
5538511	12/1995	Van Antwerp	N/A	N/A
5540828	12/1995	Yacynych	N/A	N/A
5545220	12/1995	Andrews et al.	N/A	N/A
5545223	12/1995	Neuenfeldt et al.	N/A	N/A
5549547	12/1995	Cohen et al.	N/A	N/A
5549548	12/1995	Larsson	N/A	N/A
5549569	12/1995	Lynn et al.	N/A	N/A
5549651	12/1995	Lynn	N/A	N/A
5551850	12/1995	Williamson et al.	N/A	N/A
5553616	12/1995	Ham et al.	N/A	N/A
5554339	12/1995	Cozzette et al.	N/A	N/A
5561615	12/1995	Kuo et al.	N/A	N/A
5562614	12/1995	O'Donnell	N/A	N/A
5562615	12/1995	Nassif	N/A	N/A
5564439	12/1995	Picha	N/A	N/A
5568806	12/1995	Cheney, II et al.	N/A	N/A
5569186	12/1995	Lord et al.	N/A	N/A
5569188	12/1995	Mackool	N/A	N/A
5569219	12/1995	Hakki et al.	N/A	N/A
5569462	12/1995	Martinson et al.	N/A	N/A
5575293	12/1995	Miller et al.	N/A	N/A
5575930	12/1995	Tietje-Girault et al.	N/A	N/A
5577499	12/1995	Teves	N/A	N/A
5582184	12/1995	Erickson et al.	N/A	N/A
5582593	12/1995	Hultman	N/A	N/A
5584813	12/1995	Livingston et al.	N/A	N/A
5584876	12/1995	Bruchman et al.	N/A	N/A
5586553	12/1995	Halili et al.	N/A	N/A
5589133	12/1995	Suzuki	N/A	N/A
5590651	12/1996	Shaffer et al.	N/A	N/A
5593440	12/1996	Brauker et al.	N/A	N/A
5609572	12/1996	Lang	N/A	N/A

5611900	12/1996	Worden et al.	N/A	N/A
5624409	12/1996	Seale	N/A	N/A
5624537	12/1996	Turner et al.	N/A	N/A
5626563	12/1996	Dodge et al.	N/A	N/A
5628619	12/1996	Wilson	N/A	N/A
5628890	12/1996	Carter et al.	N/A	N/A
5637083	12/1996	Bertrand et al.	N/A	N/A
5640470	12/1996	Iyer et al.	N/A	N/A
5643195	12/1996	Drevet et al.	N/A	N/A
5651767	12/1996	Schulman et al.	N/A	N/A
5653756	12/1996	Clarke et al.	N/A	N/A
5653863	12/1996	Genshaw et al.	N/A	N/A
5658250	12/1996	Blomquist et al.	N/A	N/A
5660163	12/1996	Schulman et al.	N/A	N/A
5660565	12/1996	Williams	N/A	N/A
5665061	12/1996	Antwiler	N/A	N/A
5665065	12/1996	Colman et al.	N/A	N/A
5667504	12/1996	Baumann et al.	N/A	N/A
5673694	12/1996	Rivers	N/A	N/A
5674289	12/1996	Fournier et al.	N/A	N/A
5676651	12/1996	Larson, Jr. et al.	N/A	N/A
5676820	12/1996	Wang et al.	N/A	N/A
5681572	12/1996	Seare, Jr.	N/A	N/A
5682884	12/1996	Hill et al.	N/A	N/A
5683562	12/1996	Schaffar et al.	N/A	N/A
5686829	12/1996	Girault	N/A	N/A
5688239	12/1996	Walker	N/A	N/A
5688244	12/1996	Lang	N/A	N/A
5695623	12/1996	Michel et al.	N/A	N/A
5696314	12/1996	McCaffrey et al.	N/A	N/A
5697366	12/1996	Kimball et al.	N/A	N/A
5697899	12/1996	Hillman et al.	N/A	N/A
5704354	12/1997	Preidel et al.	N/A	N/A
5706807	12/1997	Picha	N/A	N/A
5711861	12/1997	Ward et al.	N/A	N/A
5713888	12/1997	Neuenfeldt et al.	N/A	N/A
5730654	12/1997	Brown	N/A	N/A
5733259	12/1997	Valcke et al.	N/A	N/A
5733336	12/1997	Neuenfeldt et al.	N/A	N/A
5743262	12/1997	Lepper, Jr. et al.	N/A	N/A
5749832	12/1997	Vadgama et al.	N/A	N/A
5749907	12/1997	Mann	N/A	N/A
5755692	12/1997	Manicom	N/A	N/A
5756632	12/1997	Ward et al.	N/A	N/A
5758643	12/1997	Wong et al.	N/A	N/A
5763760	12/1997	Gumbrecht et al.	N/A	N/A
5771890	12/1997	Tamada	N/A	N/A
5773286	12/1997	Dionne et al.	N/A	N/A
5776324	12/1997	Usala	N/A	N/A
5779665	12/1997	Mastrototaro et al.	N/A	N/A

5781455	12/1997	Hyodo	N/A	N/A
5782880	12/1997	Lahtinen et al.	N/A	N/A
5782912	12/1997	Brauker et al.	N/A	N/A
5787900	12/1997	Butler et al.	N/A	N/A
5791344	12/1997	Schulman et al.	N/A	N/A
5791880	12/1997	Wilson	N/A	N/A
5795453	12/1997	Gilmartin	N/A	N/A
5795774	12/1997	Matsumoto et al.	N/A	N/A
5798065	12/1997	Picha	N/A	N/A
5800383	12/1997	Chandler et al.	N/A	N/A
5800420	12/1997	Gross et al.	N/A	N/A
5800529	12/1997	Brauker et al.	N/A	N/A
5806517	12/1997	Gerhardt et al.	N/A	N/A
5807274	12/1997	Henning et al.	N/A	N/A
5807312	12/1997	Dzwonkiewicz	N/A	N/A
5807375	12/1997	Gross et al.	N/A	N/A
5807406	12/1997	Brauker et al.	N/A	N/A
5810770	12/1997	Chin et al.	N/A	N/A
5811487	12/1997	Schulz, Jr. et al.	N/A	N/A
5814599	12/1997	Mitragotri et al.	N/A	N/A
5820589	12/1997	Torgerson et al.	N/A	N/A
5820622	12/1997	Gross et al.	N/A	N/A
5822715	12/1997	Worthington et al.	N/A	N/A
5836887	12/1997	Oka et al.	N/A	N/A
5836989	12/1997	Shelton	N/A	N/A
5837454	12/1997	Cozzette et al.	N/A	N/A
5837728	12/1997	Purcell	N/A	N/A
5840026	12/1997	Uber, III et al.	N/A	N/A
5840148	12/1997	Campbell et al.	N/A	N/A
5848991	12/1997	Gross et al.	N/A	N/A
5851197	12/1997	Marano et al.	N/A	N/A
5851229	12/1997	Lentz et al.	N/A	N/A
5858365	12/1998	Faller	N/A	N/A
5858747	12/1998	Schinstine et al.	N/A	N/A
5861019	12/1998	Sun et al.	N/A	N/A
5863400	12/1998	Drummond et al.	N/A	N/A
5871514	12/1998	Wiklund et al.	N/A	N/A
5873862	12/1998	Lopez	N/A	N/A
5879713	12/1998	Roth et al.	N/A	N/A
5882494	12/1998	Van Antwerp	N/A	N/A
5895235	12/1998	Droz	N/A	N/A
5897525	12/1998	Dey et al.	N/A	N/A
5897578	12/1998	Wiklund et al.	N/A	N/A
5899855	12/1998	Brown	N/A	N/A
5904666	12/1998	DeDecker et al.	N/A	N/A
5904708	12/1998	Goedeke	N/A	N/A
5911219	12/1998	Aylsworth et al.	N/A	N/A
5913998	12/1998	Butler et al.	N/A	N/A
5914026	12/1998	Blubaugh, Jr. et al.	N/A	N/A
5917346	12/1998	Gord	N/A	N/A

5919215	12/1998	Wiklund et al.	N/A	N/A
5919216	12/1998	Houben et al.	N/A	N/A
5921951	12/1998	Morris	N/A	N/A
5925021	12/1998	Castellano et al.	N/A	N/A
5928155	12/1998	Eggers et al.	N/A	N/A
5928182	12/1998	Kraus et al.	N/A	N/A
5928189	12/1998	Phillips et al.	N/A	N/A
5928195	12/1998	Malamud et al.	N/A	N/A
5931814	12/1998	Alex et al.	N/A	N/A
5932175	12/1998	Knute et al.	N/A	N/A
5933136	12/1998	Brown	N/A	N/A
5935785	12/1998	Reber et al.	N/A	N/A
5938636	12/1998	Kramer et al.	N/A	N/A
5944661	12/1998	Swette et al.	N/A	N/A
5947911	12/1998	Wong et al.	N/A	N/A
5954643	12/1998	Vanantwerp et al.	N/A	N/A
5954954	12/1998	Houck et al.	N/A	N/A
5957854	12/1998	Besson et al.	N/A	N/A
5957903	12/1998	Mirzaee et al.	N/A	N/A
5961451	12/1998	Reber et al.	N/A	N/A
5963132	12/1998	Yoakum	N/A	N/A
5964745	12/1998	Lyles et al.	N/A	N/A
5964993	12/1998	Blubaugh, Jr. et al.	N/A	N/A
5965125	12/1998	Mineau-Hanschke	N/A	N/A
5965380	12/1998	Heller et al.	N/A	N/A
5971922	12/1998	Arita et al.	N/A	N/A
5972369	12/1998	Roorda et al.	N/A	N/A
5976085	12/1998	Kimball et al.	N/A	N/A
5987352	12/1998	Klein et al.	N/A	N/A
5995208	12/1998	Sarge et al.	N/A	N/A
5995860	12/1998	Sun et al.	N/A	N/A
5997501	12/1998	Gross et al.	N/A	N/A
5999848	12/1998	Gord et al.	N/A	N/A
6001067	12/1998	Shults et al.	N/A	N/A
6001471	12/1998	Bries et al.	N/A	N/A
6002954	12/1998	Van Antwerp et al.	N/A	N/A
6007845	12/1998	Domb et al.	N/A	N/A
6011984	12/1999	Van Antwerp et al.	N/A	N/A
6014577	12/1999	Henning et al.	N/A	N/A
6016448	12/1999	Busacker et al.	N/A	N/A
6017435	12/1999	Hassard et al.	N/A	N/A
6023629	12/1999	Tamada	N/A	N/A
6024720	12/1999	Chandler et al.	N/A	N/A
6027445	12/1999	Von Bahr	N/A	N/A
6027479	12/1999	Alei et al.	N/A	N/A
6032059	12/1999	Henning et al.	N/A	N/A
6032667	12/1999	Heinonen	N/A	N/A
6036924	12/1999	Simons et al.	N/A	N/A
6043328	12/1999	Domschke et al.	N/A	N/A
6045671	12/1999	Wu et al.	N/A	N/A

6048691	12/1999	Maracas	N/A	N/A
6049727	12/1999	Crothall	N/A	N/A
6059946	12/1999	Yukawa et al.	N/A	N/A
6063637	12/1999	Arnold et al.	N/A	N/A
6066088	12/1999	Davis	N/A	N/A
6066448	12/1999	Wohlstadter et al.	N/A	N/A
6071391	12/1999	Gotoh et al.	N/A	N/A
6077299	12/1999	Adelberg et al.	N/A	N/A
6080583	12/1999	Von Bahr	N/A	N/A
6081735	12/1999	Diab et al.	N/A	N/A
6081736	12/1999	Colvin et al.	N/A	N/A
6083523	12/1999	Dionne et al.	N/A	N/A
6083710	12/1999	Heller et al.	N/A	N/A
6088608	12/1999	Schulman et al.	N/A	N/A
6090087	12/1999	Tsukada et al.	N/A	N/A
6091975	12/1999	Daddona et al.	N/A	N/A
6093172	12/1999	Funderburk et al.	N/A	N/A
6099511	12/1999	Devos et al.	N/A	N/A
6103033	12/1999	Say et al.	N/A	N/A
6103533	12/1999	Hassard et al.	N/A	N/A
6107083	12/1999	Collins et al.	N/A	N/A
6115634	12/1999	Donders et al.	N/A	N/A
6117290	12/1999	Say et al.	N/A	N/A
6120676	12/1999	Heller et al.	N/A	N/A
6121009	12/1999	Heller et al.	N/A	N/A
6122536	12/1999	Sun et al.	N/A	N/A
6123827	12/1999	Wong et al.	N/A	N/A
6127154	12/1999	Mosbach et al.	N/A	N/A
6128519	12/1999	Say	N/A	N/A
6129891	12/1999	Rolander et al.	N/A	N/A
6134461	12/1999	Say et al.	N/A	N/A
6135978	12/1999	Houben et al.	N/A	N/A
6142939	12/1999	Eppstein et al.	N/A	N/A
6144869	12/1999	Berner et al.	N/A	N/A
6159186	12/1999	Wickham et al.	N/A	N/A
6162201	12/1999	Cohen et al.	N/A	N/A
6162611	12/1999	Heller et al.	N/A	N/A
6163720	12/1999	Gyory et al.	N/A	N/A
6164921	12/1999	Moubayed et al.	N/A	N/A
6165154	12/1999	Gray et al.	N/A	N/A
6167614	12/2000	Tuttle et al.	N/A	N/A
6168568	12/2000	Gavriely	N/A	N/A
6169155	12/2000	Alvarez et al.	N/A	N/A
6171276	12/2000	Lippe et al.	N/A	N/A
6175752	12/2000	Say et al.	N/A	N/A
6180416	12/2000	Kurnik et al.	N/A	N/A
6183437	12/2000	Walker	N/A	N/A
6187062	12/2000	Oweis et al.	N/A	N/A
6189536	12/2000	Martinez et al.	N/A	N/A
6191860	12/2000	Klinger et al.	N/A	N/A

6192891	12/2000	Gravel et al.	N/A	N/A
6201980	12/2000	Darrow et al.	N/A	N/A
6201993	12/2000	Kruse et al.	N/A	N/A
6206856	12/2000	Mahurkar	N/A	N/A
6208894	12/2000	Schulman et al.	N/A	N/A
6212416	12/2000	Ward et al.	N/A	N/A
6212424	12/2000	Robinson	N/A	N/A
6213739	12/2000	Phallen et al.	N/A	N/A
6214185	12/2000	Offenbacher et al.	N/A	N/A
6219574	12/2000	Cormier et al.	N/A	N/A
6223080	12/2000	Thompson	N/A	N/A
6223083	12/2000	Rosar	N/A	N/A
6230059	12/2000	Duffin	N/A	N/A
6231879	12/2000	Li et al.	N/A	N/A
6232783	12/2000	Merrill	N/A	N/A
6233080	12/2000	Brenner et al.	N/A	N/A
6234964	12/2000	Iliff	N/A	N/A
6241863	12/2000	Monbouquette	N/A	N/A
6248067	12/2000	Causey, III et al.	N/A	N/A
6248077	12/2000	Elson et al.	N/A	N/A
6248093	12/2000	Moberg	N/A	N/A
6254586	12/2000	Mann et al.	N/A	N/A
6256522	12/2000	Schultz	N/A	N/A
6259937	12/2000	Schulman et al.	N/A	N/A
6263222	12/2000	Diab et al.	N/A	N/A
6264825	12/2000	Blackburn et al.	N/A	N/A
6270478	12/2000	Mernoee	N/A	N/A
6271332	12/2000	Lohmann et al.	N/A	N/A
6272364	12/2000	Kurnik	N/A	N/A
6272382	12/2000	Faltys et al.	N/A	N/A
6272480	12/2000	Tresp et al.	N/A	N/A
6274285	12/2000	Gries et al.	N/A	N/A
6275717	12/2000	Gross et al.	N/A	N/A
6280408	12/2000	Sipin	N/A	N/A
6281015	12/2000	Mooney et al.	N/A	N/A
6284478	12/2000	Heller et al.	N/A	N/A
6293925	12/2000	Safabash et al.	N/A	N/A
6298254	12/2000	Tamada	N/A	N/A
6299578	12/2000	Kurnik et al.	N/A	N/A
6299583	12/2000	Eggers et al.	N/A	N/A
6300002	12/2000	Webb et al.	N/A	N/A
6302855	12/2000	Lav et al.	N/A	N/A
6309351	12/2000	Kurnik et al.	N/A	N/A
6309384	12/2000	Harrington et al.	N/A	N/A
6309884	12/2000	Cooper et al.	N/A	N/A
6312388	12/2000	Marcovecchio et al.	N/A	N/A
6315738	12/2000	Nishikawa et al.	N/A	N/A
6325978	12/2000	Labuda et al.	N/A	N/A
6326160	12/2000	Dunn et al.	N/A	N/A
6329161	12/2000	Heller et al.	N/A	N/A

6329929	12/2000	Weijand et al.	N/A	N/A
6330464	12/2000	Colvin, Jr. et al.	N/A	N/A
6343225	12/2001	Clark, Jr.	N/A	N/A
6356776	12/2001	Berner et al.	N/A	N/A
6358225	12/2001	Butterfield	N/A	N/A
6365670	12/2001	Fry	N/A	N/A
6366794	12/2001	Moussy et al.	N/A	N/A
6368274	12/2001	Van Antwerp et al.	N/A	N/A
6370941	12/2001	Nakamura et al.	N/A	N/A
6372244	12/2001	Antanavich et al.	N/A	N/A
6379301	12/2001	Worthington et al.	N/A	N/A
6379317	12/2001	Kintzig et al.	N/A	N/A
6383478	12/2001	Prokop et al.	N/A	N/A
6387709	12/2001	Mason et al.	N/A	N/A
6391019	12/2001	Ito	N/A	N/A
6400974	12/2001	Lesho	N/A	N/A
6402703	12/2001	Kensey et al.	N/A	N/A
6403944	12/2001	Mackenzie et al.	N/A	N/A
6406066	12/2001	Uegane	N/A	N/A
6407195	12/2001	Sherman et al.	N/A	N/A
6409674	12/2001	Brockway et al.	N/A	N/A
6413393	12/2001	Van Antwerp et al.	N/A	N/A
6416651	12/2001	Millar	N/A	N/A
6424847	12/2001	Mastrototaro et al.	N/A	N/A
6430437	12/2001	Marro	N/A	N/A
6447448	12/2001	Ishikawa et al.	N/A	N/A
6447542	12/2001	Weadock	N/A	N/A
6459917	12/2001	Gowda et al.	N/A	N/A
6461496	12/2001	Feldman et al.	N/A	N/A
6464849	12/2001	Say et al.	N/A	N/A
6466810	12/2001	Ward et al.	N/A	N/A
6467480	12/2001	Meier et al.	N/A	N/A
6471689	12/2001	Joseph, I et al.	N/A	N/A
6474360	12/2001	Ito	N/A	N/A
6475750	12/2001	Han et al.	N/A	N/A
6477392	12/2001	Honigs et al.	N/A	N/A
6477395	12/2001	Schulman et al.	N/A	N/A
6481440	12/2001	Gielen et al.	N/A	N/A
6484045	12/2001	Holker et al.	N/A	N/A
6484046	12/2001	Say et al.	N/A	N/A
6485449	12/2001	Ito	N/A	N/A
6488652	12/2001	Weijand et al.	N/A	N/A
6494830	12/2001	Wessel	N/A	N/A
6494879	12/2001	Lennox et al.	N/A	N/A
6497729	12/2001	Moussy et al.	N/A	N/A
6498043	12/2001	Schulman et al.	N/A	N/A
6498941	12/2001	Jackson	N/A	N/A
6501976	12/2001	Sohrab	N/A	N/A
6510239	12/2002	Wieres et al.	N/A	N/A
6510329	12/2002	Heckel	N/A	N/A

6512939	12/2002	Colvin et al.	N/A	N/A
6514718	12/2002	Heller et al.	N/A	N/A
6517508	12/2002	Utterberg et al.	N/A	N/A
6520326	12/2002	McIvor et al.	N/A	N/A
6520477	12/2002	Trimmer	N/A	N/A
6520937	12/2002	Hart et al.	N/A	N/A
6520997	12/2002	Pekkarinen et al.	N/A	N/A
6526298	12/2002	Khalil et al.	N/A	N/A
6527729	12/2002	Turcott	N/A	N/A
6534711	12/2002	Pollack	N/A	N/A
6536433	12/2002	Cewers	N/A	N/A
6537318	12/2002	Ita et al.	N/A	N/A
6541266	12/2002	Modzelewski et al.	N/A	N/A
6542765	12/2002	Guy et al.	N/A	N/A
6544212	12/2002	Galley et al.	N/A	N/A
6545085	12/2002	Kilgour et al.	N/A	N/A
6546268	12/2002	Ishikawa et al.	N/A	N/A
6546269	12/2002	Kurnik	N/A	N/A
6549796	12/2002	Sohrab	N/A	N/A
6551496	12/2002	Moles et al.	N/A	N/A
6553241	12/2002	Mannheimer et al.	N/A	N/A
6553244	12/2002	Lesho et al.	N/A	N/A
6554805	12/2002	Hiejima	N/A	N/A
6554822	12/2002	Holschneider et al.	N/A	N/A
6558320	12/2002	Causey, III et al.	N/A	N/A
6558321	12/2002	Burd et al.	N/A	N/A
6558347	12/2002	Jhuboo et al.	N/A	N/A
6558351	12/2002	Steil et al.	N/A	N/A
6558955	12/2002	Kristal et al.	N/A	N/A
6561978	12/2002	Conn et al.	N/A	N/A
6562001	12/2002	Lebel et al.	N/A	N/A
6565509	12/2002	Say et al.	N/A	N/A
6565535	12/2002	Zaias et al.	N/A	N/A
6565807	12/2002	Patterson et al.	N/A	N/A
6569195	12/2002	Yang et al.	N/A	N/A
6569521	12/2002	Sheridan et al.	N/A	N/A
6571128	12/2002	Lebel et al.	N/A	N/A
6572545	12/2002	Knobbe et al.	N/A	N/A
6572579	12/2002	Raghavan et al.	N/A	N/A
6574490	12/2002	Abbink et al.	N/A	N/A
6575905	12/2002	Knobbe et al.	N/A	N/A
6577899	12/2002	Lebel et al.	N/A	N/A
6579257	12/2002	Elgas et al.	N/A	N/A
6579498	12/2002	Eglise	N/A	N/A
6579690	12/2002	Bonnecaze et al.	N/A	N/A
6585644	12/2002	Lebel et al.	N/A	N/A
6585675	12/2002	O'Mahony et al.	N/A	N/A
6585763	12/2002	Keilman et al.	N/A	N/A
6587705	12/2002	Kim et al.	N/A	N/A
6589229	12/2002	Connelly, I et al.	N/A	N/A

6591125	12/2002	Buse et al.	N/A	N/A
6594514	12/2002	Berner et al.	N/A	N/A
6595756	12/2002	Gray et al.	N/A	N/A
6595919	12/2002	Berner et al.	N/A	N/A
6602221	12/2002	Saravia et al.	N/A	N/A
6605072	12/2002	Struys et al.	N/A	N/A
6607509	12/2002	Bobroff et al.	N/A	N/A
6609071	12/2002	Shapiro et al.	N/A	N/A
6612984	12/2002	Kerr, II	N/A	N/A
6613379	12/2002	Ward et al.	N/A	N/A
6615061	12/2002	Khalil et al.	N/A	N/A
6615078	12/2002	Burson et al.	N/A	N/A
6618603	12/2002	Varalli et al.	N/A	N/A
6618934	12/2002	Feldman et al.	N/A	N/A
6620138	12/2002	Marrgi et al.	N/A	N/A
6633772	12/2002	Ford et al.	N/A	N/A
6635014	12/2002	Starkweather et al.	N/A	N/A
6641533	12/2002	Causey, III et al.	N/A	N/A
6642015	12/2002	Vachon et al.	N/A	N/A
6645181	12/2002	Lavi et al.	N/A	N/A
6648821	12/2002	Lebel et al.	N/A	N/A
6653091	12/2002	Dunn et al.	N/A	N/A
6654625	12/2002	Say et al.	N/A	N/A
6656114	12/2002	Poulsen et al.	N/A	N/A
6656157	12/2002	Duchon et al.	N/A	N/A
6663615	12/2002	Madou et al.	N/A	N/A
6673022	12/2003	Bobo et al.	N/A	N/A
6673596	12/2003	Sayler et al.	N/A	N/A
6679865	12/2003	Shekalim	N/A	N/A
6679872	12/2003	Turovskiy et al.	N/A	N/A
6683535	12/2003	Utke	N/A	N/A
6684904	12/2003	Ito	N/A	N/A
6685668	12/2003	Cho et al.	N/A	N/A
6687522	12/2003	Tamada	N/A	N/A
6689089	12/2003	Tiedtke et al.	N/A	N/A
6689265	12/2003	Heller et al.	N/A	N/A
6694191	12/2003	Starkweather et al.	N/A	N/A
6695860	12/2003	Ward et al.	N/A	N/A
6699188	12/2003	Wessel	N/A	N/A
6699218	12/2003	Flaherty et al.	N/A	N/A
6699383	12/2003	Lemire et al.	N/A	N/A
6702249	12/2003	Ito	N/A	N/A
6702857	12/2003	Brauker et al.	N/A	N/A
6702972	12/2003	Markle	N/A	N/A
6711424	12/2003	Fine et al.	N/A	N/A
6712796	12/2003	Fentis et al.	N/A	N/A
6721587	12/2003	Gough	N/A	N/A
6723086	12/2003	Bassuk et al.	N/A	N/A
6731976	12/2003	Penn et al.	N/A	N/A
6736783	12/2003	Blake et al.	N/A	N/A

6740072	12/2003	Starkweather et al.	N/A	N/A
6740075	12/2003	Lebel et al.	N/A	N/A
6741877	12/2003	Shults et al.	N/A	N/A
6742635	12/2003	Hirshberg	N/A	N/A
6743635	12/2003	Neel et al.	N/A	N/A
6749587	12/2003	Flaherty	N/A	N/A
6750055	12/2003	Connelly et al.	N/A	N/A
6770030	12/2003	Schaupp et al.	N/A	N/A
6770067	12/2003	Lorenzen et al.	N/A	N/A
6773565	12/2003	Kunimoto et al.	N/A	N/A
6780297	12/2003	Matsumoto et al.	N/A	N/A
6793632	12/2003	Sohrab	N/A	N/A
6801041	12/2003	Karinka et al.	N/A	N/A
6802957	12/2003	Jung et al.	N/A	N/A
6804002	12/2003	Fine et al.	N/A	N/A
6805693	12/2003	Gray et al.	N/A	N/A
6809653	12/2003	Mann et al.	N/A	N/A
6810290	12/2003	Lebel et al.	N/A	N/A
6811548	12/2003	Jeffrey	N/A	N/A
6813519	12/2003	Lebel et al.	N/A	N/A
6832200	12/2003	Greeven et al.	N/A	N/A
6850790	12/2004	Berner et al.	N/A	N/A
6858020	12/2004	Rusnak	N/A	N/A
6862465	12/2004	Shults et al.	N/A	N/A
6869413	12/2004	Langley et al.	N/A	N/A
6875195	12/2004	Choi	N/A	N/A
6887228	12/2004	McKay	N/A	N/A
6892085	12/2004	McIvor et al.	N/A	N/A
6893552	12/2004	Wang et al.	N/A	N/A
6895263	12/2004	Shin et al.	N/A	N/A
6895265	12/2004	Silver	N/A	N/A
6902544	12/2004	Ludin et al.	N/A	N/A
6925393	12/2004	Kalatz et al.	N/A	N/A
6926691	12/2004	Miethke	N/A	N/A
6931327	12/2004	Goode, Jr. et al.	N/A	N/A
6932584	12/2004	Gray et al.	N/A	N/A
6936006	12/2004	Sabra	N/A	N/A
6936029	12/2004	Mann et al.	N/A	N/A
6945965	12/2004	Whiting	N/A	N/A
6948492	12/2004	Wermeling et al.	N/A	N/A
6952604	12/2004	Denuzzio et al.	N/A	N/A
6954662	12/2004	Freger et al.	N/A	N/A
6960192	12/2004	Flaherty et al.	N/A	N/A
6965791	12/2004	Hitchcock et al.	N/A	N/A
6966325	12/2004	Erickson	N/A	N/A
6975893	12/2004	Say et al.	N/A	N/A
6979315	12/2004	Rogers et al.	N/A	N/A
6989891	12/2005	Braig et al.	N/A	N/A
6997921	12/2005	Gray et al.	N/A	N/A
6998247	12/2005	Monfre et al.	N/A	N/A

7008979	12/2005	Schottman et al.	N/A	N/A
7011630	12/2005	Desai et al.	N/A	N/A
7016713	12/2005	Gardner et al.	N/A	N/A
7022072	12/2005	Fox et al.	N/A	N/A
7022219	12/2005	Mansouri et al.	N/A	N/A
7025727	12/2005	Brockway et al.	N/A	N/A
7025743	12/2005	Mann et al.	N/A	N/A
7027848	12/2005	Robinson et al.	N/A	N/A
7029444	12/2005	Shin et al.	N/A	N/A
7033322	12/2005	Silver	N/A	N/A
7044911	12/2005	Drinan et al.	N/A	N/A
7048727	12/2005	Moss	N/A	N/A
7058437	12/2005	Buse et al.	N/A	N/A
7060059	12/2005	Keith et al.	N/A	N/A
7061593	12/2005	Braig et al.	N/A	N/A
7063086	12/2005	Shahbazpour et al.	N/A	N/A
7066884	12/2005	Custer et al.	N/A	N/A
7070577	12/2005	Haller et al.	N/A	N/A
7074307	12/2005	Simpson et al.	N/A	N/A
7081195	12/2005	Simpson et al.	N/A	N/A
7097775	12/2005	Greenberg et al.	N/A	N/A
7098803	12/2005	Mann et al.	N/A	N/A
7100628	12/2005	Izenson et al.	N/A	N/A
7108778	12/2005	Simpson et al.	N/A	N/A
7120483	12/2005	Russell et al.	N/A	N/A
7131967	12/2005	Gray et al.	N/A	N/A
7134999	12/2005	Brauker et al.	N/A	N/A
7136689	12/2005	Shults et al.	N/A	N/A
7146202	12/2005	Ward et al.	N/A	N/A
7150741	12/2005	Erickson et al.	N/A	N/A
7162290	12/2006	Levin	N/A	N/A
7166074	12/2006	Reghabi et al.	N/A	N/A
7168597	12/2006	Jones et al.	N/A	N/A
7169289	12/2006	Schuelein et al.	N/A	N/A
7183102	12/2006	Monfre et al.	N/A	N/A
7184810	12/2006	Caduff et al.	N/A	N/A
7207968	12/2006	Harcinske	N/A	N/A
7211074	12/2006	Sansoucy	N/A	N/A
7221970	12/2006	Parker	N/A	N/A
7223253	12/2006	Hogendijk	N/A	N/A
7225535	12/2006	Feldman et al.	N/A	N/A
7228162	12/2006	Ward et al.	N/A	N/A
7229288	12/2006	Stuart et al.	N/A	N/A
7238165	12/2006	Vincent et al.	N/A	N/A
7247138	12/2006	Reghabi et al.	N/A	N/A
7254450	12/2006	Christopherson et al.	N/A	N/A
7255690	12/2006	Gray et al.	N/A	N/A
7258681	12/2006	Houde	N/A	N/A
7261690	12/2006	Teller et al.	N/A	N/A

7266400	12/2006	Fine et al.	N/A	N/A
7267665	12/2006	Steil et al.	N/A	N/A
7276029	12/2006	Goode, Jr. et al.	N/A	N/A
7278983	12/2006	Ireland et al.	N/A	N/A
7279174	12/2006	Pacetti et al.	N/A	N/A
7282029	12/2006	Poulsen et al.	N/A	N/A
7288085	12/2006	Olsen	N/A	N/A
7291114	12/2006	Mault	N/A	N/A
7295867	12/2006	Berner et al.	N/A	N/A
7299082	12/2006	Feldman et al.	N/A	N/A
7311690	12/2006	Burnett	N/A	N/A
7313425	12/2006	Finarov et al.	N/A	N/A
7314452	12/2007	Madonia	N/A	N/A
7315767	12/2007	Caduff et al.	N/A	N/A
7316662	12/2007	Delnevo et al.	N/A	N/A
7317939	12/2007	Fine et al.	N/A	N/A
7318814	12/2007	Levine et al.	N/A	N/A
7327273	12/2007	Hung et al.	N/A	N/A
7329234	12/2007	Sansoucy	N/A	N/A
7334594	12/2007	Ludin	N/A	N/A
7335179	12/2007	Burnett	N/A	N/A
7335195	12/2007	Mehier	N/A	N/A
7338464	12/2007	Blischak et al.	N/A	N/A
7344500	12/2007	Talbot et al.	N/A	N/A
7354420	12/2007	Steil et al.	N/A	N/A
7357793	12/2007	Pacetti	N/A	N/A
7359723	12/2007	Jones	N/A	N/A
7361155	12/2007	Sage, Jr. et al.	N/A	N/A
7364562	12/2007	Braig et al.	N/A	N/A
7367942	12/2007	Grage et al.	N/A	N/A
7396353	12/2007	Lorenzen et al.	N/A	N/A
7399277	12/2007	Saidara et al.	N/A	N/A
7402153	12/2007	Steil et al.	N/A	N/A
7417164	12/2007	Suri	N/A	N/A
7426408	12/2007	Denuzzio et al.	N/A	N/A
7433727	12/2007	Ward et al.	N/A	N/A
7519408	12/2008	Rasdal et al.	N/A	N/A
7519478	12/2008	Bartkowiak et al.	N/A	N/A
7523004	12/2008	Bartkowiak et al.	N/A	N/A
7534230	12/2008	Follman et al.	N/A	N/A
7569030	12/2008	Lebel et al.	N/A	N/A
7583990	12/2008	Goode, Jr. et al.	N/A	N/A
7591801	12/2008	Brauker et al.	N/A	N/A
7599726	12/2008	Goode, Jr. et al.	N/A	N/A
7604593	12/2008	Parris et al.	N/A	N/A
7615007	12/2008	Shults et al.	N/A	N/A
7618368	12/2008	Brown	N/A	N/A
7618369	12/2008	Hayter et al.	N/A	N/A
7624028	12/2008	Brown	N/A	N/A
7640032	12/2008	Jones	N/A	N/A

7640048	12/2008	Dobbles et al.	N/A	N/A
7647237	12/2009	Malave et al.	N/A	N/A
7654955	12/2009	Polidori et al.	N/A	N/A
7657297	12/2009	Simpson et al.	N/A	N/A
7670288	12/2009	Sher	N/A	N/A
7695434	12/2009	Malecha	N/A	N/A
7727147	12/2009	Osorio et al.	N/A	N/A
7731659	12/2009	Malecha	N/A	N/A
7761126	12/2009	Gardner et al.	N/A	N/A
7766830	12/2009	Fox et al.	N/A	N/A
7857760	12/2009	Brister et al.	N/A	N/A
7901394	12/2010	Ireland et al.	N/A	N/A
7905833	12/2010	Brister et al.	N/A	N/A
7927274	12/2010	Rasdal et al.	N/A	N/A
7946985	12/2010	Mastrototaro et al.	N/A	N/A
7976492	12/2010	Brauker et al.	N/A	N/A
8000901	12/2010	Brauker et al.	N/A	N/A
8005524	12/2010	Brauker et al.	N/A	N/A
8005525	12/2010	Goode, Jr. et al.	N/A	N/A
8010174	12/2010	Goode, Jr. et al.	N/A	N/A
8460231	12/2012	Brauker et al.	N/A	N/A
8512276	12/2012	Talbot et al.	N/A	N/A
8721585	12/2013	Brauker et al.	N/A	N/A
8808228	12/2013	Brister et al.	N/A	N/A
8882741	12/2013	Brauker et al.	N/A	N/A
8920401	12/2013	Brauker et al.	N/A	N/A
8926585	12/2014	Brauker et al.	N/A	N/A
9050413	12/2014	Brauker et al.	N/A	N/A
9155843	12/2014	Brauker et al.	N/A	N/A
9451908	12/2015	Kamath	N/A	A61B 5/1473
9452258	12/2015	Dobbles et al.	N/A	N/A
9452259	12/2015	Dobbles et al.	N/A	N/A
9457146	12/2015	Dobbles et al.	N/A	N/A
9463277	12/2015	Dobbles et al.	N/A	N/A
9498155	12/2015	Brauker et al.	N/A	N/A
9572935	12/2016	Dobbles et al.	N/A	N/A
9572936	12/2016	Dobbles et al.	N/A	N/A
9586004	12/2016	Dobbles et al.	N/A	N/A
9597453	12/2016	Dobbles et al.	N/A	N/A
9750441	12/2016	Brauker et al.	N/A	N/A
9827372	12/2016	Dobbles et al.	N/A	N/A
9937293	12/2017	Brauker et al.	N/A	N/A
10278580	12/2018	Brister et al.	N/A	N/A
10653835	12/2019	Dobbles et al.	N/A	N/A
10966609	12/2020	Brister et al.	N/A	N/A
11373347	12/2021	Kamath et al.	N/A	N/A
11744943	12/2022	Dobbles et al.	N/A	N/A
2001/0007950	12/2000	North et al.	N/A	N/A
2001/0016682	12/2000	Berner et al.	N/A	N/A

2001/0021817	12/2000	Brugger et al.	N/A	N/A
2001/0039053	12/2000	Liseo et al.	N/A	N/A
2001/0041830	12/2000	Varalli et al.	N/A	N/A
2001/0044588	12/2000	Mault	N/A	N/A
2001/0051768	12/2000	Schulman et al.	N/A	N/A
2002/0009810	12/2001	O'Connor et al.	N/A	N/A
2002/0016535	12/2001	Martin et al.	N/A	N/A
2002/0016719	12/2001	Nemeth et al.	N/A	N/A
2002/0018843	12/2001	Van Antwerp et al.	N/A	N/A
2002/0019022	12/2001	Dunn et al.	N/A	N/A
2002/0019330	12/2001	Murray et al.	N/A	N/A
2002/0022883	12/2001	Burg	N/A	N/A
2002/0023852	12/2001	McIvor et al.	N/A	N/A
2002/0026110	12/2001	Parris et al.	N/A	N/A
2002/0026111	12/2001	Ackerman	N/A	N/A
2002/0042090	12/2001	Heller et al.	N/A	N/A
2002/0042561	12/2001	Schulman et al.	N/A	N/A
2002/0043471	12/2001	Ikeda et al.	N/A	N/A
2002/0045808	12/2001	Ford et al.	N/A	N/A
2002/0060692	12/2001	Broemmelsiek	N/A	N/A
2002/0065453	12/2001	Lesho et al.	N/A	N/A
2002/0068860	12/2001	Clark	N/A	N/A
2002/0071776	12/2001	Bandis et al.	N/A	N/A
2002/0084196	12/2001	Liamos et al.	N/A	N/A
2002/0099282	12/2001	Knobbe et al.	N/A	N/A
2002/0099997	12/2001	Piret	N/A	N/A
2002/0111547	12/2001	Knobbe et al.	N/A	N/A
2002/0119711	12/2001	Vanantwerp et al.	N/A	N/A
2002/0123048	12/2001	Gau	N/A	N/A
2002/0133224	12/2001	Bajgar et al.	N/A	N/A
2002/0151796	12/2001	Koulik	N/A	N/A
2002/0155615	12/2001	Novikov et al.	N/A	N/A
2002/0161288	12/2001	Shin et al.	N/A	N/A
2002/0182241	12/2001	Borenstein et al.	N/A	N/A
2002/0188185	12/2001	Sohrab	N/A	N/A
2002/0193679	12/2001	Malave et al.	N/A	N/A
2002/0193885	12/2001	Legeay et al.	N/A	N/A
2002/0198513	12/2001	Lebel et al.	N/A	N/A
2003/0004432	12/2002	Assenheimer	N/A	N/A
2003/0006669	12/2002	Pei et al.	N/A	N/A
2003/0021729	12/2002	Moller et al.	N/A	N/A
2003/0023171	12/2002	Sato et al.	N/A	N/A
2003/0023317	12/2002	Brauker et al.	N/A	N/A
2003/0028089	12/2002	Galley et al.	N/A	N/A
2003/0031699	12/2002	Van Antwerp	N/A	N/A
2003/0032874	12/2002	Rhodes et al.	N/A	N/A
2003/0050546	12/2002	Desai et al.	N/A	N/A
2003/0054428	12/2002	Monfre et al.	N/A	N/A
2003/0060692	12/2002	L. Ruchti et al.	N/A	N/A
2003/0060753	12/2002	Starkweather et al.	N/A	N/A

2003/0060765	12/2002	Campbell et al.	N/A	N/A
2003/0070548	12/2002	Clausen	N/A	N/A
2003/0072741	12/2002	Berglund et al.	N/A	N/A
2003/0076082	12/2002	Morgan et al.	N/A	N/A
2003/0078481	12/2002	McIvor et al.	N/A	N/A
2003/0078560	12/2002	Miller et al.	N/A	N/A
2003/0088238	12/2002	Poulsen et al.	N/A	N/A
2003/0091433	12/2002	Tam et al.	N/A	N/A
2003/0097082	12/2002	Purdy et al.	N/A	N/A
2003/0099682	12/2002	Moussy et al.	N/A	N/A
2003/0100040	12/2002	Bonnecaze et al.	N/A	N/A
2003/0100821	12/2002	Heller et al.	N/A	N/A
2003/0114836	12/2002	Estes et al.	N/A	N/A
2003/0117296	12/2002	Seely	N/A	N/A
2003/0119208	12/2002	Yoon et al.	N/A	N/A
2003/0120152	12/2002	Omiya	N/A	N/A
2003/0125612	12/2002	Fox et al.	N/A	N/A
2003/0125613	12/2002	Enegren et al.	N/A	N/A
2003/0130616	12/2002	Steil et al.	N/A	N/A
2003/0132227	12/2002	Geisler et al.	N/A	N/A
2003/0134347	12/2002	Heller et al.	N/A	N/A
2003/0143746	12/2002	Sage	N/A	N/A
2003/0153821	12/2002	Berner et al.	N/A	N/A
2003/0176183	12/2002	Drucker et al.	N/A	N/A
2003/0187338	12/2002	Say et al.	N/A	N/A
2003/0188427	12/2002	Say et al.	N/A	N/A
2003/0199744	12/2002	Buse et al.	N/A	N/A
2003/0199745	12/2002	Burson et al.	N/A	N/A
2003/0208113	12/2002	Mault et al.	N/A	N/A
2003/0211050	12/2002	Majeti et al.	N/A	N/A
2003/0211625	12/2002	Cohan et al.	N/A	N/A
2003/0212317	12/2002	Kovatchev et al.	N/A	N/A
2003/0212346	12/2002	Yuzhakov et al.	N/A	N/A
2003/0212347	12/2002	Sohrab	N/A	N/A
2003/0212379	12/2002	Bylund et al.	N/A	N/A
2003/0225324	12/2002	Anderson et al.	N/A	N/A
2003/0225437	12/2002	Ferguson	N/A	N/A
2003/0231550	12/2002	Macfarlane	N/A	N/A
2003/0235817	12/2002	Bartkowiak et al.	N/A	N/A
2004/0006263	12/2003	Anderson et al.	N/A	N/A
2004/0010207	12/2003	Flaherty et al.	N/A	N/A
2004/0011671	12/2003	Shults et al.	N/A	N/A
2004/0015063	12/2003	Denuzzio et al.	N/A	N/A
2004/0015134	12/2003	Lavi et al.	N/A	N/A
2004/0023253	12/2003	Kunwar et al.	N/A	N/A
2004/0023317	12/2003	Motamedi et al.	N/A	N/A
2004/0024327	12/2003	Brodnick	N/A	N/A
2004/0030285	12/2003	Lavi et al.	N/A	N/A
2004/0030294	12/2003	Mahurkar	N/A	N/A
2004/0039298	12/2003	Abreu	N/A	N/A

2004/0039406	12/2003	Jessen	N/A	N/A
2004/0040840	12/2003	Mao et al.	N/A	N/A
2004/0044272	12/2003	Moerman et al.	N/A	N/A
2004/0045879	12/2003	Shults et al.	N/A	N/A
2004/0052689	12/2003	Yao	N/A	N/A
2004/0054352	12/2003	Adams et al.	N/A	N/A
2004/0068230	12/2003	Estes et al.	N/A	N/A
2004/0074785	12/2003	Holker et al.	N/A	N/A
2004/0078219	12/2003	Kaylor et al.	N/A	N/A
2004/0106857	12/2003	Gough	N/A	N/A
2004/0122297	12/2003	Stahmann et al.	N/A	N/A
2004/0122353	12/2003	Shahmirian et al.	N/A	N/A
2004/0138543	12/2003	Russell et al.	N/A	N/A
2004/0143173	12/2003	Reghabi et al.	N/A	N/A
2004/0146909	12/2003	Duong et al.	N/A	N/A
2004/0152187	12/2003	Haight et al.	N/A	N/A
2004/0152622	12/2003	Keith et al.	N/A	N/A
2004/0162678	12/2003	Hetzel et al.	N/A	N/A
2004/0167801	12/2003	Say et al.	N/A	N/A
2004/0173472	12/2003	Jung et al.	N/A	N/A
2004/0176672	12/2003	Silver et al.	N/A	N/A
2004/0180391	12/2003	Gratzl et al.	N/A	N/A
2004/0186362	12/2003	Brauker et al.	N/A	N/A
2004/0186365	12/2003	Jin et al.	N/A	N/A
2004/0193025	12/2003	Steil et al.	N/A	N/A
2004/0199059	12/2003	Brauker et al.	N/A	N/A
2004/0204687	12/2003	Mogensen et al.	N/A	N/A
2004/0219664	12/2003	Heller et al.	N/A	N/A
2004/0220517	12/2003	Starkweather et al.	N/A	N/A
2004/0224001	12/2003	Pacetti et al.	N/A	N/A
2004/0248282	12/2003	Sobha M et al.	N/A	N/A
2004/0253365	12/2003	Warren et al.	N/A	N/A
2004/0254433	12/2003	Bandis et al.	N/A	N/A
2005/0003399	12/2004	Blackburn et al.	N/A	N/A
2005/0010265	12/2004	Baru et al.	N/A	N/A
2005/0026689	12/2004	Marks	N/A	N/A
2005/0027180	12/2004	Goode et al.	N/A	N/A
2005/0027181	12/2004	Goode et al.	N/A	N/A
2005/0027182	12/2004	Siddiqui et al.	N/A	N/A
2005/0027462	12/2004	Goode et al.	N/A	N/A
2005/0027463	12/2004	Goode et al.	N/A	N/A
2005/0031689	12/2004	Shults et al.	N/A	N/A
2005/0033132	12/2004	Shults et al.	N/A	N/A
2005/0038332	12/2004	Saidara et al.	N/A	N/A
2005/0043598	12/2004	Goode, Jr. et al.	N/A	N/A
2005/0049472	12/2004	Manda et al.	N/A	N/A
2005/0051427	12/2004	Brauker et al.	N/A	N/A
2005/0051440	12/2004	Simpson et al.	N/A	N/A
2005/0054909	12/2004	Petisce et al.	N/A	N/A
2005/0056552	12/2004	Simpson et al.	N/A	N/A

2005/0065464	12/2004	Talbot et al.	N/A	N/A
2005/0077584	12/2004	Uhland et al.	N/A	N/A
2005/0090607	12/2004	Tapsak et al.	N/A	N/A
2005/0096519	12/2004	Denuzzio et al.	N/A	N/A
2005/0101847	12/2004	Routt et al.	N/A	N/A
2005/0107677	12/2004	Ward et al.	N/A	N/A
2005/0112169	12/2004	Brauker et al.	N/A	N/A
2005/0113653	12/2004	Fox et al.	N/A	N/A
2005/0113744	12/2004	Donoghue et al.	N/A	N/A
2005/0115832	12/2004	Simpson et al.	N/A	N/A
2005/0118344	12/2004	Pacetti	N/A	N/A
2005/0119720	12/2004	Gale et al.	N/A	N/A
2005/0121322	12/2004	Say et al.	N/A	N/A
2005/0124873	12/2004	Shults et al.	N/A	N/A
2005/0131305	12/2004	Danielson et al.	N/A	N/A
2005/0139489	12/2004	Davies et al.	N/A	N/A
2005/0143635	12/2004	Kamath et al.	N/A	N/A
2005/0143675	12/2004	Neel et al.	N/A	N/A
2005/0154271	12/2004	Rasdal et al.	N/A	N/A
2005/0176136	12/2004	Burd et al.	N/A	N/A
2005/0177036	12/2004	Shults et al.	N/A	N/A
2005/0177398	12/2004	Watanabe et al.	N/A	N/A
2005/0181012	12/2004	Saint et al.	N/A	N/A
2005/0182451	12/2004	Griffin et al.	N/A	N/A
2005/0183954	12/2004	Hitchcock et al.	N/A	N/A
2005/0187720	12/2004	Goode, Jr. et al.	N/A	N/A
2005/0192557	12/2004	Brauker	604/503	A61B 5/14865
2005/0197553	12/2004	Cooper	N/A	N/A
2005/0197554	12/2004	Polcha	N/A	N/A
2005/0203360	12/2004	Brauker	600/345	A61B 5/7275
2005/0211571	12/2004	Schulein et al.	N/A	N/A
2005/0215871	12/2004	Feldman et al.	N/A	N/A
2005/0215872	12/2004	Berner et al.	N/A	N/A
2005/0239154	12/2004	Feldman et al.	N/A	N/A
2005/0242479	12/2004	Petisce et al.	N/A	N/A
2005/0245795	12/2004	Goode et al.	N/A	N/A
2005/0245799	12/2004	Brauker et al.	N/A	N/A
2005/0245904	12/2004	Estes et al.	N/A	N/A
2005/0251083	12/2004	Carr-Brendel et al.	N/A	N/A
2005/0261563	12/2004	Zhou et al.	N/A	N/A
2005/0288596	12/2004	Eigler et al.	N/A	N/A
2006/0001550	12/2005	Mann et al.	N/A	N/A
2006/0015020	12/2005	Neale et al.	N/A	N/A
2006/0015024	12/2005	Brister et al.	N/A	N/A
2006/0016700	12/2005	Brister et al.	N/A	N/A
2006/0019327	12/2005	Brister et al.	N/A	N/A
2006/0020186	12/2005	Brister et al.	N/A	N/A
2006/0020187	12/2005	Brister et al.	N/A	N/A

2006/0020188	12/2005	Kamath et al.	N/A	N/A
2006/0020189	12/2005	Brister et al.	N/A	N/A
2006/0020190	12/2005	Kamath et al.	N/A	N/A
2006/0020191	12/2005	Brister et al.	N/A	N/A
2006/0020192	12/2005	Brister et al.	N/A	N/A
2006/0036139	12/2005	Brister et al.	N/A	N/A
2006/0036140	12/2005	Brister et al.	N/A	N/A
2006/0036141	12/2005	Kamath et al.	N/A	N/A
2006/0036142	12/2005	Brister et al.	N/A	N/A
2006/0036143	12/2005	Brister et al.	N/A	N/A
2006/0036144	12/2005	Brister et al.	N/A	N/A
2006/0036145	12/2005	Brister et al.	N/A	N/A
2006/0040402	12/2005	Brauker et al.	N/A	N/A
2006/0047095	12/2005	Pacetti	N/A	N/A
2006/0052745	12/2005	Van Antwerp et al.	N/A	N/A
2006/0067908	12/2005	Ding	N/A	N/A
2006/0078908	12/2005	Pitner et al.	N/A	N/A
2006/0079740	12/2005	Silver et al.	N/A	N/A
2006/0079809	12/2005	Goldberger et al.	N/A	N/A
2006/0094946	12/2005	Kellogg et al.	N/A	N/A
2006/0100588	12/2005	Brunnberg et al.	N/A	N/A
2006/0134165	12/2005	Pacetti	N/A	N/A
2006/0171980	12/2005	Helmus et al.	N/A	N/A
2006/0173406	12/2005	Hayes et al.	N/A	N/A
2006/0177379	12/2005	Asgari	N/A	N/A
2006/0183871	12/2005	Ward et al.	N/A	N/A
2006/0183984	12/2005	Dobbles et al.	N/A	N/A
2006/0183985	12/2005	Brister et al.	N/A	N/A
2006/0189863	12/2005	Peyser et al.	N/A	N/A
2006/0195029	12/2005	Shults et al.	N/A	N/A
2006/0222566	12/2005	Brauker et al.	N/A	N/A
2006/0224141	12/2005	Rush et al.	N/A	N/A
2006/0253085	12/2005	Geismar et al.	N/A	N/A
2006/0258929	12/2005	Goode, Jr. et al.	N/A	N/A
2006/0263839	12/2005	Ward et al.	N/A	N/A
2006/0269586	12/2005	Pacetti	N/A	N/A
2006/0275857	12/2005	Kjaer et al.	N/A	N/A
2006/0281985	12/2005	Ward et al.	N/A	N/A
2007/0007133	12/2006	Mang et al.	N/A	N/A
2007/0016381	12/2006	Kamath et al.	N/A	N/A
2007/0027385	12/2006	Brister et al.	N/A	N/A
2007/0032706	12/2006	Kamath et al.	N/A	N/A
2007/0038044	12/2006	Dobbles et al.	N/A	N/A
2007/0049873	12/2006	Hansen et al.	N/A	N/A
2007/0066873	12/2006	Kamath et al.	N/A	N/A
2007/0066956	12/2006	Finkel	N/A	N/A
2007/0085995	12/2006	Pesach et al.	N/A	N/A
2007/0100222	12/2006	Mastrototaro et al.	N/A	N/A
2007/0106135	12/2006	Sloan et al.	N/A	N/A
2007/0112298	12/2006	Mueller, Jr. et al.	N/A	N/A

2007/0116600	12/2006	Kochar et al.	N/A	N/A
2007/0129619	12/2006	Ward et al.	N/A	N/A
2007/0129621	12/2006	Kellogg et al.	N/A	N/A
2007/0135698	12/2006	Shah et al.	N/A	N/A
2007/0135699	12/2006	Ward et al.	N/A	N/A
2007/0151869	12/2006	Heller et al.	N/A	N/A
2007/0173706	12/2006	Neinast et al.	N/A	N/A
2007/0173710	12/2006	Petisce et al.	N/A	N/A
2007/0173761	12/2006	Kanderian, Jr. et al.	N/A	N/A
2007/0179434	12/2006	Weinert et al.	N/A	N/A
2007/0197889	12/2006	Brister et al.	N/A	N/A
2007/0200254	12/2006	Curry	N/A	N/A
2007/0200267	12/2006	Tsai	N/A	N/A
2007/0203407	12/2006	Hoss et al.	N/A	N/A
2007/0203410	12/2006	Say et al.	N/A	N/A
2007/0203966	12/2006	Brauker et al.	N/A	N/A
2007/0206193	12/2006	Pesach	N/A	N/A
2007/0208244	12/2006	Brauker et al.	N/A	N/A
2007/0208245	12/2006	Brauker et al.	N/A	N/A
2007/0208246	12/2006	Brauker et al.	N/A	N/A
2007/0213610	12/2006	Say et al.	N/A	N/A
2007/0218097	12/2006	Heller et al.	N/A	N/A
2007/0219441	12/2006	Carlin et al.	N/A	N/A
2007/0225579	12/2006	Lucassen et al.	N/A	N/A
2007/0225675	12/2006	Robinson et al.	N/A	N/A
2007/0227907	12/2006	Shah et al.	N/A	N/A
2007/0233013	12/2006	Schoenberg	N/A	N/A
2007/0233051	12/2006	Hohl et al.	N/A	N/A
2007/0235331	12/2006	Simpson et al.	N/A	N/A
2007/0240497	12/2006	Robinson et al.	N/A	N/A
2007/0244381	12/2006	Robinson et al.	N/A	N/A
2007/0244382	12/2006	Robinson et al.	N/A	N/A
2007/0249916	12/2006	Pesach et al.	N/A	N/A
2007/0255126	12/2006	Moberg et al.	N/A	N/A
2007/0275193	12/2006	Desimone et al.	N/A	N/A
2007/0293742	12/2006	Simonsen et al.	N/A	N/A
2007/0299409	12/2006	Whitbourne et al.	N/A	N/A
2008/0021666	12/2007	Goode, Jr. et al.	N/A	N/A
2008/0021668	12/2007	Son	N/A	N/A
2008/0027301	12/2007	Ward et al.	N/A	N/A
2008/0029390	12/2007	Roche et al.	N/A	N/A
2008/0029391	12/2007	Mao et al.	N/A	N/A
2008/0033254	12/2007	Kamath et al.	N/A	N/A
2008/0034972	12/2007	Gough et al.	N/A	N/A
2008/0045824	12/2007	Tapsak et al.	N/A	N/A
2008/0071157	12/2007	McGarraugh et al.	N/A	N/A
2008/0071158	12/2007	McGarraugh et al.	N/A	N/A
2008/0072663	12/2007	Keenan et al.	N/A	N/A
2008/0086040	12/2007	Heller et al.	N/A	N/A
2008/0086041	12/2007	Heller et al.	N/A	N/A

2008/0086042	12/2007	Brister et al.	N/A	N/A
2008/0086043	12/2007	Heller et al.	N/A	N/A
2008/0086044	12/2007	Brister et al.	N/A	N/A
2008/0086273	12/2007	Shults et al.	N/A	N/A
2008/0091094	12/2007	Heller et al.	N/A	N/A
2008/0091095	12/2007	Heller et al.	N/A	N/A
2008/0097289	12/2007	Steil et al.	N/A	N/A
2008/0108942	12/2007	Brister et al.	N/A	N/A
2008/0119703	12/2007	Brister et al.	N/A	N/A
2008/0119704	12/2007	Brister et al.	N/A	N/A
2008/0119706	12/2007	Brister et al.	N/A	N/A
2008/0125751	12/2007	Fjield et al.	N/A	N/A
2008/0139910	12/2007	Mastrototaro et al.	N/A	N/A
2008/0154101	12/2007	Jain et al.	N/A	N/A
2008/0183061	12/2007	Goode et al.	N/A	N/A
2008/0183399	12/2007	Goode et al.	N/A	N/A
2008/0187655	12/2007	Markle et al.	N/A	N/A
2008/0188722	12/2007	Markle et al.	N/A	N/A
2008/0188725	12/2007	Markle et al.	N/A	N/A
2008/0188731	12/2007	Brister et al.	N/A	N/A
2008/0189051	12/2007	Goode et al.	N/A	N/A
2008/0193936	12/2007	Squirrell	N/A	N/A
2008/0194837	12/2007	Kim et al.	N/A	N/A
2008/0194935	12/2007	Brister et al.	N/A	N/A
2008/0194936	12/2007	Goode et al.	N/A	N/A
2008/0194937	12/2007	Goode et al.	N/A	N/A
2008/0195967	12/2007	Goode et al.	N/A	N/A
2008/0197024	12/2007	Simpson et al.	N/A	N/A
2008/0200788	12/2007	Brister et al.	N/A	N/A
2008/0200789	12/2007	Brister et al.	N/A	N/A
2008/0200791	12/2007	Simpson et al.	N/A	N/A
2008/0208025	12/2007	Shults et al.	N/A	N/A
2008/0210557	12/2007	Heller et al.	N/A	N/A
2008/0214915	12/2007	Brister et al.	N/A	N/A
2008/0262469	12/2007	Brister et al.	N/A	N/A
2008/0269723	12/2007	Mastrototaro et al.	N/A	N/A
2008/0287764	12/2007	Rasdal et al.	N/A	N/A
2008/0287765	12/2007	Rasdal et al.	N/A	N/A
2008/0287766	12/2007	Rasdal et al.	N/A	N/A
2008/0296155	12/2007	Shults et al.	N/A	N/A
2008/0300572	12/2007	Rankers et al.	N/A	N/A
2008/0305009	12/2007	Gamsey et al.	N/A	N/A
2008/0305506	12/2007	Suri	N/A	N/A
2008/0306368	12/2007	Goode, Jr. et al.	N/A	N/A
2008/0306433	12/2007	Cesaroni	N/A	N/A
2008/0306434	12/2007	Dobbles et al.	N/A	N/A
2008/0306435	12/2007	Kamath et al.	N/A	N/A
2008/0306444	12/2007	Brister et al.	N/A	N/A
2009/0005666	12/2008	Shin et al.	N/A	N/A
2009/0012379	12/2008	Goode, Jr. et al.	N/A	N/A

2009/0018418	12/2008	Markle et al.	N/A	N/A
2009/0018424	12/2008	Kamath et al.	N/A	N/A
2009/0018426	12/2008	Markle et al.	N/A	N/A
2009/0036758	12/2008	Brauker et al.	N/A	N/A
2009/0043181	12/2008	Brauker et al.	N/A	N/A
2009/0043182	12/2008	Brauker et al.	N/A	N/A
2009/0043525	12/2008	Brauker et al.	N/A	N/A
2009/0043541	12/2008	Brauker et al.	N/A	N/A
2009/0043542	12/2008	Brauker et al.	N/A	N/A
2009/0061528	12/2008	Suri	N/A	N/A
2009/0062635	12/2008	Brauker et al.	N/A	N/A
2009/0062645	12/2008	Fehre et al.	N/A	N/A
2009/0076356	12/2008	Simpson et al.	N/A	N/A
2009/0076360	12/2008	Brister et al.	N/A	N/A
2009/0076361	12/2008	Kamath et al.	N/A	N/A
2009/0081803	12/2008	Gamsey et al.	N/A	N/A
2009/0099434	12/2008	Liu et al.	N/A	N/A
2009/0124877	12/2008	Goode, Jr. et al.	N/A	N/A
2009/0124878	12/2008	Goode, Jr. et al.	N/A	N/A
2009/0124964	12/2008	Leach et al.	N/A	N/A
2009/0131768	12/2008	Simpson et al.	N/A	N/A
2009/0131769	12/2008	Leach et al.	N/A	N/A
2009/0131776	12/2008	Simpson et al.	N/A	N/A
2009/0131777	12/2008	Simpson et al.	N/A	N/A
2009/0137886	12/2008	Shariati et al.	N/A	N/A
2009/0137887	12/2008	Shariati et al.	N/A	N/A
2009/0143659	12/2008	Li et al.	N/A	N/A
2009/0156924	12/2008	Shariati et al.	N/A	N/A
2009/0177143	12/2008	Markle et al.	N/A	N/A
2009/0178459	12/2008	Li et al.	N/A	N/A
2009/0182217	12/2008	Li et al.	N/A	N/A
2009/0192366	12/2008	Mensinger et al.	N/A	N/A
2009/0192380	12/2008	Shariati et al.	N/A	N/A
2009/0192722	12/2008	Shariati et al.	N/A	N/A
2009/0192724	12/2008	Brauker et al.	N/A	N/A
2009/0192745	12/2008	Kamath et al.	N/A	N/A
2009/0192751	12/2008	Kamath et al.	N/A	N/A
2009/0203981	12/2008	Brauker et al.	N/A	N/A
2009/0204341	12/2008	Brauker et al.	N/A	N/A
2009/0216103	12/2008	Brister et al.	N/A	N/A
2009/0240120	12/2008	Mensinger et al.	N/A	N/A
2009/0240128	12/2008	Mensinger et al.	N/A	N/A
2009/0240193	12/2008	Mensinger et al.	N/A	N/A
2009/0242399	12/2008	Kamath et al.	N/A	N/A
2009/0242425	12/2008	Kamath et al.	N/A	N/A
2009/0264719	12/2008	Markle et al.	N/A	N/A
2009/0264856	12/2008	Lebel et al.	N/A	N/A
2009/0287074	12/2008	Shults et al.	N/A	N/A
2009/0299155	12/2008	Yang et al.	N/A	N/A
2009/0299156	12/2008	Simpson et al.	N/A	N/A

2009/0299162	12/2008	Brauker et al.	N/A	N/A
2009/0299276	12/2008	Brauker et al.	N/A	N/A
2010/0010324	12/2009	Brauker et al.	N/A	N/A
2010/0010331	12/2009	Brauker et al.	N/A	N/A
2010/0010332	12/2009	Brauker et al.	N/A	N/A
2010/0016687	12/2009	Brauker et al.	N/A	N/A
2010/0022855	12/2009	Brauker et al.	N/A	N/A
2010/0030053	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0030484	12/2009	Brauker et al.	N/A	N/A
2010/0030485	12/2009	Brauker et al.	N/A	N/A
2010/0036215	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0036216	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0036222	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0036223	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0036224	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0036225	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0041971	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0045465	12/2009	Brauker et al.	N/A	N/A
2010/0049024	12/2009	Saint et al.	N/A	N/A
2010/0076283	12/2009	Simpson et al.	N/A	N/A
2010/0081908	12/2009	Dobbles et al.	N/A	N/A
2010/0081910	12/2009	Brister et al.	N/A	N/A
2010/0161269	12/2009	Kamath et al.	N/A	N/A
2010/0179401	12/2009	Rasdal et al.	N/A	N/A
2010/0179407	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0179408	12/2009	Kamath et al.	N/A	N/A
2010/0179409	12/2009	Kamath et al.	N/A	N/A
2010/0234707	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0235106	12/2009	Kamath et al.	N/A	N/A
2010/0240975	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0240976	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0331656	12/2009	Mensinger et al.	N/A	N/A
2010/0331657	12/2009	Mensinger et al.	N/A	N/A
2011/0009727	12/2010	Mensinger et al.	N/A	N/A
2011/0118579	12/2010	Goode, Jr. et al.	N/A	N/A
2011/0124997	12/2010	Goode, Jr. et al.	N/A	N/A
2011/0130970	12/2010	Goode, Jr. et al.	N/A	N/A
2011/0137601	12/2010	Goode, Jr. et al.	N/A	N/A
2011/0201910	12/2010	Rasdal et al.	N/A	N/A
2011/0218414	12/2010	Kamath et al.	N/A	N/A
2011/0231107	12/2010	Brauker et al.	N/A	N/A
2011/0231140	12/2010	Goode, Jr. et al.	N/A	N/A
2011/0231141	12/2010	Goode, Jr. et al.	N/A	N/A
2011/0231142	12/2010	Goode, Jr. et al.	N/A	N/A
2011/0257895	12/2010	Brauker et al.	N/A	N/A
2011/0270158	12/2010	Brauker et al.	N/A	N/A
2012/0059673	12/2011	Cohen et al.	N/A	N/A
2012/0097289	12/2011	Chun et al.	N/A	N/A
2012/0186581	12/2011	Brauker et al.	N/A	N/A
2012/0190953	12/2011	Brauker et al.	N/A	N/A

2012/0191063	12/2011	Brauker et al.	N/A	N/A
2012/0215201	12/2011	Brauker et al.	N/A	N/A
2012/0220979	12/2011	Brauker et al.	N/A	N/A
2012/0227737	12/2011	Mastrototaro et al.	N/A	N/A
2012/0238852	12/2011	Brauker et al.	N/A	N/A
2012/0259278	12/2011	Hayes et al.	N/A	N/A
2012/0296311	12/2011	Brauker et al.	N/A	N/A
2018/0043096	12/2017	Dobbles et al.	N/A	N/A
2018/0185587	12/2017	Brauker et al.	N/A	N/A
2019/0070360	12/2018	Sloan et al.	N/A	N/A
2019/0209009	12/2018	Brister et al.	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
2127172	12/1997	CA	N/A
10103803	12/2000	DE	N/A
0098592	12/1983	EP	N/A
0107634	12/1983	EP	N/A
0127958	12/1983	EP	N/A
0286118	12/1987	EP	N/A
0288793	12/1987	EP	N/A
0320109	12/1988	EP	N/A
0352610	12/1989	EP	N/A
0352631	12/1989	EP	N/A
0353328	12/1989	EP	N/A
0390390	12/1989	EP	N/A
0396788	12/1989	EP	N/A
0406473	12/1990	EP	N/A
0440044	12/1990	EP	N/A
0441252	12/1990	EP	N/A
0441394	12/1990	EP	N/A
0467078	12/1991	EP	N/A
0534074	12/1992	EP	N/A
0535898	12/1992	EP	N/A
0539751	12/1992	EP	N/A
0563795	12/1992	EP	N/A
0323605	12/1993	EP	N/A
0647849	12/1994	EP	N/A
0424633	12/1995	EP	N/A
0729366	12/1995	EP	N/A
0747069	12/1995	EP	N/A
0776628	12/1996	EP	N/A
0817809	12/1997	EP	N/A
0838230	12/1997	EP	N/A
0880936	12/1997	EP	N/A
0885932	12/1997	EP	N/A
0967788	12/1998	EP	N/A
0995805	12/1999	EP	N/A
1077634	12/2000	EP	N/A

1078258	12/2000	EP	N/A
1102194	12/2000	EP	N/A
0789540	12/2000	EP	N/A
1153571	12/2000	EP	N/A
0817809	12/2001	EP	N/A
1266607	12/2001	EP	N/A
1338295	12/2002	EP	N/A
1067862	12/2003	EP	N/A
1144028	12/2003	EP	N/A
1498067	12/2004	EP	N/A
1571582	12/2004	EP	N/A
2223710	12/2009	EP	N/A
2226086	12/2009	EP	N/A
2228642	12/2009	EP	N/A
2656423	12/1990	FR	N/A
2760962	12/1997	FR	N/A
1442303	12/1975	GB	N/A
2149918	12/1984	GB	N/A
S6283649	12/1986	JP	N/A
S6283849	12/1986	JP	N/A
H0783871	12/1994	JP	N/A
2000060826	12/1999	JP	N/A
2002515302	12/2001	JP	N/A
2002189015	12/2001	JP	N/A
2003079723	12/2002	JP	N/A
2003108679	12/2002	JP	N/A
2004000555	12/2003	JP	N/A
WO-8902720	12/1988	WO	N/A
WO-9000738	12/1989	WO	N/A
WO-9010861	12/1989	WO	N/A
WO-9013021	12/1989	WO	N/A
WO-9116416	12/1990	WO	N/A
WO-9213271	12/1991	WO	N/A
WO-9314693	12/1992	WO	N/A
WO-9323744	12/1992	WO	N/A
WO-9422367	12/1993	WO	N/A
WO-9507109	12/1994	WO	N/A
WO-9513838	12/1994	WO	N/A
WO-9601611	12/1995	WO	N/A
WO-9603117	12/1995	WO	N/A
WO-9614026	12/1995	WO	N/A
WO-9625089	12/1995	WO	N/A
WO-9630431	12/1995	WO	N/A
WO-9632076	12/1995	WO	N/A
WO-9637246	12/1995	WO	N/A
WO-9701986	12/1996	WO	N/A
WO-9706727	12/1996	WO	N/A
WO-9719188	12/1996	WO	N/A
WO-9728737	12/1996	WO	N/A
WO-9743633	12/1996	WO	N/A

WO-9824358	12/1997	WO	N/A
WO-9838906	12/1997	WO	N/A
WO-9948419	12/1998	WO	N/A
WO-9956613	12/1998	WO	N/A
WO-9958051	12/1998	WO	N/A
WO-9958973	12/1998	WO	N/A
WO-9959657	12/1998	WO	N/A
WO-0012720	12/1999	WO	N/A
WO-0013002	12/1999	WO	N/A
WO-0013003	12/1999	WO	N/A
WO-0019887	12/1999	WO	N/A
WO-0032098	12/1999	WO	N/A
WO-0033065	12/1999	WO	N/A
WO-0049941	12/1999	WO	N/A
WO-0059373	12/1999	WO	N/A
WO-0074753	12/1999	WO	N/A
WO-0078210	12/1999	WO	N/A
WO-0112158	12/2000	WO	N/A
WO-0116579	12/2000	WO	N/A
WO-0120019	12/2000	WO	N/A
WO-0120334	12/2000	WO	N/A
WO-0134243	12/2000	WO	N/A
WO-0143660	12/2000	WO	N/A
WO-0152727	12/2000	WO	N/A
WO-0158348	12/2000	WO	N/A
WO-0168901	12/2000	WO	N/A
WO-0169222	12/2000	WO	N/A
WO-0188524	12/2000	WO	N/A
WO-0188534	12/2000	WO	N/A
WO-0205702	12/2001	WO	N/A
WO-0224065	12/2001	WO	N/A
WO-0078210	12/2001	WO	N/A
WO-02082989	12/2001	WO	N/A
WO-02089666	12/2001	WO	N/A
WO-02100266	12/2001	WO	N/A
WO-03000127	12/2002	WO	N/A
WO-03022125	12/2002	WO	N/A
WO-03022327	12/2002	WO	N/A
03047426	12/2002	WO	N/A
WO-03063700	12/2002	WO	N/A
WO-03072269	12/2002	WO	N/A
WO-03101862	12/2002	WO	N/A
WO-2004009161	12/2003	WO	N/A
WO-2004110256	12/2003	WO	N/A
WO-2005011489	12/2004	WO	N/A
WO-2005012873	12/2004	WO	N/A
WO-2005026689	12/2004	WO	N/A
WO-2005032400	12/2004	WO	N/A
WO-2005057168	12/2004	WO	N/A
WO-2005057175	12/2004	WO	N/A

WO-2005078424	12/2004	WO	N/A
WO-2005026689	12/2004	WO	N/A
WO-2005093629	12/2004	WO	N/A
2005106446	12/2004	WO	N/A
WO-2006017358	12/2005	WO	N/A
WO-2006021430	12/2005	WO	N/A
WO-2006050405	12/2005	WO	N/A
WO-2006105146	12/2005	WO	N/A
WO-2006118713	12/2005	WO	N/A
WO-2006131288	12/2005	WO	N/A
WO-2007002209	12/2006	WO	N/A
WO-2007002579	12/2006	WO	N/A
WO-2007065285	12/2006	WO	N/A
WO-2007097754	12/2006	WO	N/A
WO-2007114943	12/2006	WO	N/A
WO-2007127606	12/2006	WO	N/A
WO-2007137286	12/2006	WO	N/A
WO-2007143225	12/2006	WO	N/A
WO-2008001091	12/2007	WO	N/A
WO-2008076868	12/2007	WO	N/A

OTHER PUBLICATIONS

US 7,530,950 B2, 05/2009, Brister et al. (withdrawn) cited by applicant
Machine Translation of DE10103803A1, 2001, 1 page. cited by applicant
Machine Translation of JP2003079723A, 2003, 16 pages. cited by applicant
Aalders, et al., "Development of a Wearable Glucose Sensor; Studies in Healthy Volunteers and in Diabetic Patients," The International Journal of Artificial Organs, 1991, vol. 14, No. 2, pp. 102-108. cited by applicant
Abe, et al., "Characterization of Glucose Microsensors for Intracellular Measurements," Analytical Chemistry, 1992, vol. 64, No. 18, pp. 2160-2163. cited by applicant
Abel, et al., "Biosensors for in Vivo Glucose Measurements: Can We Cross the Experimental Stage," Biosensors & Bioelectronics, 2002, vol. 17, pp. 1059-1070. cited by applicant
Abel, et al., "Experience With an Implantable Glucose Sensor as a Prerequisite of an Artificial Beta Cell," Biomed. Biochim. Actan, 1984, vol. 43, No. 5, pp. 577-584. cited by applicant
Adilman, et al., "Videogames: Knowing the Score, Creative Computing," Dec. 1983, Dialog: File 148; IAC Trade & Industry Database, vol. 9, p. 224(5) (9 pages). cited by applicant
Alcock S.J., et al., "Continuous Analyte Monitoring to Aid Clinical Practice," IEEE Engineering in Medicine & Biology, 1994, vol. 13, pp. 319-325. cited by applicant
Amer M.M.B., "An Accurate Amperometric Glucose Sensor Based Glucometer with Eliminated Cross-Sensitivity," Journal of Medical Engineering & Technology, vol. 26 (5), Sep./Oct. 2002, pp. 208-213. cited by applicant
American Diabetes Association., "Position Statement: Diagnosis and Classification of Diabetes Mellitus," Diabetes Care, vol. 30, Supplement 01, Jan. 2007, pp. S42-S47. cited by applicant
American Diabetes Association., "Position Statement: Standards of Medical Care in Diabetes," Diabetes Care, vol. 30, Supplement 01, Jan. 2007, pp. S4-S41. cited by applicant
American Diabetes Association., "Summary of Revisions for the 2007 Clinical Practice Recommendations," Diabetes Care, vol. 30, Supplement 01, Jan. 2007, pp. S3. cited by applicant
Amin R., et al., "Hypoglycemia Prevalence in Prepubertal Children With Type 1 Diabetes on Standard Insulin Regimen: Use of Continuous Glucose Monitoring System," Diabetes Care, 2003, vol. 26, No. 3, pp. 662-667. cited by applicant

Armour J.C., et al., “Application of Chronic Intravascular Blood Glucose Sensor in Dogs,” Diabetes, Dec. 1990, vol. 39, pp. 1519-1526. cited by applicant
Asberg P., et al., “Hydrogels of a Conducting Conjugated Polymer as 3-D Enzyme Electrode,” Biosensors Bioelectronics, 2003, vol. 19, pp. 199-207. cited by applicant
Assolant-Vinet C.H., et al., “New Immobilized Enzyme Membranes for Tailor-Made Biosensors,” Analytical Letters, 1986, vol. 19(7&8), pp. 875-885. cited by applicant
Atanasov P., et al., “Biosensor for Continuous Glucose Monitoring,” Biotechnology and Bioengineering, John Wiley & sons Inc, 1994, vol. 43, pp. 262-266. cited by applicant
Atanasov P., et al., “Implantation of a Refillable Glucose Monitoring-Telemetry Device,” Biosensors and Bioelectronics, vol. 12 (7), 1997, pp. 669-680. cited by applicant
Aussedat B., et al., “A User-Friendly Method for Calibrating a Subcutaneous Glucose Sensor-Based Hypoglycaemic Alarm,” Elsevier Science Limited, Biosensors & Bioelectronic, 1997, vol. 12, No. 11, pp. 1061-1071. cited by applicant
Aussedat B., et al., “Interstitial Glucose Concentration and Glycemia: Implications for Continuous Subcutaneous Glucose Monitoring,” American Journal of Physiology—Endocrinology and Metabolism, vol. 278 (4), Apr. 1, 2000, pp. E716-E728. cited by applicant
Bailey T.S., et al., “Reduction in Hemoglobin A1C with Real-Time Continuous Glucose Monitoring: Results from a 12-Week Observational Study,” Diabetes Technology & Therapeutics, vol. 9 (3), 2007, pp. 203-210. cited by applicant
Baker D.A., et al., “Dynamic Concentration Challenges for Biosensor Characterization,” Biosensors & Bioelectronics, vol. 8, 1993, pp. 433-441. cited by applicant
Baker D.A., et al., “Dynamic Delay and Maximal Dynamic Error in Continuous Biosensors,” Analytical Chemistry, vol. 68 (8), Apr. 15, 1996, pp. 1292-1297. cited by applicant
Bard A.J., et al., “Electrochemical Methods,” Fundamentals and Applications, John Wiley & Sons, New York, 1980, pp. 173-175. cited by applicant
Bardeletti G., et al., “A Reliable L-Lactate Electrode with a New Membrane for Enzyme Immobilization for Amperometric Assay of Lactate,” Analytica Chemica Acta, vol. 187, 1986, pp. 47-54. cited by applicant
Beach R.D., et al., “Subminiature Implantable Potentiostat and Modified Commercial Telemetry Device for Remote Glucose Monitoring,” IEEE Transactions on Instrumentation and Measurement, vol. 48 (6), Dec. 1999, pp. 1239-1245. cited by applicant
Bellucci F., et al., “Electrochemical Behaviour of Graphite-Epoxy Composite Materials (GECM) in Aqueous Salt Solutions,” Journal of Applied Electrochemistry, vol. 16 (1), Jan. 1986, pp. 15-22. cited by applicant
Berger M., et al., “Computer Programs to Assist the Physician in the Analysis of Self- Monitored Blood Glucose Data,” Proceedings of the Annual Symposium on Computer Applications in Medical Care, 1988, pp. 52-57. cited by applicant
Bertrand C., et al., “Multipurpose Electrode with Different Enzyme Systems Bound to Collagen Films,” Analytica Chemica Acta, 1981, vol. 126, pp. 23-34. cited by applicant
Bessman S.P., et al., “Progress toward a Glucose Sensor for the Artificial Pancreas,” Proceedings of a Workshop on Ion-Selective Microelectrodes, Jun. 4-5, 1973, Boston University, 1973, pp. 189-197. cited by applicant
Biermann E., et al., “How Would Patients Behave if they were Continually Informed of their Blood Glucose Levels? A Simulation Study Using a “Virtual” Patient,” Diabetes Technology & Therapeutics, vol. 10 (3), 2008, pp. 178-187. cited by applicant
Bindra D.S., et al., “Design and in Vitro Studies of a Needle-Type Glucose Sensor for Subcutaneous Monitoring,” Analytical Chemistry, vol. 63, Sep. 1, 1991, pp. 1692-1696. cited by applicant
Bindra D.S., et al., “Pulsed Amperometric Detection of Glucose in Biological Fluids at a Surface-Modified Gold Electrode,” Analytical Chemistry, vol. 61 (22), Nov. 15, 1989, pp. 2566-2570. cited

by applicant
Bisenberger M., et al., “A Triple-Step Potential Waveform at Enzyme Multisensors with Thick-Film Gold Electrodes for Detection of Glucose and Sucrose,” Sensors and Actuators B, vol. 28, 1995, pp. 181-189. cited by applicant
Bland J.M., et al., “A Note on the Use of the Intraclass Correlation Coefficient in the Evaluation of Agreement between Two Methods of Measurement,” Computers in Biology and Medicine, vol. 20 (5), 1990, pp. 337-340. cited by applicant
Bland J.M., et al., “Statistical Methods for Assessing Agreement Between Two Methods of Clinical Measurement,” The Lancet, Feb. 8, 1986, pp. 307-310. cited by applicant
Bobbioni-Harsch E., et al., “Lifespan of Subcutaneous Glucose Sensors and their Performances during Dynamic Glycaemia Changes in Rats,” J. Biomed. Eng., vol. 15, 1993, pp. 457-463. cited by applicant
Bode B.W., “Clinical Utility of the Continuous Glucose Monitoring System,” Diabetes Technology & Therapeutics, vol. 2, Supplement 1, 2000, pp. S35-S41. cited by applicant
Bode B.W., et al., “Continuous Glucose Monitoring Used to Adjust Diabetes Therapy Improves Glycosylated Hemoglobin: A Pilot Study,” Diabetes Research and Clinical Practice, vol. 46, 1999, pp. 183-190. cited by applicant
Bode B.W., et al., “Using the Continuous Glucose Monitoring System to Improve the Management of Type 1 Diabetes,” Diabetes Technology & Therapeutics, vol. 2, Supplement 1, 2000, pp. S43-S48. cited by applicant
Boedeker Plastics Inc, “Polyethylene Specifications,” Polyethylene Data Sheet, Retrieved from http://www.boedeker.com/polye.sub.--p.htm on Aug. 19, 2009, 4 pages. cited by applicant
Boland E., et al., “Limitations of Conventional Methods of Self-Monitoring of Blood Glucose,” Diabetes Care, vol. 24 (11), Nov. 2001, pp. 1858-1862. cited by applicant
Bolinder J., et al., “Self-Monitoring of Blood Glucose in Type I Diabetic Patients: Comparison with Continuous Microdialysis Measurements of Glucose in Subcutaneous Adipose Tissue during Ordinary Life Conditions,” Diabetes Care, vol. 20 (1), Jan. 1997, pp. 64-70. cited by applicant
Bolinder J., et al., “Microdialysis Measurement of the Absolute Glucose Concentration in Subcutaneous Adipose Tissue Allowing Glucose Monitoring in Diabetic Patients,” Rapid Communication, Diabetologia, vol. 35, 1992, pp. 1177-1180. cited by applicant
Bott A.W., “A Comparison of Cyclic Voltammetry and Cyclic Staircase Voltammetry,” Current Separations, vol. 16 (1), 1997, pp. 23-26. cited by applicant
Bott A.W., “Electrochemical Methods for the Determination of Glucose,” Current Separations, vol. 17 (1), 1998, pp. 25-31. cited by applicant
Bowman L., et al., “The Packaging of Implantable Integrated Sensors,” IEEE Transactions in Biomedical Engineering, vol. BME-33 (2), Feb. 1986, pp. 248-255. cited by applicant
Brauker, et al., “Sustained Expression of High Levels of Human Factor IX from Human Cells Implanted within an Immunoisolation Device into Athymic Rodents,” Human Gene Therapy, Apr. 10, 1998, vol. 9, pp. 879-888. cited by applicant
Brauker J., et al., “Local Inflammatory Response Around Diffusion Chambers Containing Xenografts,” Transplantation, vol. 61 (12), Jun. 27, 1996, pp. 1671-1677. cited by applicant
Brauker J H., et al., “Neovascularization of Synthetic Membranes Directed by Membrane Microarchitecture,” Journal of Biomedical Material Research, 1995, vol. 29, pp. 1517-1524. cited by applicant
Brauker J., “Unraveling Mysteries at the Biointerface: Molecular Mediator of Inhibition of Blood Vessel Formation in the Foreign Body Capsule Revealed,” SurFACTS in Biomaterials, vol. 6 (3), 2001, pp. 1,5. cited by applicant
Braunwald E., “Biomarkers in Heart Failure,” Medical Progress, The New England Journal of Medicine, vol. 358, May 15, 2008, pp. 2148-2159. cited by applicant
Bremer T., et al., “Is Blood Glucose Predictable from Previous Values? A Solicitation for Data,”

Perspectives in Diabetes, vol. 48, Mar. 1999, pp. 445-451. cited by applicant
Bremer T.M., et al., “Benchmark Data from the Literature for Evaluation of New Glucose Sensing Technologies,” Diabetes Technology & Therapeutics, vol. 3 (3), 2001, pp. 409-418. cited by applicant
Brooks S.L., et al., “Development of an On-line Glucose Sensor for Fermentation Monitoring,” Biosensors, vol. 3, 1987/1988, pp. 45-56. cited by applicant
Bruckel J., et al., “In Vivo Measurement of Subcutaneous Glucose Concentrations with an Enzymatic Glucose Sensor and a Wick Method,” Klin Wochenschr, vol. 67, 1989, pp. 491-495. cited by applicant
Brunner G.A., et al., “Validation of Home Blood Glucose Meters with Respect to Clinical and Analytical Approaches,” Diabetes Care, vol. 21, No. 4, Apr. 1998, pp. 585-590. cited by applicant
Brunstein E., et al., “Preparation and Validation of Implantable Electrodes for the Measurement of Oxygen and Glucose,” Biomed Biochim. Acta, vol. 48 (11/12), 1989, pp. 911-917. cited by applicant
Cai Q., et al., “A Wireless, Remote Query Glucose Biosensor Based on a pH-Sensitive Polymer,” Analytical Chemistry, vol. 76 (14), Jul. 15, 2004, pp. 4038-4043. cited by applicant
Cameron T., et al., “Micromodular Implants to Provide Electrical Stimulation of Paralyzed Muscles and Limbs,” IEEE Transactions on Biomedical Engineering, vol. 44 (9), Sep. 1997, pp. 781-790. cited by applicant
Campanella L., et al., “Biosensor for Direct Determination of Glucose and Lactate in Undiluted Biological Fluids,” Biosensors & Bioelectronics, vol. 8, 1993, pp. 307-314. cited by applicant
Candas B., et al., “An Adaptive Plasma Glucose Controller Based on a Nonlinear Insulin/Glucose Model,” IEEE Transactions on Biomedical Engineering, vol. 41 (2), Feb. 1994, pp. 116-124. cited by applicant
Cass A.E.G., et al., “Ferrocene-Mediated Enzyme Electrodes for Amperometric Determination of Glucose,” Analytical Chemistry, vol. 56 (4), Apr. 1984, pp. 667-671. cited by applicant
Cassidy J.F., et al., “Novel Electrochemical Device for the Detection of Cholesterol or Glucose,” Analyst, vol. 118, Apr. 1993, pp. 415-418. cited by applicant
Chase H.P., et al., “Continuous Subcutaneous Glucose Monitoring in Children with Type 1 Diabetes,” Pediatrics, vol. 107 (2), Feb. 2001, pp. 222-226. cited by applicant
Chase J.G., et al., “Targeted Glycemic Reduction in Critical Care Using Closed-Loop Control,” Diabetes Technology & Therapeutics, vol. 7 (2), 2005, pp. 274-282. cited by applicant
Chen C., et al., “A Noninterference Polypyrrole Glucose Biosensor,” Biosensors and Bioelectronics, vol. 22, 2006, pp. 639-643. cited by applicant
Chen T., et al., “Defining the Period of Recovery of the Glucose Concentration after its Local Perturbation by the Implantation of a Miniature Sensor,” Clinical Chemistry and Laboratory Medicine, vol. 40 (8), 2002, pp. 786-789. cited by applicant
Chia C.W., et al., “Glucose Sensors: Toward Closed Loop Insulin Delivery,” Endocrinology and Metabolism Clinics of North America, vol. 33, 2004, pp. 175-195. cited by applicant
Choleau C., et al., “Calibration of a Subcutaneous Amperometric Glucose Sensor Implanted for 7 Days in Diabetic Patients Part 2. Superiority of the One-point Calibration Method,” Biosensors and Bioelectronics, vol. 17 (8), 2002, pp. 647-654. cited by applicant
Choleau C., et al., “Calibration of a Subcutaneous Amperometric Glucose Sensor Part 1. Effect of Measurement Uncertainties on the Determination of Sensor Sensitivity and Background Current,” Biosensors and Bioelectronics, vol. 17, 2002, pp. 641-646. cited by applicant
CIBA Specialty Chemicals, “Ciba® IRGACURE® 2959,” Coating Effects Segment, Photoinitiator Product Description, Basel Switzerland, Apr. 2, 1998, 3 pages. cited by applicant
Claremont D.J., et al., “Potentially-Implantable, Ferrocene-Mediated Glucose Sensor,” Journal of Biomedical Engineering, vol. 8, Jul. 1986, pp. 272-274. cited by applicant
Claremont D.J., et al., “Subcutaneous Implantation of a Ferrocene-Mediated Glucose Sensor in

Pigs," Diabetologia, vol. 29, 1986, pp. 817-821. cited by applicant
Clark L.C., et al., "Configurational Cyclic Voltammetry: Increasing the Specificity and Reliability of Implanted Electrodes," IEEE/Ninth Annual Conference of the Engineering in Medicine and Biology Society, 1987, pp. 0782-0783. cited by applicant
Clark L.C., et al., "Long-Term Stability of Electroenzymatic Glucose Sensors Implanted in Mice," vol. XXXIV, Transactions—American Society for Artificial Internal Organs, 1988, vol. 34, pp. 259-265. cited by applicant
Clark L.C., et al., "One-Minute Electrochemical Enzymic Assay for Cholesterol in Biological Materials," Clinical Chemistry, vol. 27 (12), 1981, pp. 1978-1982. cited by applicant
Clarke W.L., et al., "Evaluating Clinical Accuracy of Systems for Self Monitoring of Blood Glucose," Technical Articles, Diabetes Care, vol. 10 (5), Sep.-Oct. 1987, pp. 622-628. cited by applicant
Colangelo V.J., et al., "Corrosion Rate Measurements in Vivo," Journal of Biomedical Materials Research, vol. 1, 1967, pp. 405-414. cited by applicant
Colowick S.P., et al., "Methods in Enzymology," vol. XLIV, Immobilized Enzymes, Edited by Mosbach K, New York Academic Press, 1976, 11 pages. cited by applicant
Coulet P.R., et al., "Enzymes Immobilized on Collagen Membranes: A Tool for Fundamental Research and Enzyme Engineering," Journal of Chromatography, vol. 215, 1981, pp. 65-72. cited by applicant
Coulet P.R., "Polymeric Membranes and Coupled Enzymes in the Design of Biosensors," Journal of Membrane Science, 1992, vol. 68, pp. 217-228. cited by applicant
Cox D.J., et al., "Accuracy of Perceiving Blood Glucose in IDDM," Diabetes Care, vol. 8 (6), Nov.-Dec. 1985, pp. 529-536. cited by applicant
Csoregi E., et al., "Amperometric Microbiosensors for Detection of Hydrogen Peroxide and Glucose Based on Peroxidase-Modified Carbon Fibers," Electroanalysis, vol. 6, 1994, pp. 925-933. cited by applicant
Csoregi E., et al., "Design, Characterization and One-Point in Vivo Calibration of a Subcutaneously Implanted Glucose Electrode," American Chemical Society, Analytical Chemistry, vol. 66 (19), Oct. 1, 1994, pp. 3131-3138. cited by applicant
Currie J.F., et al., "Novel Non-Intrusive Trans-Dermal Remote Wireless Micro-Fluidic Monitoring System Applied to Continuous Glucose and Lactate Assays for Casualty Care and Combat Readiness Assessment," RTO HFM Symposium, RTO-MP-HFM-109, Aug. 16-18, 2004, pp. '24-1'-'24-18'. cited by applicant
Dai W.S., et al., "Hydrogel Membranes with Mesh Size Asymmetry based on the Gradient Crosslinking of Poly(Vinyl Alcohol)," Journal of Membrane Science, 1999, vol. 156, pp. 67-79. cited by applicant
Danielsson B., et al., "Enzyme Thermistors," Methods in Enzymology, vol. 137, 1988, pp. 181-197. cited by applicant
D'Arrigo G., et al., "Porous-Si Based Bio Reactors for Glucose Monitoring and Drugs Production," Proceedings of SPIE, 2003, vol. 4982, pp. 178-184. cited by applicant
Dassau E., et al., "In Silico Evaluation Platform for Artificial Pancreatic β-Cell Development—A Dynamic Simulator for Closed-Loop Control with Hardware-in-the-loop," Diabetes Technology & Therapeutics, vol. 11 (3), 2009, pp. 1-8. cited by applicant
Davies M.L., et al., "Polymer Membranes in Clinical Sensor Applications," An overview of membrane function, Biomaterials, vol. 13 (14), 1992, pp. 971-978. cited by applicant
Davis G., et al., "Bioelectrochemical Fuel Cell and Sensor Based on a Quinoprotein, Alcohol Dehydrogenase," Enzyme and Microbial Technology, vol. 5 (5), Sep. 1983, pp. 383-388. cited by applicant
De Vos P., et al., "Considerations for Successful Transplantation of Encapsulated Pancreatic Islets," Diabetologia, vol. 45, 2002, pp. 159-173. cited by applicant

Deutsch T., et al., “Time Series Analysis and Control of Blood Glucose Levels in Diabetic Patients,” Computer Methods and Programs in Biomedicine, Elsevier Scientific Publishers, vol. 41, 1994, pp. 167-182. cited by applicant
Dixon B.M., et al., “Characterization in Vitro and in Vivo of the Oxygen Dependence of an Enzyme/Polymer Biosensor for Monitoring Brain Glucose,” Journal of Neuroscience Methods, vol. 119, 2002, pp. 135-142. cited by applicant
DuPont, “Dimension® AR Clinical Chemistry System,” The Chemistry Analyzer that Makes the most of your Time, Money and Effort, Dade International, Chemistry Systems, Newark, 1998, 18 pages. cited by applicant
Durliat H., et al., “Spectrophotometric and Electrochemical Determinations of L(+)-Lactate in Blood by Use of Lactate Dehydrogenase from Yeast,” Clinical Chemistry, vol. 22 (11), 1976, pp. 1802-1805. cited by applicant
Edwards Lifesciences, “Accuracy for You and Your Patients,” Marketing materials, 2002, 4 pages. cited by applicant
El Degheidy M.M., et al., “Optimization of an Implantable Coated Wire Glucose Sensor,” Journal of Biomedical Engineering, vol. 8, Apr. 1986, pp. 121-129. cited by applicant
Elco Diagnostics Company, “Direct 30/30® Blood Glucose Sensor,” Markwell Medical Catalog, 1990, 1 page. cited by applicant
El-Khatib F.H., et al., “Adaptive Closed-Loop Control Provides Blood-Glucose Regulation Using Dual Subcutaneous Insulin and Glucagon Infusion in Diabetic Swine,” Journal of Diabetes Science and Technology, Diabetes Technology Society, vol. 1 (2), 2007, pp. 181-192. cited by applicant
El-Sa'ad L., et al., “Moisture Absorption by Epoxy Resins: The Reverse Thermal Effect,” Journal of Materials Science, vol. 25, 1990, pp. 3577-3582. cited by applicant
Ernst H., et al., “Reliable Glucose Monitoring Through the Use of Microsystem Technology,” Analytical Bioanalytical Chemistry, vol. 373, 2002, pp. 758-761. cited by applicant
Fabietti P.G., et al., “Clinical Validation of a New Control-Oriented Model of Insulin and Glucose Dynamics in Subjects with Type 1 Diabetes,” Diabetes Technology & Therapeutics, vol. 9 (4), 2007, pp. 327-338. cited by applicant
Fahy B.G., et al., “An Analysis: Hyperglycemic Intensive Care Patients Need Continuous Glucose Monitoring-Easier Said Than Done,” Journal of Diabetes Science and Technology, Diabetes Technology Society, vol. 2 (2), Mar. 2008, pp. 201-204. cited by applicant
Fare T.L., et al., “Functional Characterization of a Conducting Polymer-Based Immunoassay System,” Biosensors & Bioelectronics, vol. 13 (3-4), 1998, pp. 459-470. cited by applicant
Feldman B., et al., “A Continuous Glucose Sensor Based on Wired EnzymeTM Technology-Results from a 3-Day Trial in Patients with Type 1 Diabetes,” Diabetes Technology & Therapeutics, vol. 5 (5), 2003, pp. 769-779. cited by applicant
Fischer U., et al., “Assessment of Subcutaneous Glucose Concentration: Validation of the Wick Technique as a Reference for Implanted Electrochemical Sensors in Normal and Diabetic Dogs,” Diabetologia, vol. 30, 1987, pp. 940-945. cited by applicant
Fischer U., et al., “Hypoglycaemia-Warning by Means of Subcutaneous Electrochemical Glucose Sensors: An Animal Study,” Horm. Metab. Res, vol. 27, 1995, p. 53. (Abstract Only). cited by applicant
Fischer U., et al., “Oxygen Tension at the Subcutaneous Implantation Site of Glucose Sensors,” Biomed. Biochim. Acta, vol. 48 (11/12), 1989, pp. 965-971. cited by applicant
Freedman D., et al., “Statistics,” Second Edition, W.W. Norton & Company, New York & London, 1991, p. 74 (3 pages). cited by applicant
Freiberger P., “Video Game Takes on Diabetes Superhero ‘Captain Novolin’ Offers Treatment Tips,” Fourth Edition, Jun. 26, 1992, Business Section, 2 pages. cited by applicant
Frohnauer M.K., et al., “Graphical Human Insulin Time-Activity Profiles Using Standardized Definitions,” Diabetes Technology & Therapeutics, vol. 3 (3), 2001, pp. 419-429. cited by

applicant
Frost M.C., et al., “Implantable Chemical Sensors for Real-Time Clinical Monitoring: Progress and Challenges,” Current Opinion in Chemical Biology, Analytical Techniques, vol. 6, 2002, pp. 633-641. cited by applicant
Gabby R.A., et al., “Optical Coherence Tomography-Based Continuous Noninvasive Glucose Monitoring in Patients with Diabetes,” Diabetes Technology & Therapeutics, vol. 10, Nov. 3, 2008, pp. 188-193. cited by applicant
Ganesan N., et al., “Gold Layer-Based Dual Crosslinking Procedure of Glucose Oxidase with Ferrocene Monocarboxylic Acid Provides a Stable Biosensor,” Analytical Biochemistry, Notes & Tips, vol. 343, 2005, pp. 188-191. cited by applicant
Ganesh A., et al., “Evaluation of the VIA® Blood Chemistry Monitor for Glucose in Healthy and Diabetic Volunteers,” Journal of Diabetes Science and Technology, vol. 2 (2), Mar. 2008, pp. 182-193. cited by applicant
Garg S.K., et al., “Correlation of Fingerstick Blood Glucose Measurements With GlucoWatch Biographer Glucose Results in Young Subjects With Type 1 Diabetes,” Emerging Treatments and Technologies, Diabetes Care, vol. 22 (10), Oct. 1999, pp. 1708-1714. cited by applicant
Garg S.K., et al., “Improved Glucose Excursions Using an Implantable Real-Time Continuous Glucose Sensor in Adults With Type 1 Diabetes,” Emerging Treatments and Technologies, Diabetes Care, vol. 27 (3), 2004, pp. 734-738. cited by applicant
Garg S.K., “New Insulin Analogues,” Diabetes Technology & Therapeutics, vol. 7 (5), 2005, pp. 813-817. cited by applicant
Geller R.I., et al., “Use of an Immunoisolation Device for Cell Transplantation and Tumor Immunotherapy,” Annals of the New York Academy of Science, 1997, vol. 831, pp. 438-451. cited by applicant
Gerritsen M., et al., “Influence of Inflammatory Cells and Serum on the Performance of Implantable Glucose Sensors,” Journal of Biomedical Material Research, 2001, vol. 54, pp. 69-75. cited by applicant
Gerritsen M., et al., “Performance of Subcutaneously Implanted Glucose Sensors for Continuous Monitoring,” The Netherlands Journal of Medicine, vol. 54, 1999, pp. 167-179. cited by applicant
Gerritsen M., et al., “Problems Associated with Subcutaneously Implanted Glucose Sensors,” Diabetes Care, vol. 23 (2), Feb. 2000, pp. 143-145. cited by applicant
Gilligan B.J., et al., “Evaluation of a Subcutaneous Glucose Sensor Out to 3 Months in a Dog Model” Diabetes Care, vol. 17 (8), Aug. 1994, pp. 882-887. cited by applicant
Gilligan B.J., et al., “Feasibility of Continuous Long-Term Glucose Monitoring from a Subcutaneous Glucose Sensor in Humans,” Diabetes Technology & Therapeutics, vol. 6 (3), 2004, pp. 378-386. cited by applicant
Godsland I.F., et al., “Maximizing the Success Rate of Minimal Model Insulin Sensitivity Measurement in Humans: The Importance of Basal Glucose Levels,” The Biochemical Society and the Medical Research Society, Clinical Science, vol. 101, 2001, pp. 1-9. cited by applicant
Gouda M.D., et al., “Thermal Inactivation of Glucose Oxidase,” The Journal of Biological Chemistry, vol. 278 (27), Issue of Jul. 4, 2003, pp. 24324-24333. cited by applicant
Gough D.A., et al., “Frequency Characterization of Blood Glucose Dynamics,” Annals of Biomedical Engineering, vol. 31, 2003, pp. 91-97. cited by applicant
Gough D.A., et al., “Immobilized Glucose Oxidase in Implantable Glucose Sensor Technology,” Diabetes Technology & Therapeutics, vol. 2 (3), 2000, pp. 377-380. cited by applicant
Gough D.A., “The implantable Glucose Sensor: An Example of Bioengineering Design,” Introduction to Bioengineering, 2001, Chapter 3, pp. 57-66. cited by applicant
Gregg B A., et al., “Cross-Linked Redox Gels Containing Glucose Oxidase for Amperometric Biosensor Applications,” Anal Chem, 1990, vol. 62, pp. 258-263. cited by applicant
Gross, et al., “Diabetes Technology & Therapeutics,” Letters to the Editor, Diabetes Technology &

Therapeutics, vol. 3 (1), 2001, pp. 129-131. cited by applicant
Gross T.M., et al., “Efficacy and Reliability of the Continuous Glucose Monitoring System,” Diabetes Technology & Therapeutics, vol. 2, Supplement 1, 2000, pp. S19-S26. cited by applicant
Gross T.M., et al., “Performance Evaluation of the Minimed® Continuous Glucose Monitoring System During Patient Home Use,” Diabetes Technology & Therapeutics, vol. 2(1), 2000, pp. 49-56. cited by applicant
Guerci B., et al., “Clinical Performance of CGMS in Type 1 Diabetic Patients Treated by Continuous Subcutaneous Insulin Infusion Using Insulin Analogs,” Diabetes Care, vol. 26, 2003, pp. 582-589. cited by applicant
Hagvik J., “Glucose Measurement: Time for a Gold Standard,” Journal of Diabetes Science and Technology, vol. 1 (2), Mar. 2007, pp. 169-172. cited by applicant
Hall S.B., et al., “Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part 1. An Adsorption-controlled Mechanism,” Electrochimica Acta, vol. 43, Nos. 5/6, 1998, pp. 579-588. cited by applicant
Hall S.B., et al., “Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part II: Effect of potential,” Electrochimica Acta, vol. 43 (14-15), 1998, pp. 2015-2024. cited by applicant
Hall S.B., et al., “Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part III: Effect of Temperature,” Electrochimica Acta, vol. 44, 1999, pp. 2455-2462. cited by applicant
Hall S.B., et al., “Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part IV: Phosphate Buffer Dependence,” Electrochimica Acta, vol. 44, 1999, pp. 4573-4582. cited by applicant
Hall S.B., et al., “Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part V: Inhibition by Chloride,” Electrochimica Acta, vol. 45, 2000, pp. 3573-3579. cited by applicant
Hamilton, “Complete Guide to Selecting the Right Hamilton Gastight, Microliter, and Specialty Syringe for your Application,” Syringe Selection, www.hamiltoncompany.com 2006, 20 pages. cited by applicant
Harrison, et al., “Characterization of Perfluorosulfonic Acid Polymer Coated Enzyme Electrodes and a Miniaturized Integrated Potentiostat for Glucose Analysis in Whole Blood,” Analytical Chemistry, 1988, vol. 60, pp. 2002-2007. cited by applicant
Hashiguchi Y., et al., “Development of a Miniaturized Glucose Monitoring System by Combining a Needle-Type Glucose Sensor with Microdialysis Sampling Method: Long-term subcutaneous tissue glucose monitoring in ambulatory diabetic patients,” Diabetes Care, vol. 17, No. 5, May 1994, pp. 387-396. cited by applicant
Heinemann L., et al., “Review: Measurement of Insulin Absorption and Insulin Action,” Diabetes Technology & Therapeutics, vol. 6 (5), 2004, pp. 698-718. cited by applicant
Heinemann L., “Measurement Quality of Blood Glucose Meters: Is There a Need for an Institution with an Unbiased View?,” Journal of Diabetes Science and Technology, vol. 1 (2), Mar. 2007, pp. 178-180. cited by applicant
Heinemann L., “Review: Variability of Insulin Absorption and Insulin Action,” Diabetes Technology & Therapeutics, vol. 4 (5), 2002, pp. 673-682. cited by applicant
Heise T., et al., “Hypoglycemia warning signal and glucose sensors: Requirements and concepts,” Diabetes Technology & Therapeutics, vol. 5, No. 4, 2003, pp. 563-571. cited by applicant
Heller A., “Electrical Connection of Enzyme Redox Centers to Electrodes,” J. Phys. Chem., vol. 96, 1992, pp. 3579-3587. cited by applicant
Heller A., “Electrical Wiring of Redox Enzymes,” Ace. Chem. Res., vol. 23, 1990, pp. 128-134. cited by applicant
Heller A., “Implanted Electrochemical Glucose Sensors for the Management of Diabetes,” Annu. Rev., Biomed Eng., vol. 1, 1999, pp. 153-175. cited by applicant
Heller A., “Plugging Metal Connectors into Enzymes,” Nature Biotechnology, vol. 21, No. 6, Jun. 2003, pp. 631-632. cited by applicant

Hicks J.M., “In Situ Monitoring,” Clinical Chemistry, vol. 31 (12), 1985, pp. 1931-1935. cited by applicant
Hitchman M.L., “Measurement of Dissolved Oxygen,” Edited by Elving P.J et al., Chemical Analysis, New York, John Wiley & Sons, vol. 49, Chapter 3, 1978, pp. 34-49 and 59-123. cited by applicant
Hoel P.G., “Elementary Statistics,” Fourth Edition, John Wiley & Sons, Inc., 1976, pp. 113-114. cited by applicant
Houghton Mifflin Company, “American Heritage Dictionary,” 4th Edition, 2000, pp. 82. cited by applicant
Houghton Mifflin Company, “Xenogenic, the American Heritage Stedman's Medical Dictionary,” 2002, Answers.Com, retrieved from http://www.answers.com/topic/xenogenic, on Nov. 7, 2006, 2 Pages. cited by applicant
Hovorka R., et al., “Closing the Loop: The Adicol Experience,” Diabetes Technology & Therapeutics, vol. 6 (3), 2004, pp. 307-318. cited by applicant
Hrapovic S., et al., “Picoamperometric Detection of Glucose at Ultrasmall Platinum-Based Biosensors Preparation and Characterization,” Anal. Chem, vol. 75, 2003, pp. 3308-3315. cited by applicant
Hu Y., et al., “A Needle-Type Enzyme-Based Lactate Sensor for In Vivo Monitoring,” Analytica Chimica Acta, vol. 281, 1993, pp. 503-511. cited by applicant
Huang C., et al., “Electrochemical Generation of Oxygen. 1: The Effects of Anions and Cations on Hydrogen Chemisorption and Anodic Oxide Film Formation on Platinum Electrode. 2: The Effects of Anions and Cations on Oxygen Generation on Platinum Electrode,” U.S. Department of Commence/NTIS, 1975, 126 pages. cited by applicant
Huang Q., et al., “A 0.5mW Passive Telemetry IC for Biomedical Applications,” Proceedings of the 23rd European Solid-State Circuits Conference (ESSCIRC '97), Southampton, UK, Sep. 16-18, 1997, pp. 172-175. cited by applicant
Hunsley B., et al., “Whole Blood Glucose Standard Is Key to Accurate Insulin Dosages,” Journal of Diabetes Science and Technology, vol. 1 (2), Mar. 2007, pp. 173-177. cited by applicant
Hunter I., et al., “Minimally Invasive Glucose Sensor and Insulin Delivery System,” MIT Home Automation and Healthcare Consortium, Mar. 31, 2000, Progress Report No. 25, 17 pages. cited by applicant
International Preliminary Report on Patentability for Application No. PCT/US2005/006301, mailed Aug. 30, 2006, 4 pages. cited by applicant
International Preliminary Report on Patentability for Application No. PCT/US2007/080848 mailed Apr. 13, 2010, 6 pages. cited by applicant
International Preliminary Report on Patentability for Application No. PCT/US2008/058158, mailed Sep. 29, 2009, 9 pages. cited by applicant
International Preliminary Report on Patentability for Application No. PCT/US2008/065978 mailed Jun. 19, 2008, 14 pages. cited by applicant
International Search Report and Written Opinion for Application No. PCT/US2005/006301, mailed Jun. 22, 2005, 4 pages. cited by applicant
International Search Report and Written Opinion for Application No. PCT/US2007/080848 mailed Aug. 28, 2008, 6 pages. cited by applicant
International Search Report and Written Opinion for Application No. PCT/US2008/058158, mailed Aug. 8, 2008, 10 pages. cited by applicant
International Search Report and Written opinion for Application No. PCT/US2008/065978 mailed Oct. 2, 2008, 14 pages. cited by applicant
Ishikawa M., et al., “Initial Evaluation of a 290-Mm Diameter Subcutaneous Glucose Sensor: Glucose Monitoring With a Biocompatible, Flexible-Wire, Enzyme-Based Amperometric Microsensor in Diabetic and Nondiabetic Humans,” Journal of Diabetes and Its Complications, vol.

12, 1998, pp. 295-301. cited by applicant
Jablecki M., et al., “Simulations of the Frequency Response of Implantable Glucose Sensors,” Analytical Chemistry, vol. 72, 2000, 1853-1859. cited by applicant
Jaffari S.A., et al., “Recent Advances in Amperometric Glucose Biosensors for In Vivo Monitoring,” Physiological Measurement, 1995, vol. 16, pp. 1-15. cited by applicant
Jaremko J., et al., “Advances Toward the Implantable Artificial Pancreas for Treatment of Diabetes,” Diabetes Care, vol. 21 (3), Mar. 1998, pp. 444-450. cited by applicant
Jensen M.B., et al., “Fast Wave Forms for Pulsed Electrochemical Detection of Glucose by Incorporation of Reductive Desorption of Oxidation Products,” Analytical Chemistry, vol. 69 (9), May 1997, pp. 1776-1781. cited by applicant
Jeong R.A., et al., “In Vivo Calibration of the Subcutaneous Amperometric Glucose Sensors Using a Non-Enzyme Electrode,” Biosensors and Bioelectronics, Elsevier, vol. 19, 2003, pp. 313-319. cited by applicant
Jeutter D.C., “A Transcutaneous Implanted Battery Recharging and Biotelemeter Power Switching System,” IEEE Transactions on Biomedical Engineering, vol. BME-29 (5), May 1982, pp. 314-321. cited by applicant
Jeutter D.C., et al., “Design of a Radio-Linked Implantable Cochlear Prosthesis Using Surface Acoustic Wave Devices,” IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control, vol. 40 (5), Sep. 1993, pp. 469-477. cited by applicant
Jobst G., et al., “Thin-Film Microbiosensors for Glucose-Lactate Monitoring,” Anal Chem, Sep. 15, 1996, vol. 68(18), pp. 3173-3179. cited by applicant
Johnson K.W., et al., “In Vivo Evaluation of an Electroenzymatic Glucose Sensor Implanted in Subcutaneous Tissue,” Biosensors and Bioelectronics, 1992, vol. 7, pp. 709-714. cited by applicant
Johnson K.W., “Reproducible Electrodeposition of Biomolecules for the Fabrication of Miniature Electroenzymatic Biosensors,” Sensors and Actuators B, vol. 5, 1991, pp. 85-89. cited by applicant
Jones S.M., et al., “Optimal Insulin Pump Dosing and Postprandial Glycemia Following a Pizza Meal Using the Continuous Glucose Monitoring System,” Diabetes Technology & Therapeutics, vol. 7 (2), Apr. 2005, pp. 233-240. cited by applicant
Joung G.B., et al., “An Energy Transmission System for an Artificial Heart Using Leakage Inductance Compensation of Transcutaneous Transformer,” IEEE Transactions on Power Electronics, vol. 13 (6), Nov. 1998, pp. 1013-1022. cited by applicant
Jovanovic L.M.D., “The Role of Continuous Glucose Monitoring in Gestational Diabetes Mellitus,” Diabetes Technology and Therapeutics, vol. 2 (1), 2000, pp. S67-S71. cited by applicant
Kacaniklic V., et al., “Amperometric Biosensors for Detection of L- and D-Amino Acids Based on Coimmoblized Peroxidase and L- and D-Amino Acid Oxidases in Carbon Paste Electrodes,” Electroanalysis, vol. 6, May-Jun. 1994, pp. 381-390. cited by applicant
Kamath A., et al., “Calibration of a Continuous Glucose Monitor: Effect of Glucose Rate of Change,” Eighth Annual Diabetes Technology Meeting, Nov. 13-15, 2008, pp. A88 (2 pages). cited by applicant
Kang S.K., et al., “In Vitro and Short-Term in Vivo Characteristics of a Kel-F Thin Film Modified Glucose Sensor,” Analytical Sciences, vol. 19, Nov. 2003, pp. 1481-1486. cited by applicant
Kaplan S.M., “Wiley Electrical and Electronics Engineering Dictionary,” IEEE Press, John Wiley & Sons, Inc., 2004, pp. 141, 142, 548 & 549. cited by applicant
Kargol M., et al., “Studies on the Structural Properties of Porous Membranes: Measurement of Linear Dimensions of Solutes,” Biophysical Chemistry, 2001, vol. 91, pp. 263-271. cited by applicant
Karube I., et al., “Microbiosensors for Acetylcholine and Glucose,” Biosensors & Bioelectronics, 1993, vol. 8, pp. 219-228. cited by applicant
Kaufman F.R., et al., “A Pilot Study of the Continuous Glucose Monitoring System,” Diabetes Care, vol. 24 (12), Dec. 2001, pp. 2030-2034. cited by applicant

Kaufman F.R., "Role of the Continuous Glucose Monitoring System in Pediatric Patients," Diabetes Technology and Therapeutics, vol. 2 (1), 2000, S49-S52. cited by applicant
Kawagoe J.L., et al., "Enzyme-Modified Organic Conducting Salt Microelectrode," Analytical Chemistry, vol. 63, 1991, pp. 2961-2965. cited by applicant
Keedy F.H., et al., "Determination of Urate in Undiluted Whole Blood by Enzyme Electrode," Biosensors and Bioelectronics, vol. 6, 1991, pp. 491-499. cited by applicant
Kerner, et al., "A Potentially Implantable Enzyme Electrode for Amperometric Measurement of Glucose," Hormone and Metabolic Research Supplement, vol. 20, 1988, pp. 8-13. cited by applicant
Kerner W., et al., "The Function of a Hydrogen Peroxide-Detecting Electroenzymatic Glucose Electrode is Markedly Impaired in Human Sub-Cutaneous Tissue and Plasma," Biosensors and Bioelectronics, vol. 8, 1993, pp. 473-482. cited by applicant
Kerner W., "Implantable Glucose Sensors: Present Status and Future Developments," Experimental and Clinical Endocrinol Diabetes, vol. 109 (2), 2001, pp. S341-S346. cited by applicant
Kiechle F.L., "The Impact of Continuous Glucose Monitoring on Hospital Point-of-Care Testing Programs," Diabetes Technology and Therapeutics, vol. 3 (4), 2001, pp. 647-649. cited by applicant
Kizilel S., et al., "Review: The Bioartificial Pancreas: Progress and Challenges," Diabetes Technology & Therapeutics, vol. 7 (6), 2005, pp. 968-985. cited by applicant
Klonoff D., et al., "Performance Metrics for Continuous Interstitial Glucose Monitoring; Approved Guideline," Clinical and Laboratory Standards Institute, POCT05-A, vol. 28 (33), 2008, 72 pages. cited by applicant
Klonoff D.C., "Editorial: Current, Emerging, and Future Trends in Metabolic Monitoring," Diabetes Technology & Therapeutics, vol. 4 (5), 2002, pp. 583-588. cited by applicant
Klueh U., et al., "Inflammation and Glucose Sensors: Use of Dexamethasone to Extend Glucose Sensor Function and Life Span in Vivo," Journal of Diabetes Science and Technology, vol. 1 (4), Jul. 2007, pp. 496-504. cited by applicant
Klueh U., et al., "Use of Vascular Endothelial Cell Growth Factor Gene Transfer to Enhance Implantable Sensor Function in Vivo," Biosensor Function and VEGF-Gene Transfer, vol. 67 (4), 2003, pp. 1072-1086. cited by applicant
Kondo T., et al., "A Miniature Glucose Sensor, Implantable in the Blood Stream," Diabetes Care, vol. 5 (3), May-Jun. 1982, 218-221. cited by applicant
Koschinsky T., et al., "Sensors For Glucose Monitoring: Technical and Clinical Aspects," Diabetes Metabolism Research and Reviews, vol. 17, No. 2, Jan. 1, 2001, pp. 113-123. cited by applicant
Koschinsky T., et al., "New Approach to Technical and Clinical Evaluation of Devices for Self-Monitoring of Blood Glucose," Diabetes Care, vol. 11 (8), Sep. 1988, pp. 619-629. cited by applicant
Koschinsky T., et al., "Review: Glucose Sensors and the Alternate Site Testing-like Phenomenon: Relationship Between Rapid Blood Glucose Changes and Glucose Sensor Signals," Diabetes Technology & Therapeutics, vol. 5 (5), 2003, pp. 829-842. cited by applicant
Kost J., et al., "Glucose-Sensitive Membranes Containing Glucose Oxidase: Activity, Swelling, and Permeability Studies," Journal of Biomedical Materials Research, vol. 19, 1985, pp. 1117-1133. cited by applicant
Koudelka M., et al., "In Vivo Response of Microfabricated Glucose Sensors to Glycemia Changes in Normal Rats," Biomed. Biochim. Acta, vol. 48 (11/12), Nov.-Dec. 1989, pp. 953-956. cited by applicant
Koudelka M., et al., "In-Vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors," Biosensors and Bioelectronics, vol. 6, 1991, pp. 31-36. cited by applicant
Kovatchev B.P., et al., "Evaluating the Accuracy of Continuous Glucose-Monitoring Sensors: Continuous Glucose-Error Grid Analysis Illustrated by TheraSense Freestyle Navigator Data,"

Diabetes Care, vol. 27 (8), Aug. 2004, pp. 1922-1928. cited by applicant
Kraver., et al., “A Mixed-Signal Sensor Interface Microinstrument,” Sensors and Actuators A, Physical 2001, vol. 91, pp. 266-277. cited by applicant
Krouwer J.S., “Setting Performance Goals and Evaluating Total Analytical Error for Diagnostic Assays,” Clinical Chemistry, vol. 48 (6), 2002, pp. 919-927. cited by applicant
Kruger D., et al., “Psychological Motivation and Patient Education: A Role for Continuous Glucose Monitoring,” Diabetes Technology and Therapeutics, vol. 2 (1), 2000, pp. S93-S97. cited by applicant
Kulys J., et al., “Carbon-Paste Biosensors Array for Long-Term Glucose Measurement,” Biosensors & Bioelectronics, vol. 9, 1994, pp. 491-500. cited by applicant
Kunjan K., et al., “Automated Blood Sampling and Glucose Sensing in Critical Care Settings,” Journal of Diabetes Science and Technology, vol. 2 (2), Mar. 2008, pp. 194-200. cited by applicant
Kunzler J., et al.,“Hydrogels based on Hydrophilic Side Chain Siloxanes,” Poly Mat Sci and Eng, 1993, vol. 69, pp. 226-227. cited by applicant
Kunzler J F., et al., “Contact Lens Materials,” Chemistry & Industry, Aug. 21, 1995, pp. 651-655. cited by applicant
Kurnik R.T., et al., “Application of the Mixtures of Experts Algorithm for Signal Processing in a Noninvasive Glucose Monitoring System,” Sensors and Actuators B, vol. 60, 1999, pp. 19-26. cited by applicant
Kurtz T.W., et al., “Recommendations for Blood Pressure Measurement in Humans and Experimental Animals, Part 2: Blood Pressure Measurement in Experimental Animals: A Statement for Professionals From the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research,” Hypertension, Feb. 2005, vol. 45, pp. 299-310. cited by applicant
Lacourse W.R., et al., “Optimization of Waveforms for Pulsed Amperometric Detection of Carbohydrates Based on Pulsed Voltammetry,” Analytical Chemistry, vol. 65, 1993, pp. 50-52. cited by applicant
Ladd M.F.C., et al., “Structure Determination by X-Ray Crystallography,” 3rd Edition, Plenum Press, 1994, Ch. 1, pp. xxi-xxiv and 1-58. cited by applicant
Lee E., et al., “Effects of Pore Size, Void Volume and Pore Connectivity on Tissue Responses to Porous Silicone Implants,” Society for Biomaterials, 25th Annual Meeting, 1999, p. 171. cited by applicant
Lee S.W., et al., “Combined Insulin Pump Therapy with Real-Time Continuous Glucose Monitoring Significantly Improves Glycemic Control Compared to Multiple Daily Injection Therapy in Pump Naïve Patients with Type 1 Diabetes; Single Center Pilot Study Experience,” Journal of Diabetes Science and Technology, vol. 1 (3), May 2007, pp. 400-404. cited by applicant
Lehmann E.D., et al., Retrospective Validation of a Physiological Model of Glucose-Insulin Interaction in Type 1 Diabetes Mellitus. Medical Engineering & Physics, vol. 16, May 1994, pp. 193-202. cited by applicant
Lerner., et al., “An Implantable Electrochemical Glucose Sensor,” Ann. N. Y. Acad. Sci., vol. 428, May 1984, pp. 263-278. cited by applicant
Lewandowski J.J., et al., “Evaluation of a Miniature Blood Glucose Sensor,” Transactions—American Society for Artificial Internal Organs, vol. 34, 1988, pp. 255-258. cited by applicant
Leypoldt J.K., et al., “Model of a Two-Substrate Enzyme Electrode for Glucose,” Analytical Chemistry, vol. 56, 1984, pp. 2896-2904. cited by applicant
Linke B., et al., “Amperometric Biosensor for In Vivo Glucose Sensing Based on Glucose Oxidase Immobilized in a Redox Hydrogel,” Biosensors and Bioelectronics, vol. 9, 1994, pp. 151-158. cited by applicant
Loffler P., et al., “Separation and Determination of Traces of Ammonia in Air by Means of Chromatomembrane Cells,” Fresenius Journal of Analytical Chemistry, 1995, vol. 352, pp. 613-

614. cited by applicant
Lohn A., et al., “A Knowledge-Based System for Real-Time Validation of Calibrations and Measurements,” Chemometrics and Intelligent Laboratory Systems, vol. 46, 1999, pp. 57-66. cited by applicant
Lowe C.R., “Biosensors,” Trends in Biotechnology, vol. 2 (3), 1984, pp. 59-65. cited by applicant
Luong J.H.T., et al., “Solubilization of Multiwall Carbon Nanotubes by 3-Aminopropyltriethoxysilane towards the Fabrication of Electrochemical Biosensors with Promoted Electron Transfer,” Electroanalysis, vol. 16 (1-2), 2004, pp. 132-139. cited by applicant
Lyandres O., et al. “Progress toward an In Vivo Surface-Enhanced Raman Spectroscopy Glucose Sensor,” Diabetes Technology and Therapeutics, vol. 10 (4), 2008, pp. 257-265. cited by applicant
Lyman D J., “Polyurethanes. I. The Solution Polymerization of Diisocyanates with Ethylene Glycol,” Journal of Polymer Science, 1960, vol. XLV, pp. 49-59. cited by applicant
Lynch S.M., et al., “Estimation-Based Model Predictive Control of Blood Glucose in Type I Diabetics: A Simulation Study,” Proceedings of the IEEE 27th Annual Northeast Bioengineering Conference, 2001, pp. 79-80. cited by applicant
Lynn P.A., “Recursive Digital Filters for Biological Signals,” Med. & Biol. Engineering, vol. 9, 1971, pp. 37-43. cited by applicant
Madaras M B., et al., “Microfabricated Amperometric Creatine and Creatinine Biosensors,” Analytica Chimica Acta, 1996, vol. 319, pp. 335-345. cited by applicant
Maidan R., et al., “Elimination of Electrooxidizable Interferent-Produced Currents in Amperometric Biosensors,” Analytical Chemistry, vol. 64, 1992, pp. 2889-2896. cited by applicant
Makale M.T., et al., “Tissue Window Chamber System for Validation of Implanted Oxygen Sensors,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 284, Feb. 21, 2003, pp. 1-27. cited by applicant
Malin S.F., et al., “Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectroscopy,” Clinical Chemistry, vol. 45 (9), 1999, pp. 1651-1658. cited by applicant
Mancy K.H., et al., “A Galvanic Cell Oxygen Analyzer,” Journal of Electroanalytical Chemistry, vol. 4, 1962, pp. 65-92. cited by applicant
Maran A., et al., “Continuous Subcutaneous Glucose Monitoring in Diabetic Patients,” A Multicenter Analysis, Diabetes Care, vol. 25 (2), Feb. 2002, pp. 347-352. cited by applicant
March W.F., “Dealing with the Delay,” Diabetes Technology & Therapeutics, vol. 4 (1), 2002, pp. 49-50. cited by applicant
Marena S., et al., “The Artificial Endocrine Pancreas in Clinical Practice and Research,” Panminerva Medica, vol. 35 (2), 1993, pp. 67-74. cited by applicant
Martin R.F., “General Deming Regression for Estimating Systematic Bias and its Confidence Interval in Method-Comparison Studies,” Clinical Chemistry, vol. 46 (1), 2000, pp. 100-104. cited by applicant
Mascini M., et al., “Glucose Electrochemical Probe with Extended Linearity for Whole Blood,” Journal Pharmaceutical and Biomedical Analysis, vol. 7 (12), 1989, pp. 1507-1512. cited by applicant
Mastrototaro J.J., et al., “An Electroenzymatic Glucose Sensor Fabricated on a Flexible Substrate,” Sensors and Actuators B, vol. 5, 1991, pp. 139-144. cited by applicant
Mastrototaro J.J., et al., “Reproducibility of the Continuous Glucose Monitoring System Matches Previous Reports and the Intended Use of the Product,” Diabetes Care, vol. 26 (1), Jan. 2003, pp. 256-257. cited by applicant
Mastrototaro J.J., “The MiniMed Continuous Glucose Monitoring System,” Diabetes Technology & Therapeutics, vol. 2, Supplement 1, 2000, pp. S13-S18. cited by applicant
Matsuki H., “Energy Transfer System Utilizing Amorphous Wires for Implantable Medical Devices,” IEEE Transactions on Magnetics, vol. 31 (2), 1994, pp. 1276-1282. cited by applicant
Matsumoto T., et al., “A long-Term Lifetime Amperometric Glucose Sensor with a Perfluorocarbon

Polymer Coating," Biosensors & Bioelectronics, vol. 16, 2001, pp. 271-276. cited by applicant
Matsumoto T., et al., "A Micro-Planar Amperometric Glucose Sensor Unsusceptible to Interference Species," Sensors and Actuators B, 49, 1998, pp. 68-72. cited by applicant
Matthews D.R., et al., "An Amperometric Needle-Type Glucose Sensor Testing in Rats and Man," Diabetic Medicine, vol. 5, 1988, pp. 248-252. cited by applicant
Mazze R.S., et al., "Characterizing Glucose Exposure for Individuals with Normal Glucose Tolerance Using Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis," Diabetes Technology & Therapeutics, vol. 10 (3), 2008, pp. 149-159. cited by applicant
Mazzola F., et al., "Video Diabetes: A Teaching Tool for Children with Insulin-Dependent Diabetes," IEEE, Proceedings 7th Annual Symposium on Computer Applications in Medical Care, Oct. 1983, 1 page Abstract. cited by applicant
McCartney L.J., et al., "Near-Infrared Fluorescence Lifetime Assay for Serum Glucose Based on Allophycocyanin-Labeled Concanavalin A," Analytical Biochemistry, vol. 292, 2001, pp. 216-221. cited by applicant
McGrath M.J., et al., "The Use of Differential Measurements with a Glucose Biosensor for Interference Compensation During Glucose Determinations by Flow Injection Analysis," Biosens Bioelectron, vol. 10, 1995, pp. 937-943. cited by applicant
McKean B.D., et al., "A Telemetry Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors," IEEE Transactions on Biomedical Engineering, vol. 35 (7), Jul. 1988, pp. 526-532. cited by applicant
Memoli A., et al., "A Comparison between Different Immobilised Glucoseoxidase-Based Electrodes," Journal of Pharmaceutical and Biomedical Analysis, vol. 29, 2002, pp. 1045-1052. cited by applicant
Merriam Webster Online Dictionary, Definition for "Aberrant," retrieved from https://www.merriam-webster.com/dictionary/aberrant Aug. 19, 2008, 1 page. cited by applicant
Merriam-Webster Online Dictionary, Definition of "Acceleration" retrieved from http://www.merriam-webster.com/dictionary/Acceleration Jan. 11, 2010, 1 page. cited by applicant
Merriam-Webster Online Dictionary, Definition of "Nominal" retrieved from http://www.merriam-webster.com/dictionary/nominal Apr. 23, 2007, 1 page. cited by applicant
Merriam-Webster Online Dictionary, Definition of "System". http://www.merriamwebster.com/dictionary/System Jan. 11, 2010, 2 pages. cited by applicant
Metzger M., et al., "Reproducibility of Glucose Measurements using the Glucose Sensor," Diabetes Care, vol. 25 (6), Jul. 2002, pp. 1185-1191. cited by applicant
Meyerhoff C., et al., "On Line Continuous Monitoring of Subcutaneous Tissue Glucose in Men by Combining Portable Glucosensor With Microdialysis," Diabetologia, vol. 35 (11), 1992, pp. 1087-1092. cited by applicant
Miller J.A., et al., "Development of an Autotuned Transcutaneous Energy Transfer System," ASAIO Journal, vol. 39, 1993, pp. M706-M710. cited by applicant
Miller K.M., et al., "Generation of IL-1 like Activity in Response to Biomedical Polymer Implants: a Comparison of in Vitro and in Vivo Models," Journal of Biomedical Materials Research, vol. 23(9), 1989, pp. 1007-1026. cited by applicant
Miller K.M., et al., "Human monocyte/macrophage activation and interleukin 1 generation by biomedical polymers," Journal of Biomedical Materials Research, vol. 22 (8), 1988, pp. 713-731. cited by applicant
Miller K.M., et al., "In Vitro Stimulation of Fibroblast Activity by Factors Generated from Human Monocytes Activated by Biomedical Polymers," Journal of Biomedical Materials Research, vol. 23(8), 1989, pp. 911-930. cited by applicant
Moatti-Sirat D., et al., "Evaluating In Vitro and In Vivo the Interference of Ascorbate and Acetaminophen on Glucose Detection by a Needle-Type Glucose Sensor," Biosensors and Bioelectronics, vol. 7, 1992, pp. 345-352. cited by applicant

Moatti-Sirat D., et al., “Reduction of Acetaminophen Interference in Glucose Sensors by a Composite Nafion Membrane: Demonstration in Rats and Man,” Diabetologia, vol. 37 (6), Jun. 1994, pp. 610-616. cited by applicant
Moatti-Sirat., et al., “Towards Continuous Glucose Monitoring: In Vivo Evaluation of a Miniaturized Glucose Sensor Implanted for Several Days in Rat Subcutaneous Tissue,” Diabetologia, vol. 35, 1992, pp. 224-230. cited by applicant
Monsod T.P., et al., “Do Sensor Glucose Levels Accurately Predict Plasma Glucose Concentrations During Hypoglycemia and Hyperinsulinemia?,”Diabetes Care, vol. 25 (5), 2002, pp. 889-893. cited by applicant
Morff R.J., et al., “Microfabrication of Reproducible, Economical, Electroenzymatic Glucose Sensors,” Annual International Conference of the IEEE Engineering in Medicine and Biology Society, vol. 12 (2), 1990, pp. 0483-0484. cited by applicant
Mosbach K., et al., “Determination of Heat Changes in the Proximity of Immobilized Enzymes with an Enzyme Thermistor and its Use for the Assay of Metabolites,” Biochimica Biophysica Acta, vol. 403, 1975, pp. 256-265. cited by applicant
Motonaka J., et al., “Determination of Cholesterol and Cholesterol Ester with Novel enzyme Microsensors,” Anal. Chem., vol. 65, 1993, pp. 3258-3261. cited by applicant
Moussy F., et al., “A Miniaturized Nafion-Based Glucose Sensor: In Vitro and In Vivo Evaluation in Dogs,” International Journals of Artificial Organs, vol. 17 (2), 1994, pp. 88-94. cited by applicant
Moussy F., et al., “Biomaterials community examines biosensor biocompatibility,” Diabetes Technology & Therapeutics, vol. 2(3), 2000, pp. 473-477. cited by applicant
Moussy F., et al., “Performance of Subcutaneously Implanted Needle-Type Glucose Sensors Employing a Novel Trilayer Coating,” Analytical Chemistry, vol. 65, Aug. 1, 1993, pp. 2072-2077. cited by applicant
Moussy F., “Implantable Glucose Sensor: Progress and Problems,” IEEE, Nov. 2002, pp. 270-273. cited by applicant
Mowery K.A., et al., “Preparation and Characterization by Hydrophobic Polymeric Films that are Thromboresistant via Nitric Oxide Release,” Biomaterials, vol. 21, 2000, pp. 9-21. cited by applicant
Murphy S.M., et al., “Polymer Membranes in Clinical Sensor Applications, II. The Design and Fabrication of Permselective Hydrogels for Electrochemical Devices,” Biomaterials, 1992, vol. 13 (14), pp. 979-990. cited by applicant
Muslu, “Trickling Filter Performance,” Applied Biochemistry and Biotechnology, vol. 37, 1992, pp. 211-224. cited by applicant
Myler S., et al., “Ultra-Thin-Polysiloxane-Film-Composite Membranes for the Optimisation of Amperometric Oxidase Enzyme Electrodes,” Biosensors & Bioelectronics, vol. 17, 2002, pp. 35-43. cited by applicant
Nakayama Y., et al., “Surface Fixation of Hydrogels: Heparin and Glucose Oxidase Hydrogelated Surfaces” ASAIO Journal, 1992, pp. M421-M424. cited by applicant
Nam Y.S., et al., “A Novel Fabrication Method of Macroporous Biodegradable Polymer Scaffolds Using Gas Foaming Salt as a Porogen Additive,” J Biomed Mater Res, 2000, vol. 53, pp. 1-7. cited by applicant
Neuburger G.G., et al., “Pulsed Amperometric Detection of Carbohydrates at Gold Electrodes with a Two-Step Potential Waveform,” Anal. Chem., vol. 59, 1987, pp. 150-154. cited by applicant
NewsRx, “Glucose Monitoring: FDA OKs New Device to Manage Diabetes,” Medical Letter on the CDC & FDA via NewsRx.com, Aug. 3, 2003, 1 page. cited by applicant
Nintendo Healthcare, Wired, Dec. 1993, 1 page. cited by applicant
Novo Nordisk Pharmaceuticals Inc., “Diabetes Educational Video Game Recognized by Software Publishers Association,” Press Release, Mar. 14, 1994, 4 pages. cited by applicant

Ohara T.J., et al., “Glucose Electrodes Based on Cross-Linked [Os(bpy)2Cl](+/2+) Complexed Poly(1-Vinylimidazole) Films,” Analytical Chemistry, vol. 65, Dec. 1993, pp. 3512-3517. cited by applicant
Ohara T.J., et al., ““Wired” Enzyme Electrodes for Amperometric Determination of Glucose or Lactate in the Presence of Interfering Substances,” Anal Chem, vol. 66, 1994, pp. 2451-2457. cited by applicant
Okuda, et al., “Mutarotase Effect on Micro Determinations of D-Glucose and its Anomers with β D-Glucose Oxidase,” Anal Biochem, vol. 43 (1), 1971, pp. 312-315. cited by applicant
Oxford English Dictionary Online, Definition of “Impending,” http://www.askoxford.com/results/?view=devdic&field-12668446_Impending&branch Jan. 11, 2010, 1 page. cited by applicant
Palmisano F., et al., “Simultaneous Monitoring of Glucose and Lactate by an Interference and Cross-Talk Free Dual Electrode Amperometric Biosensor Based on Electropolymerized Thin Films,” Biosensors & Bioelectronics, vol. 15, 2000, pp. 531-539. cited by applicant
Panetti T.S., “Differential Effects of Sphingosine 1-Phosphate and Lysophosphatidic Acid on Endothelial Cells,” Biochimica et Biophysica Acta, vol. 1582, 2002, pp. 190-196. cited by applicant
Panteleon A.E., et al., “The Role of the Independent Variable to Glucose Sensor Calibration,” Diabetes Technology & Therapeutics, vol. 5 (3), 2003, pp. 401-410. cited by applicant
Parker R.S., et al., “A Model-Based Algorithm for Blood Glucose Control in Type I Diabetic Patients,” IEEE Trans Biomed Engg (BME), vol. 46(2), 1999, pp. 148-157. cited by applicant
Patel H., et al., “Amperometric Glucose Sensors Based on Ferrocene Containing Polymeric Electron Transfer Systems—A Preliminary Report,” Biosensors & Bioelectronics, vol. 18, 2003, pp. 1073-1076. cited by applicant
Peacock W.F., et al., “Cardiac Troponin and Outcome in Acute Heart Failure,” N. Engl. J. Med., vol. 358, 2008, pp. 2117-2126. cited by applicant
Peguin S., et al., “Pyruvate Oxidase and Oxaloacetate Decarboxylase Enzyme Electrodes—Simultaneous Determination of Transaminases with a Two-electrode-based Analyzer,” Analytica Chimica Acta, vol. 222, 1989, pp. 83-93. cited by applicant
Pfeiffer E.F., et al., “On Line Continuous Monitoring of Subcutaneous Tissue Glucose is Feasible by Combining Portable Glucosensor with Microdialysis,” Horm. Metab. Res., vol. 25, 1993, pp. 121-124. cited by applicant
Pfeiffer E.F., “The Glucose Sensor: The Missing Link in Diabetes Therapy,” Horm Metab Res Suppl., vol. 24, 1990, pp. 154-164. cited by applicant
Phillips R.E., et al., “Biomedical Applications of Polyurethanes: Implications of Failure Mechanisms,” Journal of Biomedical application, vol. 3, Oct. 1988, pp. 206-227. cited by applicant
Phillips R.P., “A High Capacity Transcutaneous Energy Transmission System,” ASIAO Journal, vol. 41, 1995, pp. M259-M262. cited by applicant
Pichert J.W., et al., “Issues for the Coming Age of Continuous Glucose Monitoring,” Diabetes Educator, vol. 26 (6), Nov.-Dec. 2000, pp. 969-980. cited by applicant
Pickup J.C., et al., “Developing Glucose Sensors for In Vivo Use,” Elsevier Science Publishers Ltd (UK), Tibtech, vol. 11, 1993, pp. 285-291. cited by applicant
Pickup J.C., et al., “Implantable Glucose Sensors: Choosing the Appropriate Sensor Strategy,” Biosensors, vol. 3, (1987/1988), pp. 335-346. cited by applicant
Pickup J.C., et al., “In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer,” Diabetologia, vol. 32, 1989, pp. 213-217. cited by applicant
Pickup J.C., et al., “Potentially-Implantable, Amperometric Glucose Sensors with Mediated Electron Transfer: Improving the Operating Stability,” Biosensors, vol. 4, 1989, pp. 109-119. cited by applicant
Pickup J.C., et al., “Progress Towards in Vivo Glucose Sensing with a Ferrocene-Mediated

Amperometric Enzyme Electrode," Horm Metab Res Suppl, vol. 20, 1988, pp. 34-36. cited by applicant
Pickup J.C., et al., "Responses and Calibration of Amperometric Glucose Sensors Implanted in the Subcutaneous Tissue of Man," ACTA Diabetol, vol. 30, 1993, pp. 143-148. cited by applicant
Pineda L.M., et al., "Bone Regeneration with Resorbable Polymeric Membranes. III. Effect of Poly(L-lactide) Membrane Pore Size on the Bone Healing Process in Large Defects," Journal of Biomedical Materials Research, vol. 31, 1996, pp. 385-394. cited by applicant
Pinner S.H., et al., "Cross-Linking of Cellulose Acetate by Ionizing Radiation," Nature, vol. 184, Oct. 24, 1959, pp. 1303-1304. cited by applicant
Pishko M.V., et al., "Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels," Analytical Chemistry, vol. 63 (20), 1991, pp. 2268-2272. cited by applicant
Pitzer K.R., et al., "Detection of Hypoglycemia with the Glucowatch Biographer," Diabetes Care, vol. 24 (5), 2001, pp. 881-885. cited by applicant
Poirier J.Y., et al., "Clinical and Statistical Evaluation of Self-Monitoring Blood Glucose Meters," Diabetes Care, vol. 21 (11), Nov. 1998, pp. 1919-1924. cited by applicant
Poitout V., et al., "A Glucose Monitoring System for on Line Estimation in Man of Blood Glucose Concentration Using a Miniaturized Glucose Sensor Implanted in the Subcutaneous Tissue and a Wearable Control Unit," Diabetologia, vol. 36, 1993, pp. 658-663. cited by applicant
Poitout V., et al., "Development of a Glucose Sensor for Glucose Monitoring in Man: The Disposable Implant Concept," Clinical Materials, vol. 15, 1994, pp. 241-246. cited by applicant
Poitout V., et al., "In Vitro and In Vivo Evaluation in Dogs of a Miniaturized Glucose Sensor," ASAIO Transactions, vol. 37, 1991, pp. M298-M300. cited by applicant
Postlethwaite T.A., et al., "Interdigitated Array Electrode as an Alternative to the Rotated Ring-Disk Electrode for Determination of the Reaction Products of Dioxygen Reduction," Analytical Chemistry, vol. 68 (17), Sep. 1996, pp. 2951-2958. cited by applicant
Prabhu V.G., et al., "Electrochemical Studies of Hydrogen Peroxide at a Platinum Disc Electrode," Electrochimica Acta, vol. 26 (6), 1981, pp. 725-729. cited by applicant
Quinn C.A.P., et al., "Biocompatible, Glucose-Permeable Hydrogel for In situ Coating of Implantable Biosensors," Biomaterials, vol. 18 (24), 1997, pp. 1665-1670. cited by applicant
Quinn C.P., et al., "Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors," The American Physiological Society, vol. 269, 1995, pp. E155-E161. cited by applicant
Rabah M.A., et al., "Electrochemical Wear of Graphite Anodes During Electrolysis of Brine," Carbon, vol. 29 (2), 1991, pp. 165-171. cited by applicant
Rafael E., "Cell Transplantation and Immunoisolation: Studies on a Macroencapsulation Device," Departments of Transplantation Surgery and Pathology, Karolinska Institutet, Huddinge Hospital, Stockholm, Sweden, 1999, pp. 1-83. cited by applicant
Ratner B.D., "Reducing Capsular Thickness and Enhancing Angiogenesis around Implant Drug Release Systems," Journal of Controlled Release, vol. 78, 2002, pp. 211-218. cited by applicant
RAYA Systems Pioneers, "Raya Systems Pioneers Healthy Video Games," PlayRight, Nov. 1993, pp. 14-15. cited by applicant
Reach G., "A Method for Evaluating in vivo the Functional Characteristics of Glucose Sensors," Biosensors, vol. 2, 1986, pp. 211-220. cited by applicant
Reach G., et al., "Can Continuous Glucose Monitoring Be Used for the Treatment of Diabetes?," Analytical Chemistry, vol. 64 (6), Mar. 15, 1992, pp. 381A-386A. cited by applicant
Reach G., "Which Threshold to Detect Hypoglycemia? Value of Receiver-Operator Curve Analysis to Find a Compromise Between Sensitivity and Specificity," Diabetes Care, vol. 24 (5), May 2001, pp. 803-804. cited by applicant
Rebrin K., et al., "Automated Feedback Control of Subcutaneous Glucose Concentration in

Diabetic Dogs," Diabetologia, vol. 32, 1989, pp. 573-576. cited by applicant
Rebrin K., et al., "Subcutaneous Glucose Monitoring by Means of Electrochemical Sensors: Fiction or Reality?," Journal of Biomedical Engineering, vol. 14, Jan. 1992, pp. 33-40. cited by applicant
Rebrin K., et al., "Subcutaneous Glucose Predicts Plasma Glucose Independent of Insulin: Implications for Continuous Monitoring," The American Physiological Society, vol. 277, 1999, pp. E561-E571. cited by applicant
Renard E., "Implantable Closed-Loop Glucose Sensing and Insulin Delivery: The Future for Insulin Pump Therapy," Current Opinion in Pharmacology, vol. 2 (6), 2002, pp. 708-716. cited by applicant
Reush, "Organometallic Compounds," Chemical Reactivity, Virtual Textbook of Organic Chemistry, Retrieved from http://www.cem.msu.edu/-reuschlVirtualText/orgmetal.htm 2004, pp. 1-16. cited by applicant
Rhodes R.K., et al., "Prediction of Pocket-Portable and Implantable Glucose Enzyme Electrode Performance from Combined Species Permeability and Digital Simulation Analysis," Analytical Chemistry, vol. 66 (9), May 1, 1994, pp. 1520-1529. cited by applicant
Rigla M., et al., "Real-Time Continuous Glucose Monitoring Together with Telemedical Assistance Improves Glycemic Control and Glucose Stability in Pump-Treated Patients," Diabetes Technology & Therapeutics, vol. 10 (3), 2008, pp. 194-199. cited by applicant
Rinken T., et al., "Calibration of Glucose Biosensors by Using Pre-Steady State Kinetic Data," Biosensors & Bioelectronics, vol. 13, 1998, pp. 801-807. cited by applicant
Ristic S., et al., "Review: Effects of Rapid-Acting Insulin Analogs on Overall Glycemic Control in Type 1 and Type 2 Diabetes Mellitus," Diabetes Technology & Therapeutics, vol. 5 (1), 2003, pp. 57-66. cited by applicant
Rivers E.P., et al., "Central Venous Oxygen Saturation Monitoring in the Critically Ill Patient," Current Opinion in Critical Care, 2001, vol. 7, pp. 204-211. cited by applicant
Sachlos E., et al., "Making Tissue Engineering Scaffolds Work Review on the Application of Solid Freeform Fabrication Technology to the Production of Tissue Engineering Scaffolds," European Cells and Materials, vol. 5, 2003, pp. 29-40. cited by applicant
Sakakida M., et al., "Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations," Artif. Organs Today, vol. 2 (2), 1992, pp. 145-158. cited by applicant
Sakakida M., et al., "Ferrocene-Mediated Needle Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane," Sensors and Actuators B, vol. 13-14, 1993, pp. 319-322. cited by applicant
Salardi S., et al., "The Glucose Area Under the Profiles Obtained with Continuous Glucose Monitoring System Relationships with HbA1C in Pediatric Type 1 Diabetic Patients," Diabetes Care, vol. 25 (10), Oct. 2002, pp. 1840-1844. cited by applicant
Samuels M.P., "The Effects of Flight and Altitude," Arch Dis Child, vol. 89, 2004, pp. 448-455. cited by applicant
San Diego Plastics Inc, "Polyethylene," Datasheet, Retrieved from http://www.sdplastics.com/polyeth.html on Aug. 19, 2009, 7 pages. cited by applicant
Sanders E., et al., "Fibrous Encapsulation of Single Polymer Microfibers Depends on their Vertical Dimension in Subcutaneous Tissue Polymer Microfibers," Journal of Biomedical Material Research, vol. 67A, 2003, pp. 1181-1187. cited by applicant
Sansen W., et al., "A Smart Sensor for the Voltammetric Measurement of Oxygen or Glucose Concentrations," Sensors and Actuators B1, 1990, pp. 298-302. cited by applicant
Sansen W., et al., "Glucose Sensor with Telemetry System," In Implantable Sensors for Closed Loop Prosthetic Systems edited by Ko W.H, Chapter 12, 1985, pp. 167-175. cited by applicant
Schaffar B.P.H., "Thick Film Biosensors for Metabolites in Undiluted Whole Blood and Plasma

Samples," Analytical Bioanalytical Chemistry, Dec. 2001, vol. 372, pp. 254-260. cited by applicant
Schmidt F.J., et al., "Calibration of a Wearable Glucose Sensor," The International Journal of Artificial Organs, Wichtig Publishing, IT, vol. 15 (1), Jan. 1, 1992, pp. 55-61. cited by applicant
Schmidt F.J., et al., "Glucose Concentration in Subcutaneous Extracellular Space," Diabetes Care, vol. 16 (5), May 1993, pp. 695-700. cited by applicant
Schmidtke D.W., et al., "Accuracy of the One-Point in Vivo Calibration of "Wired" Glucose Oxidase Electrodes Implanted in Jugular Veins of Rats in Periods of Rapid Rise and Decline of the Glucose Concentration," Analytical Chemistry, vol. 70 (10), May 15, 1998, pp. 2149-2155. cited by applicant
Schmidtke D.W., et al., "Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin," Proceedings of the National Academy of Sciences, vol. 95, Jan. 1998, pp. 294-299. cited by applicant
Schoemaker M., et al., "The SCGMI System: Subcutaneous Continuous Glucose Monitoring Based on Microdialysis Technique," Diabetes Technology & Therapeutics, vol. 5 (4), 2003, pp. 599-608. cited by applicant
Schoonen A.J.M., et al., "Development of a Potentially Wearable Glucose Sensor for Patients with Diabetes Mellitus: Design and In-vitro Evaluation," Biosensors & Bioelectronics, vol. 5, 1990, pp. 37-46. cited by applicant
Schuler, et al., "Modified Gas-Permeable Silicone Rubber Membranes for Covalent Immobilisation of Enzymes and their Use in Biosensor Development," Analyst, 1999, vol. 124, pp. 1181-1184. cited by applicant
Selam J.L., "Management of Diabetes with Glucose Sensors and Implantable Insulin Pumps," From the Dream of the 60s to the Realities of the 90s, ASAIO Journal 1997, vol. 43, pp. 137-142. cited by applicant
Service F.J., et al., "Mean Amplitude of Glycemic Excursions, A Measure of Diabetic Instability," Diabetes, vol. 19 (9), Sep. 1970, pp. 644-655. cited by applicant
Service F.J., et al., "Measurements of Glucose Control," Diabetes Care, vol. 10 (2), Mar.-Apr. 1987, pp. 225-237. cited by applicant
Service R.F., "Can Sensors Make a Home in the Body?," Science, Materials Science: Soft Surface, vol. 297, Aug. 9, 2002, pp. 962-963. cited by applicant
Sharkawy A.A., et al., "Engineering the Tissue Which Encapsulates Subcutaneous Implants. I. Diffusion Properties," Journal of Biomedical Materials Research, vol. 37, 1996, pp. 401-412. cited by applicant
Shaw G.W., et al., "In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients," Biosensors & Bioelectronics, vol. 6, 1991, pp. 401-406. cited by applicant
Shichiri M., et al., "Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas," Diabetologia, vol. 24, 1983, pp. 179-184. cited by applicant
Shichiri M., et al., "Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor," Diabetes Nutrition & Metabolism, vol. 2 (4), 1989, pp. 309-313. cited by applicant
Shichiri M., et al., "Needle Type Glucose Sensor for Wearable Artificial Endocrine Pancreas," In Implantable Sensors for Closed-Loop Prosthetic Systems edited by Ko W.H, Chapter 15, 1985, pp. 197-210. cited by applicant
Shichiri M., et al., "Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals," Diabetes Care, vol. 9 (3), May-Jun. 1986, pp. 298-301. cited by applicant
Shichiri M., et al., "Wearable Artificial Endocrine Pancreas with Needle-Type Glucose Sensor," Preliminary Communication, Lancet, vol. 2, Nov. 20, 1982, pp. 1129-1131. cited by applicant
Shults M.C., et al., "A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors," IEEE Transactions on Biomedical Engineering, vol. 41 (10), Oct.

1994, pp. 937-942. cited by applicant
Sieminski, et al., “Biomaterial-Microvasculature Interactions,” Biomaterials, 2000, vol. 21, pp. 2233-2241. cited by applicant
Sigma-Aldrich Corp., “Cellulose Acetate,” Product Description, Product No. 419028, St. Louis, MO, 2005, 1 page. cited by applicant
Sigma-Aldrich Corp. “Nafion® 117 Solution Product Description, Product No. 70160,” retrieved from https//:www.sigmaaldrich.com/cgi-bin/hsrun/Suite7/Suite/HAHTpage/Suite.HsExternalProd on Apr. 7, 2005, 1 page. cited by applicant
Skyler J.S., “The Economic Burden of Diabetes and the Benefits of Improved Glycemic Control: The Potential Role of a Continuous Glucose Monitoring System,” Diabetes Technology & Therapeutics, vol. 2, Supplement 1, 2000, pp. S7-S12. cited by applicant
Slater-Maclean L., et al., “Accuracy of Glycemic Measurements in the Critically Ill,” Diabetes Technology and Therapeutics, vol. 10 (3), 2008, pp. 169-177. cited by applicant
Smith B., et al., “An Externally Powered, Multichannel, Implantable Stimulator-Telemeter for Control of Paralyzed Muscle,” IEEE Transactions on Biomedical Engineering, vol. 45 (4), Apr. 1998, pp. 463-475. cited by applicant
Smith, et al.,“ A Comparison of Islet Transplantation and Subcutaneous Insulin Injections for the Treatment of Diabetes Mellitus,” Computers in Biology and Medicine, 1991, vol. 21 (6), pp. 417-427. cited by applicant
Sokol L., et al., “Immobilized-Enzyme Rate-Determination Method for Glucose Analysis,” Clinical Chemistry, vol. 26 (1), 1980, pp. 89-92. cited by applicant
Sokolov S., et al., “Metrological Opportunities of the Dynamic Mode of Operating an Enzyme Amperometric Biosensor,” Medical Engineering & Physics, vol. 17 (6), 1995, pp. 471-476. cited by applicant
Sparacino G., et al., “Continuous Glucose Monitoring Time Series and Hypo-Hyperglycemia Prevention: Requirements, Methods, Open Problems,” Current Diabetes Reviews, vol. 4 (3), 2008, pp. 181-192. cited by applicant
Sproule B.A., et al., “Fuzzy Pharmacology: Theory and Applications,” Trends in Pharmacological Sciences, vol. 23 (9), Sep. 2002, pp. 412-417. cited by applicant
Sriyudthsak M., et al., “Enzyme-Epoxy Membrane Based Glucose Analyzing System and Medical Applications,” Biosensors & Bioelectronics, vol. 11 (8), 1996, pp. 735-742. cited by applicant
Steil G.M., et al., “Determination of Plasma Glucose During Rapid Glucose Excursions with a Subcutaneous Glucose Sensor,” Diabetes Technology & Therapeutics, vol. 5 (1), 2003, pp. 27-31. cited by applicant
Stern M., et al., “Electrochemical Polarization: I. A Theoretical Analysis of the Shape of Polarization Curves,” Journal of the Electrochemical Society, vol. 104 (1), Jan. 1957, pp. 56-63. cited by applicant
Sternberg, et al., “Covalent Enzyme Coupling on Cellulose Acetate Membranes for Glucose Sensor Development,” Anal Chem, Dec. 1988, vol. 60(24), pp. 2781-2786. cited by applicant
Sternberg F., et al., “Does Fall in Tissue Glucose Precede Fall in Blood Glucose?,” Diabetologia, vol. 39, 1996, pp. 609-612. cited by applicant
Sternberg R., et al., “Study and Development of Multilayer Needle-type Enzyme Based Glucose Microsensors,” Biosensors, Mar. 20, 1988, vol. 4 (1), pp. 27-40. cited by applicant
Stokes, “Polyether Polyurethanes: Biostable or Not,” Journal of Biomaterials Applications, Oct. 1988, vol. 3, pp. 228-259. cited by applicant
Street, et al., “Islet Graft Assessment in the Edmonton Protocol: Implications for Predicting Long-Term Clinical Outcome,” Diabetes, 2004, vol. 53, pp. 3107-3114. cited by applicant
Street J.O., et al., “A Note on Computing Robust Regression Estimates via Iteratively Reweighted Least Squares,” The American Statistician, vol. 42 (2), May 1988, pp. 152-154. cited by applicant
Suh, et al., “Behavior of Fibroblasts on a Porous Hyaluronic Acid Incorporated Collagen Matrix,”

Yonsei Medical Journal, 2002, vol. 43 (2), pp. 193-202. cited by applicant
Sumino T., et al., “Preliminary Study of Continuous Glucose Monitoring with a Microdialysis Technique,” Proceedings of the 20th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, vol. 20 (4), 1998, pp. 1775-1778. cited by applicant
Takatsu I., et al., “Solid State Biosensors Using Thin-Film Electrodes,” Sensors and Actuators, 1987, vol. 11, pp. 309-317. cited by applicant
Takegami S., et al., “Pervaporation of Ethanol/Water Mixtures Using Novel Hydrophobic Membranes Containing Polydimethylsiloxane,” Journal of Membrane Science, vol. 75, 1992, pp. 93-105. cited by applicant
Tamura T., et al., “Preliminary Study of Continuous Glucose Monitoring with a Microdialysis Technique and a Null Method-A Numerical Analysis,” Frontiers of Medical & Biological Engineering, vol. 10 (2), 2000, pp. 147-156. cited by applicant
Tanenberg R.J., et al., “Continuous Glucose Monitoring System: A New Approach to the Diagnosis of Diabetic Gastroparesis,” Diabetes Technology & Therapeutics, vol. 2, Supplement 1, 2000, pp. S73-S80. cited by applicant
Tang, et al., “Fibrin(ogen) Mediates Acute Inflammatory Responses to Biomaterials,” J.Exp.Med, 1993, vol. 178, pp. 2147-2156. cited by applicant
Tang, et al., “Inflammatory Responses to Biomaterials,” Am J Clin Pathol, 1995, vol. 103, pp. 466-471. cited by applicant
Tang, et al., “Mast Cells Mediate Acute Inflammatory Responses to Implanted Biomaterials,” Proceedings of the National Academy of Sciences of the USA, 1998, vol. 95, pp. 8841-8846. cited by applicant
Tang, et al., “Molecular Determinants of Acute Inflammatory Responses to Biomaterials,” J Clin Invest, 1996, vol. 97, pp. 1329-1334. cited by applicant
Tatsuma T., et al., “Oxidase/Peroxidase Bilayer-Modified Electrodes as Sensors for Lactate, Pyruvate, Cholesterol and Uric Acid,” Analytica Chimica Acta, vol. 242, 1991, pp. 85-89. cited by applicant
Thennadil S.N., et al., “Comparison of Glucose Concentration in Interstitial Fluid, and Capillary and Venous Blood During Rapid Changes in Blood Glucose Levels,” Diabetes Technology & Therapeutics, vol. 3 (3), 2001, pp. 357-365. cited by applicant
Thijssen, et al., “A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems,” Part 1, Theory and Simulations, Analytica chimica Acta, 1984, vol. 156, pp. 87-101. cited by applicant
Thijssen, et al., “A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems,” Part 3, Variance Reduction ,Analytica chimica Acta, 1985, vol. 173, pp. 265-272. cited by applicant
Thijssen, et al., “A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems,” Part 4, Flow Injection Analysis, Analytica chimica Acta, 1985, vol. 174, pp. 27-40. cited by applicant
Thijssen P.C., “A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems,” Part 2,Optimal Designs, Analytica chimica Acta, vol. 162, 1984, pp. 253-262. cited by applicant
Thome V., et al., “(Abstract) Can the Decrease in Subcutaneous Glucose Concentration Precede the Decrease in Blood Glucose Level? Proposition for a Push-Pull Kinetics Hypothesis,” Horm. metab. Res., vol. 27, 1995, p. 53. cited by applicant
Thome-Duret V., et al., “Continuous Glucose Monitoring in the Free-Moving Rat,” Metabolism, vol. 47 (7), Jul. 1998, pp. 799-803. cited by applicant
Thome-Duret V., et al., “Modification of the Sensitivity of Glucose Sensor Implanted into Subcutaneous Tissue,” Diabetes & Metabolism, vol. 22, 1996, pp. 174-178. cited by applicant
Thome-Duret V., et al., “Use of a Subcutaneous Glucose Sensor to Detect Decreases in Glucose

Concentration Prior to Observation in Blood," Analytical Chemistry, vol. 68 (21), Nov. 1, 1996, pp. 3822-3826. cited by applicant
Thompson M., et al., "In Vivo Probes: Problems and Perspectives," Clinical Biochemistry, vol. 19 (5), Oct. 1986, pp. 255-261. cited by applicant
Tibell, et al., "Survival of Macroencapsulated Allogeneic Parathyroid Tissue One Year after Transplantation in Nonimmunosuppressed Humans," Cell Transplantation, 2001, vol. 10, pp. 591-599. cited by applicant
Tierney M.J., et al., "Effect of Acetaminophen on the Accuracy of Glucose Measurements Obtained with the GlucoWatch Biographer," Diabetes Technology & Therapeutics, vol. 2 (2), 2000, pp. 199-207. cited by applicant
Tierney M.J., et al., "The Gluco Watch® Biographer: A Frequent, Automatic and Noninvasive Glucose Monitor," Annals of Medicine, vol. 32, 2000, pp. 632-641. cited by applicant
Tilbury J.B., et al., "Receiver Operating Characteristic Analysis for Intelligent Medical Systems—A New Approach for Finding Confidence Intervals," IEEE Transactions on Biomedical Engineering, vol. 47 (7), Jul. 2000, pp. 952-963. cited by applicant
Torjman M.C., et al., "Glucose Monitoring in Acute Care: Technologies on the Horizon," Journal of Diabetes Science and Technology, vol. 2 (2), Mar. 2008, pp. 178-181. cited by applicant
Trajanoski Z., et al., "Neural Predictive Controller for Insulin Delivery Using the Subcutaneous Route," IEEE Transactions on Biomedical Engineering, vol. 45(9), 1998, pp. 1122-1134. cited by applicant
Trecroci D., "A Glimpse into the Future-Continuous Monitoring of Glucose with a Microfiber," Diabetes Interview, Jul. 2002, pp. 42-43. cited by applicant
Tse P.S.H., et al., "Time-Dependent Inactivation of Immobilized Glucose Oxidase and Catalase," Biotechnology & Bioengineering, vol. 29, 1987, pp. 705-713. cited by applicant
Turner A.P.F., "Amperometric Biosensor based on Mediator-Modified Electrodes," Methods in Enzymology, 1988, vol. 137, pp. 90-103. cited by applicant
Turner A.P.F., et al., "Carbon Monoxide: Acceptor Oxidoreductase from Pseudomonas Thermocarboxydovorans Strain C2 and its Use in a Carbon Monoxide Sensor," Analytica Chimica Acta, vol. 163, 1984, pp. 161-174. cited by applicant
Turner A.P.F., et al., "Diabetes Mellitus: Biosensors for Research and Management," Biosensors, vol. 1, 1985, pp. 85-115. cited by applicant
Unger J., et al., "Glucose Control in the Hospitalized Patient," Emergency Medicine, vol. 36 (9), 2004, pp. 12-18. cited by applicant
Updike S.J., et al., "A Subcutaneous Glucose Sensor with Improved Longevity, Dynamic Range, and Stability of Calibration," Diabetes Care, vol. 23 (2), Feb. 2000, pp. 208-214. cited by applicant
Updike S.J., et al., "Continuous Glucose Monitor Based on an Immobilized Enzyme Electrode Detector," Journal of Laboratory and Clinical Medicine, vol. 93(4), 1979, pp. 518-527. cited by applicant
Updike S.J., et al., "Enzymatic Glucose Sensor: Improved Long-Term Performance in Vitro and In Vivo," ASAIO Journal, vol. 40 (2), Apr.-Jun. 1994, pp. 157-163. cited by applicant
Updike S.J., et al., "Implanting the Glucose Enzyme Electrode: Problems, Progress, and Alternative Solutions," Diabetes Care, vol. 5 (3), May-Jun. 1982, pp. 207-212. cited by applicant
Updike S.J., et al., "Laboratory Evaluation of New Reusable Blood Glucose Sensor," Diabetes Care, vol. 11 (10), Nov.-Dec. 1988, pp. 801-807. cited by applicant
Updike S.J., et al., "Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose Form Inside a Subcutaneous Foreign Body Capsule (FBC)," Edited by Fraser D M, Biosensors in the Body: Continuous in vivo Monitoring, John Wiley & Sons Ltd., New York, 1997, Chapter 4, pp. 117-137. cited by applicant
Updike S.J., et al., "The Enzyme Electrode," Nature, vol. 214, Jun. 3, 1967, pp. 986-988. cited by applicant

Utah Medical Products Inc., “Deltran—Disposable Blood Pressure Transducers,” Product Specifications, 2003-2006, 6 pages. cited by applicant
Vadgama P., “Diffusion Limited Enzyme Electrodes,” NATO ASI Series: Series C, Math and Phys. Sci, vol. 226, 1988, pp. 359-377. cited by applicant
Vadgama P., “Enzyme Electrodes as Practical Biosensors,” Journal of Medical Engineering & Technology, vol. 5 (6), Nov. 1981, pp. 293-298. cited by applicant
Valdes T.I., et al., “In Vitro and In Vivo Degradation of Glucose Oxidase Enzyme used for an Implantable Glucose Biosensor,” Diabetes Technology & Therapeutics, vol. 2 (3), 2000, pp. 367-376. cited by applicant
Van Den Berghe, “Tight Blood Glucose Control with Insulin in “Real-Life” Intensive Care,” Mayo Clinic Proceedings, vol. 79 (8), Aug. 2004, pp. 977-978. cited by applicant
Velho G., et al., “In Vitro and In Vivo Stability of Electrode Potentials in Needle-Type Glucose Sensors,” Influence of Needle Material, Diabetes, vol. 38, Feb. 1989, pp. 164-171. cited by applicant
Velho G., et al., “Strategies for Calibrating a Subcutaneous Glucose Sensor,” Biomed Biochim Acta, vol. 48 (11/12), 1989, pp. 957-964. cited by applicant
Vesper H.W., et al., “Assessment of Trueness of a Glucose Monitor Using Interstitial Fluid and Whole Blood as Specimen Matrix,” Diabetes Technology & Therapeutics, vol. 8 (1), 2006, pp. 76-80. cited by applicant
Von Woedtke T., et al., “In Situ Calibration of Implanted Electrochemical Glucose Sensors,” Biomed. Biochim. Acta 48 vol. 11/12, 1989, pp. 943-952. cited by applicant
Wade L.G., “Reactions of Aromatic Compounds,” Organic Chemistry, Chapter 17, 5th edition, 2003, pp. 762-763. cited by applicant
Wagner, et al., “Continuous Amperometric Monitoring of Glucose in a Brittle Diabetic Chimpanzee with a Miniature Subcutaneous Electrode,” Proc. Natl. Acad. Sci. USA, vol. 95, May 1998, pp. 6379-6382. cited by applicant
Wang J., et al., “Highly Selective Membrane-Free Mediator-Free Glucose Biosensor,” Analytical Chemistry, vol. 66 (21), Nov. 1, 1994, pp. 3600-3603. cited by applicant
Wang X., et al., “Improved Ruggedness for Membrane-Based Amperometric Sensors using a Pulsed Amperometric Method,” Analytical Chemistry, vol. 69 (21), Nov. 1, 1997, pp. 4482-4489. cited by applicant
Ward W.K., et al., “A New Amperometric Glucose Microsensor: In Vitro and Short-Term In Vivo Evaluation,” Biosensors & Bioelectronics, vol. 17, 2002, pp. 181-189. cited by applicant
Ward W.K., et al., “Assessment of Chronically Subcutaneous Glucose Sensors in Dogs: The Effect of Surrounding Fluid Masses,” ASAIO Journal, 1999, vol. 45 (6), pp. 555-561. cited by applicant
Ward W.K., et al., “Rise in Background Current Over Time in a Subcutaneous Glucose Sensor in the Rabbit,” Relevance to Calibration and Accuracy, Biosensors & Bioelectronics, vol. 15, 2000, pp. 53-61. cited by applicant
Ward W.K., et al., “Understanding Spontaneous Output Fluctuations of an Amperometric Glucose Sensor: Effect of Inhalation Anesthesia and Use of a Nonenzyme Containing Electrode,” ASAIO Journal, 2000, pp. 540-546. cited by applicant
Wentholt I.M.E., et al., “Relationship between Interstitial and Blood Glucose in Type 1 Diabetes Patients: Delay and the Push-pull Phenomenon Revisited,” Diabetes Technology & Therapeutics, vol. 9 (2), 2007, pp. 169-175. cited by applicant
Wientjes K.J.C., “Development of a Glucose Sensor for Diabetic Patients,” (Ph.D. Thesis), 2000, 212 pages. cited by applicant
Wikipedia., “Intravenous Therapy,” http://en.wikipedia.org/wiki/Intravenous_therapy, Aug. 15, 2006, 6 pages. cited by applicant
Wilkins E., et al., “Glucose Monitoring: State of the Art and Future Possibilities,” Med. Eng. Phys., vol. 18 (4), 1996, pp. 273-288. cited by applicant

Wilkins E., et al., “Integrated Implantable Device for Long-Term Glucose Monitoring,” Biosensors & Bioelectronics, vol. 10, 1995, pp. 485-494. cited by applicant
Wilkins E.S., et al., “The Coated Wire Electrode Glucose Sensor,” Horm Metab Res Suppl., vol. 20, 1988, pp. 50-55. cited by applicant
Wilson G.S., et al., “Enzyme-Based Biosensors for In Vivo Measurements,” Chem. Rev., vol. 100, 2000, pp. 2693-2704. cited by applicant
Wilson G.S., et al., “Progress Toward the Development of an Implantable Sensor for Glucose,” Clinical Chemistry, vol. 38 (9), 1992, pp. 1613-1617. cited by applicant
Wolpert H., “Establishing a Continuous Glucose Monitoring Program,” Journal of Diabetes Science and Technology, Mar. 2008, vol. 2 (2), pp. 307-310. cited by applicant
Wolpert H.A., “Commentary: A Clinician's Perspective on Some of the Challenges in Closed Loop,” Diabetes Technology & Therapeutics, vol. 5 (5), 2003, pp. 843-846. cited by applicant
Wood W D., et al., “Hermetic Sealing with Epoxy,” Pave Technology-Mechanical Engineering, Mar. 1990, 3 pages. cited by applicant
Woodward S.C., “How Fibroblasts and Giant Cells Encapsulate Implants: Considerations in Design of Glucose Sensors,” Diabetes Care, vol. 5 (3) May-Jun. 1982, pp. 278-281. cited by applicant
Worsley G.J et al., “Measurement of Glucose in Blood with a Phenylboronic Acid Optical Sensor,” Journal of Diabetes Science and Technology, vol. 2 (2), Mar. 2008, pp. 213-220. cited by applicant
Wright M., et al., “Bioelectrochemical Dehalogenations via Direct Electrochemistry of Poly(ethylene oxide)-Modified Myoglobin,” Electrochemistry Communications, vol. 1, 1999, pp. 609-613. cited by applicant
Wu H., et al., “In Situ Electrochemical Oxygen Generation with an Immunoisolation Device,” Annals New York Academy of Sciences, vol. 875, 1999, pp. 105-125. cited by applicant
Yamasaki Y., et al., “Direct Measurement of Whole Blood Glucose by a Needle-Type Sensor,” Clinica Chimica Acta. 93, 1989, pp. 93-98. cited by applicant
Yamasaki Y., “The Development of a Needle-Type Glucose Sensor for Wearable Artificial Endocrine Pancreas,” Medical Journal of Osaka University, vol. 35 (1-2), Sep. 1984, pp. 25-34. cited by applicant
Yang C., et al., “A Comparison of Physical Properties and Fuel Cell Performance of Nafion and Zirconium Phosphate/Nation Composite Membranes,” Journal of Membrane Science, vol. 237, 2004, pp. 145-161. cited by applicant
Yang Q., et al., “Development of Needle-Type Glucose Sensor with High Selectivity,” Science and Actuators B, vol. 46, 1998, pp. 249-256. cited by applicant
Yang S., et al., “A Glucose Biosensor Based on an Oxygen Electrode: In-Vitro Performances in a Model Buffer Solution and in Blood Plasma,” Biomedical Instrumentation & Technology, vol. 30 (1), 1996, pp. 55-61. cited by applicant
Yang S., et al., “Glucose Biosensors with Enzyme Entrapped in Polymer Coating,” Biomedical Instrument and Technology, Mar./Apr. 1995, vol. 29 (2), pp. 125-133. cited by applicant
Ye L., et al., “High Current Density Wired' Quinoprotein Glucose Dehydrogenase Electrode,” Analytical Chemistry, vol. 65, 1993, pp. 238-241. cited by applicant
Zamzow K.L., et al., “Development and Evaluation of a Wearable Blood Glucose Monitor,” ASAIO Transactions, vol. 36 (3), 1990, pp. M588-M591. cited by applicant
Zavalkoff S.R., et al., “Evaluation of Conventional Blood Glucose Monitoring as an Indicator of Integrated Glucose Values Using a Continuous Subcutaneous Sensor,” Diabetes Care, vol. 25(9), 2002, pp. 1603-1606. cited by applicant
Zethelius B., et al., “Use of Multiple Biomarkers to Improve the Prediction of Death From Cardiovascular Causes,” N. Engl. J. Med., vol. 358, May 2008, pp. 2107-2116. cited by applicant
Zhang, et al., “Elimination of the Acetaminophen Interference in an Implantable Glucose Sensor,” Analytical Chemistry, 1994, vol. 66 (7), pp. 1183-1188. cited by applicant
Zhang Y., et al., “Electrochemical Oxidation of H2O2 on Pt and Pt + Ir Electrodes in Physiological

Buffer and its Applicability to H2O2-Based Biosensors," J. Electro Analytical Chemistry, vol. 345, 1993, pp. 253-271. cited by applicant
Zhang Y., et al., "In Vitro and In Vivo Evaluation of Oxygen Effects on a Glucose Oxidase Based Implantable Glucose Sensor," Analytica Chimica Acta, vol. 281, 1993, pp. 513-520. cited by applicant
Zhu, et al., "Fabrication and Characterization of Glucose Sensors Based on a Microarray H2O2 Electrode," Biosensors & Bioelectronics, 1994, vol. 9, pp. 295-300. cited by applicant
Zhu, et al., "Planar Amperometric Glucose Sensor Based on Glucose Oxidase Immobilized by Chitosan Film on Prussian blue Layer," Sensors, 2002, vol. 2, pp. 127-136. cited by applicant
Ziaie, et al., "A Single-Channel Implantable Microstimulator for Functional Neuromuscular Stimulation," IEEE Transactions on Biomedical Engineering, 1997, vol. 44(10), pp. 909-920. cited by applicant

---

Primary Examiner: Flick; Jason E

Attorney, Agent or Firm: Kaplan Breyer Schwarz LLP

Background/Summary

INCORPORATION BY REFERENCE TO RELATED APPLICATIONS (1) This application is a continuation of, and claims priority to, U.S. patent application Ser. No. 16/513,380, filed Jul. 16, 2019 and titled "Integrated Medicament Delivery Device For Use With Continuous Analyte Sensor," which is a continuation of U.S. application Ser. No. 15/653,394, filed Jul. 18, 2017, which is a divisional of U.S. application Ser. No. 13/963,416, filed Aug. 9, 2013, now U.S. Pat. No. 9,741,139, which is a continuation of U.S. application Ser. No. 12/133,786, filed Jun. 5, 2008, now U.S. Pat. No. 8,562,558, which claims the benefit of U.S. Provisional Application No. 60/942,787, filed Jun. 8, 2007, the disclosure of which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION
(1) The present invention relates generally to systems and methods monitoring glucose in a host. More particularly, the present invention relates to an integrated medicament delivery device and continuous glucose sensor.
BACKGROUND OF THE INVENTION
(2) Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or non-insulin dependent). In the diabetic state, the victim suffers from high blood sugar, which can cause an array of physiological derangements (for example, kidney failure, skin ulcers, or bleeding into the vitreous of the eye) associated with the deterioration of small blood vessels. A hypoglycemic reaction (low blood sugar) can be induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.
(3) Conventionally, a diabetic person carries a self-monitoring blood glucose (SMBG) monitor, which typically comprises uncomfortable finger pricking methods. Due to the lack of comfort and convenience, a diabetic will normally only measures his or her glucose level two to four times per day. Unfortunately, these time intervals are so far spread apart that the diabetic will likely find out too late, sometimes incurring dangerous side effects, of a hyper- or hypo-glycemic condition. In fact, it is not only unlikely that a diabetic will take a timely SMBG value, but the diabetic will not know if their blood glucose value is going up (higher) or down (lower) based on conventional methods, inhibiting their ability to make educated insulin therapy decisions.
(4) Home diabetes therapy requires personal discipline of the user, appropriate education from a

doctor, proactive behavior under sometimes-adverse situations, patient calculations to determine appropriate therapy decisions, including types and amounts of administration of insulin and glucose into his or her system, and is subject to human error. Technologies are needed that ease the burdens faced by diabetic patients, simplify the processes involved in treating the disease, and minimize user error which can cause unnecessarily dangerous situations in some circumstances.

SUMMARY OF THE INVENTION

(5) Systems and methods for monitoring glucose are provided that offer one or more benefits and/or advantages, for example, easing the burdens faced by diabetic patients, simplifying the processes involved in treating diabetes, and minimizing user error which can cause unnecessarily dangerous situations in some circumstances.

(6) Accordingly, in a first aspect, an integrated system for monitoring and treating diabetes is provided, the system comprising: a medicament injection pen configured and arranged for injecting an amount of a medicament into a host; and an integrated receiver configured and arranged to receive sensor data from a continuous glucose sensor, wherein the sensor data is indicative of a glucose concentration of the host in vivo, wherein the integrated receiver comprises electronics configured and arranged to process the sensor data.

(7) In an embodiment of the first aspect, the electronics are further configured to calculate at least one of time of medicament therapy and amount of medicament therapy.

(8) In an embodiment of the first aspect, the integrated receiver comprises a housing, wherein the medicament injection pen is integrally formed with the housing.

(9) In an embodiment of the first aspect, the integrated receiver comprises a housing, and wherein the medicament injection pen is detachably connectable to the housing.

(10) In an embodiment of the first aspect, communication between the medicament injection pen and the receiver is initiated based at least in part on detachable connection of the medicament injection pen and the housing.

(11) In an embodiment of the first aspect, the integrated system further comprises a user interface configured and arranged for at least one of input of host information, output of sensor data, and medicament therapy.

(12) In an embodiment of the first aspect, the user interface is further configured to display a graphical representation of at least one of sensor data and medicament delivery data, wherein a solid line represents at least one of a target glucose concentration and a range.

(13) In an embodiment of the first aspect, the integrated electronics are configured and arranged to require validation prior to injecting an amount of medicament into the host.

(14) In an embodiment of the first aspect, the receiver is configured to communicate in at least one of wiredly with a single-point glucose monitor and wirelessly with a single-point glucose monitor.

(15) In an embodiment of the first aspect, the medicament injection pen comprises a motor.

(16) In an embodiment of the first aspect, the motor is configured to set the amount of medicament.

(17) In an embodiment of the first aspect, the motor is configured to control a rate of medicament injection into a host.

(18) In an embodiment of the first aspect, the receiver is configured to remotely control the motor.

(19) In an embodiment of the first aspect, the medicament injection pen and the receiver each comprise mutually engaging electrical contacts, and wherein the mutually engaging electrical contacts are configured to allow communication between the medicament injection pen and the receiver.

(20) In an embodiment of the first aspect, the system is configured to initiate communication between the medicament injection pen and the receiver in response to engagement of the electrical contacts.

(21) In an embodiment of the first aspect, the system is configured to communicate medicament delivery data between the medicament injection pen and the receiver in response to engagement of the electrical contacts.

(22) In an embodiment of the first aspect, the integrated system further comprises a receptacle configured and arranged to receive at least one of parts associated with the medicament injection pen and accessories associated with the medicament injection pen.
(23) In an embodiment of the first aspect, at least one of the parts associated with the medicament injection pen and accessories associated with the medicament injection pen comprise a medicament cartridge.
(24) In an embodiment of the first aspect, the integrated system further comprises a medicament injection pen kit, wherein the medicament injection pen kit is configured to receive the medicament injection pen, and wherein the medicament injection pen kit comprises a housing comprising a user interface, and wherein the integrated receiver is located within the housing and operably connected to the user interface.
(25) In a second aspect an integrated system for monitoring and treating diabetes is provided, the system comprising: a receiver configured and arranged to receive sensor data from an operably connected continuous glucose sensor, wherein the continuous glucose sensor is configured and arranged to generate sensor data associated with a glucose concentration of a host; integrated electronics configured to process the sensor data and to generate a medicament therapy; and a medicament injection pen configured to inject an amount of medicament into the host.
(26) In an embodiment of the second aspect, the medicament therapy comprises at least one of an amount of medicament therapy and a time of medicament therapy delivery.
(27) In an embodiment of the second aspect, the receiver and the medicament injection pen are integrally formed.
(28) In an embodiment of the second aspect, the integrated system further comprises a receptacle configured and arranged to receive at least one of parts associated with the medicament injection pen and accessories associated with the medicament injection pen.
(29) In an embodiment of the second aspect, the medicament injection pen is detachably connectable to the receiver.
(30) In an embodiment of the second aspect, the medicament injection pen and receiver each comprise mutually engaging electrical contacts, and wherein the mutually engaging electrical contacts are configured to allow communication between the medicament injection pen and the receiver.
(31) In an embodiment of the second aspect, the system is configured to initiate communication between the medicament injection pen and the receiver in response to engagement of the mutually engaging electrical contacts.
(32) In an embodiment of the second aspect, the system is configured to communicate the medicament therapy between the receiver and the medicament injection pen in response to engagement of the mutually engaging electrical contacts.
(33) In an embodiment of the second aspect, the integrated system further comprises a housing integrally formed with the receiver, wherein the integrated electronics are located with the housing.
(34) In an embodiment of the second aspect, the medicament injection pen is detachably connectable with the housing.
(35) In an embodiment of the second aspect, the receiver further comprises a user interface, wherein the integrated electronics are configured to display at least one of sensor data and the medicament therapy thereon.
(36) In an embodiment of the second aspect, the receiver comprises a housing, and wherein the user interface is located on the receiver housing.
(37) In an embodiment of the second aspect, the integrated system further comprises a user interface configured to display at least one of the sensor data and the medicament therapy.
(38) In an embodiment of the second aspect, the integrated electronics are further configured to display a representation of medicament delivery on the user interface, and wherein the representation of medicament delivery is substantially adjacent to substantially time-corresponding

sensor data.
(39) In an embodiment of the second aspect, the integrated electronics are further configured to display a representation of sensor data on the user interface, wherein the representation comprises at least one of a target glucose concentration and a range.
(40) In an embodiment of the second aspect, the user interface comprises a flexible LED screen operably connected to at least one of the receiver and the medicament injection pen, and wherein the integrated electronics are configured to display continuous glucose sensor data on the flexible LED screen.
(41) In an embodiment of the second aspect, the user interface comprises an image projection system configured to project continuous glucose sensor data onto a surface.
(42) In an embodiment of the second aspect, the medicament injection pen comprises a motor.
(43) In an embodiment of the second aspect, the motor is configured to automatically set the amount of medicament.
(44) In an embodiment of the second aspect, the motor is configured to control a rate of medicament injection into the host.
(45) In an embodiment of the second aspect, the receiver is configured to remotely control the motor.
(46) In an embodiment of the second aspect, the integrated system further comprises a medicament injection pen kit comprising the receiver and the integrated electronics, wherein the medicament injection pen kit is configured to receive the medicament injection pen.
(47) In an embodiment of the second aspect, the integrated system further comprises a user interface, wherein the integrated electronics are configured to display at least one of sensor data and the medicament therapy thereon.
(48) In an embodiment of the second aspect, the medicament injection pen kit further comprises a receptacle configured and arranged to receive at least one of a medicament cartridge and a medicament injection pen needle.
(49) In a third aspect, a method for monitoring and treating diabetes using an integrated diabetes monitoring and treatment device is provided, the method comprising: receiving sensor data from a continuous glucose sensor, wherein the sensor data is associated with a glucose concentration of a host; processing the sensor data; generating a medicament therapy; and injecting an amount of medicament into the host based at least in part on the generated medicament therapy.
(50) In an embodiment of the third aspect, the step of generating a medicament therapy comprises determining at least one of an amount of medicament to be delivered and a time of medicament delivery.
(51) In an embodiment of the third aspect, the step of injecting comprises setting the amount of medicament.
(52) In an embodiment of the third aspect, the step of setting the amount of medicament comprises setting a medicament injection rate.
(53) In an embodiment of the third aspect, the step of setting the amount of medicament comprises remotely setting the amount of medicament.
(54) In a fourth aspect, an integrated system for monitoring and treating diabetes is provided, the system comprising: a sensor, the sensor comprising a continuous glucose sensor configured to continuously detect a signal associated with a glucose concentration of a host, a processor module configured and arranged to process the signal to generate a therapy, and a communication module configured and arranged to communicate the therapy instruction to a medicament delivery device; and at least one medicament delivery device configured and arranged to deliver a medicament therapy to the host based at least in part on the communicated therapy instruction.
(55) In an embodiment of the fourth aspect, the medicament therapy comprises at least one of a medicament type, a medicament amount, and a delivery time.
(56) In an embodiment of the fourth aspect, the sensor further comprises an input module

configured to receive host information, and wherein the processor module is further configured to process the host information.
(57) In an embodiment of the fourth aspect, the input module is configured to receive information from at least one of a user interface, a medicament delivery device, an infusion pump, a patient monitor, and a single-point glucose monitor.
(58) In an embodiment of the fourth aspect, the integrated system further comprises a display module configured and arranged to display of host information, sensor data, the therapy instruction, an alert and/or an alarm.
(59) In an embodiment of the fourth aspect, the communication module is configured to communication wirelessly with the medicament delivery device.
(60) In an embodiment of the fourth aspect, the communication module is further configured to communicate the therapy instruction responsive to interrogation by the medicament delivery device.
(61) In an embodiment of the fourth aspect, the medicament delivery device is configured for communication with a plurality of sensors.
(62) In an embodiment of the fourth aspect, the medicament delivery device is configured for medicament delivery to a plurality of different hosts, based at least in part on a therapy instruction from a sensor.
(63) In an embodiment of the fourth aspect, the medicament delivery device is a hand-held injector pen.
(64) In an embodiment of the fourth aspect, the medicament delivery device is configured and arranged for aseptic medicament delivery to a plurality of hosts.
(65) In an embodiment of the fourth aspect, at least one of the sensor and delivery device is configured transmit data to a data repository.
(66) In a fifth aspect, a method for monitoring and treating diabetes using an integrated diabetes monitoring and treatment system is provided, the method comprising: continuously detecting a signal associated with a glucose concentration of a host; processing the signal; generating a therapy instruction; communicating the therapy instruction to at least one medicament delivery device; and delivering a medicament therapy to the host based at least in part on the communicated therapy instruction.
(67) In an embodiment of the fifth aspect, the method further comprises receiving and processing host information.
(68) In an embodiment of the fifth aspect, the method further comprises remotely programming the system.
(69) In an embodiment of the fifth aspect, the step of generating the therapy instruction comprises determining at least one of a type of medicament, a medicament amount, and a delivery time.
(70) In an embodiment of the fifth aspect, the method further comprises receiving information from at least one of a user interface, a medicament delivery device, an infusion pump, a patient monitor, and a single-point glucose monitor.
(71) In an embodiment of the fifth aspect, the method further comprises displaying at least one of host information, sensor data, the therapy instruction, an alert, and an alarm.
(72) In an embodiment of the fifth aspect, the step of communicating further comprises communicating wirelessly.
(73) In an embodiment of the fifth aspect, the step of communicating further comprises communicating the therapy instruction based at least in part on interrogation by the medicament delivery device.
(74) In an embodiment of the fifth aspect, the step of communicating further comprises communicating to a medicament delivery device configured for medicament delivery to a plurality of hosts, based at least in part on a therapy instruction communicated by an integrated system worn by each host.

(75) In an embodiment of the fifth aspect, the step of communicating further comprises communicating to a hand-held injector pen.
(76) In an embodiment of the fifth aspect, the step of communicating further comprises communicating to a medicament delivery device configured and arranged for aseptic medicament delivery to a plurality of hosts.
(77) In an embodiment of the fifth aspect, the step of communicating further comprises transmitting data to a data repository.
(78) In a sixth aspect, a medicament delivery device for monitoring and treating at least one of a plurality of hosts is provided, the medicament delivery device comprising: a communication module configured to interrogate a continuous glucose sensor and to receive sensor data therefrom, wherein the sensor data comprises a signal associated with an analyte concentration of a host; a processor module configured to process the sensor data and calculate a medicament therapy, wherein the processor module comprises programming for calculating the medicament therapy based at least in part on the sensor data; and a hand-held injector pen configured and arranged to deliver a medicament to the host, based at least in part on the medicament therapy.
(79) In an embodiment of the sixth aspect, the medicament delivery device further comprises a user interface configured and arranged for at least one of input of at least some medical information and display of at least some medical information, wherein medical information comprises at least one of host information, received sensor data, processed sensor data, the calculated medicament therapy, a delivered medicament therapy, an instruction, an alert, an alarm, and a failsafe.
(80) In an embodiment of the sixth aspect, the user interface is detachably connected to the hand-held injector pen.
(81) In an embodiment of the sixth aspect, host information comprises at least one of a host information, type of medicament to be delivered, a glucose target, predicted hypoglycemia, predicted hypoglycemia, a therapy protocol, an alert, and an alarm.
(82) In an embodiment of the sixth aspect, the processor module is further configured for validation of the medicament therapy.
(83) In an embodiment of the sixth aspect, the medicament therapy comprises at least one of a type of medicament to be delivered, an amount of medicament to be delivered and a time of delivery.
(84) In an embodiment of the sixth aspect, the communication module is further configured to communicate treatment information to a central monitor, wherein the treatment information comprises at least one of host information, sensor data, the medicament therapy, and delivered medicament information.
(85) In an embodiment of the sixth aspect, the communication module is configured for wireless communication.
(86) In an embodiment of the sixth aspect, the wireless communication is selected from the group consisting of RF communication, IR communication, Bluetooth communication, and inductive coupling.
(87) In an embodiment of the sixth aspect, the communication module and the medicament delivery device are integrally formed.
(88) In an embodiment of the sixth aspect, the communication module and the medicament delivery device are detachably connected.
(89) In an embodiment of the sixth aspect, the injector pen is configured for aseptic medicament delivery to a plurality of hosts.
(90) In an embodiment of the sixth aspect, the injector pen is configured and arranged for pneumatic aseptic medicament delivery.
(91) In an embodiment of the sixth aspect, the injector pen comprises a cartridge comprising a plurality of single-use needles.
(92) In an embodiment of the sixth aspect, the cartridge is configured and arranged for automatic installation of a clean needle after a medicament delivery.

(93) In a seventh aspect, a method for monitoring and treating diabetes in one of a plurality of hosts is provided, the method comprising: interrogating a continuous glucose sensor; receiving sensor data from the continuous glucose sensor, wherein the sensor data comprises a signal associated with an analyte concentration of a first host; processing the sensor data; calculating a medicament therapy based at least in part on the sensor data; and delivering an amount of a medicament to the first host, based at least in part on the calculated medicament therapy.
(94) In an embodiment of the seventh aspect, the steps of interrogating, receiving, processing, calculating and delivering are repeated with a second host.
(95) In an embodiment of the seventh aspect, the method further comprises a step of at least one of inputting at least some medical information and displaying at least some medical information, wherein medical information comprises at least one of host information, received sensor data, processed sensor data, the calculated medicament therapy, a delivered medicament therapy, an instruction, an alert, an alarm, and a failsafe.
(96) In an embodiment of the seventh aspect, the method further comprises detachably connecting a user interface.
(97) In an embodiment of the seventh aspect, the method further comprises validating the medicament therapy.
(98) In an embodiment of the seventh aspect, the method further comprises communicating treatment information to a central monitor, wherein the treatment information comprises at least one of host information, sensor data, the medicament therapy, and delivered medicament information.
(99) In an embodiment of the seventh aspect, the step of communicating comprises communicating wirelessly.
(100) In an embodiment of the seventh aspect, the steps of interrogating and receiving comprise communicating wirelessly.
(101) In an embodiment of the seventh aspect, the step of delivering comprises aseptically delivering the medicament to a plurality of hosts.
(102) In an embodiment of the seventh aspect, the step of delivering comprises pneumatically aseptically delivering the medicament.
(103) In an embodiment of the seventh aspect, the step of delivering comprises automatically installing a clean needle after medicament delivery.
(104) In an eighth aspect, an integrated system for monitoring and treating diabetes is provided, the system comprising: a receiver configured and arranged to receive continuous glucose sensor data from a continuous glucose sensor; a processor module configured to process the continuous glucose sensor data and to provide first and second medicament dosing information based at least in part on the continuous glucose sensor data; and a communication module configured and arranged to communicate the medicament dosing information with a first integrated medicament delivery device and a second integrated medicament delivery device.
(105) In an embodiment of the eighth aspect, the first medicament dosing information comprises a basal medicament dose and the first integrated medicament delivery device comprises a basal medicament delivery device.
(106) In an embodiment of the eighth aspect, the basal medicament delivery device comprises a medicament pump configured to infuse a first medicament.
(107) In an embodiment of the eighth aspect, the processor module comprises programming to calculate a basal dose based at least in part on the continuous glucose sensor data.
(108) In an embodiment of the eighth aspect, the second medicament dosing information comprises a bolus medicament dose and the second integrated medicament delivery device comprises a bolus medicament delivery device.
(109) In an embodiment of the eighth aspect, the processor module comprises programming to calculate a bolus dose based at least in part on the continuous glucose sensor data.

(110) In an embodiment of the eighth aspect, the bolus medicament delivery device comprises a hand-held medicament injection pen configured to infuse a second medicament.
(111) In an embodiment of the eighth aspect, the bolus medicament delivery device comprises a motor configured to automatically set the amount of medicament and the medicament dosing information comprises an instruction for the medicament delivery device to automatically portion out the bolus dose, whereby the portioned out bolus dose can be manually delivered by the host.
(112) In an embodiment of the eighth aspect, the bolus medicament delivery device comprises a motor to control a rate of medicament injection into the host.
(113) In an embodiment of the eighth aspect, the integrated system further comprises a user interface configured and arranged to display at least one of continuous glucose sensor data and medicament dosing information.
(114) In an embodiment of the eighth aspect, the user interface is further configured for input of at least one of host information and medicament delivery device information.
(115) In an embodiment of the eighth aspect, the host information comprises at least one of host identity, host physical state, target glucose concentration and type of medicament to be delivered.
(116) In an embodiment of the eighth aspect, the medicament delivery information comprises at least one of host identity, identification of a functionally connected medicament delivery device, a type of medicament to be delivered, a medicament delivery profile, a medicament delivery protocol, and a failsafe.
(117) In an embodiment of the eighth aspect, the communication module comprises a communication module configured and arranged to interrogate and/or provide medicament dosing information to the first medicament delivery device and the second medicament delivery device.
(118) In an embodiment of the eighth aspect, the receiver comprises the communication module and the processor module, and wherein the receiver wirelessly communicates with the first and second medicament delivery devices.
(119) In an embodiment of the eighth aspect, the receiver comprises the communication module and the processor module, and wherein the receiver is physically connected to at least one of the first medicament delivery device and the second medicament delivery device.
(120) In a ninth aspect, a method of self-monitoring and self-treating diabetes is provided, the method comprising: receiving continuous glucose sensor data from an operably connected continuous glucose sensor; processing the continuous glucose sensor data; calculating medicament dosing information for at least two integrated medicament delivery devices based at least in part on the continuous glucose sensor data; and communicating the medicament dosing information with the integrated medicament delivery devices.
(121) In an embodiment of the ninth aspect, the step of calculating medicament dosing information comprises calculating a basal dose based at least in part on the continuous glucose sensor data.
(122) In an embodiment of the ninth aspect, the step of communicating comprises communicating the basal medicament dose to a medicament pump.
(123) In an embodiment of the ninth aspect, the method further comprises infusing the basal medicament dose.
(124) In an embodiment of the ninth aspect, the step of providing medicament dosing information comprises calculating a bolus dose based at least in part on the continuous glucose sensor data.
(125) In an embodiment of the ninth aspect, the step of communicating comprises communicating the bolus medicament dose to a hand-held injector pen.
(126) In an embodiment of the ninth aspect, the step of delivering comprises injecting the bolus medicament dose.
(127) In an embodiment of the ninth aspect, the step of communicating the bolus dose further comprises providing an instruction to automatically set at least one of the amount of medicament and rate of delivery based at least in part on the medicament dosing information.
(128) In an embodiment of the ninth aspect, the step of delivering the bolus dose further comprises

automatically setting the amount of medicament based at least in part on the provided instruction.
(129) In an embodiment of the ninth aspect, the step of delivering the bolus dose further comprises automatically setting the rate of delivery based at least in part on the provided instruction.
(130) In an embodiment of the ninth aspect, the method further comprises displaying at least one of continuous glucose sensor data and medicament dosing information.
(131) In an embodiment of the ninth aspect, the method further comprises inputting at least one of host information and medicament delivery device information.
(132) In an embodiment of the ninth aspect, the step of communicating comprises wirelessly communicating.
(133) In an embodiment of the ninth aspect, the step of wirelessly communicating comprises interrogating and/or providing medicament dosing information.

Description

BRIEF DESCRIPTION OF THE DRAWINGS
(1) FIG. **1** is a block diagram of an integrated system of the preferred embodiments, including a continuous glucose sensor, a receiver for processing and displaying sensor data, a hand-held medicament injection pen, and an optional single point glucose-monitoring device.
(2) FIG. **2**A is a perspective view of a wholly implantable continuous glucose sensor, in one embodiment.
(3) FIG. **2**B is a perspective view of an in vivo portion of a continuous glucose sensor, in one embodiment.
(4) FIG. **2**C is a cross-section of the continuous glucose sensor of FIG. **2**B, taken on line **2**C-**2**C, in one embodiment.
(5) FIG. **2**D is a perspective view of an in vivo portion of a continuous glucose sensor including two working electrodes, in one embodiment.
(6) FIG. **2**E illustrates a continuous glucose sensor implanted in a vein/artery, in one embodiment.
(7) FIG. **3** is a perspective view of an integrated system in one embodiment, showing an LCD screen on a hand-held medicament injection pen housing.
(8) FIG. **4** is a perspective view of an integrated system in another embodiment, showing an LCD screen on a hand-held medicament injection pen housing.
(9) FIG. **5** is a perspective view of an integrated system in another embodiment, showing a housing configured to receive a hand-held medicament injection pen, wherein the housing includes an LCD screen thereon.
(10) FIG. **6** is a perspective view of an integrated system in another embodiment, showing a housing configured to receive a hand-held medicament injection pen, wherein the housing includes an LCD screen thereon.
(11) FIG. **7** is a perspective view of an integrated system in another embodiment, showing a housing configured to receive a hand-held medicament injection pen, a receiver, integrated electronics, and a user interface.
(12) FIG. **8** is a perspective view of an integrated system in another embodiment, showing a hand-held medicament injection pen, a receiver, integrated electronics, and a user interface integrally formed and/or incorporated therein.
(13) FIG. **9** is a perspective view of an integrated system in another embodiment, showing a receiver housing including a receiver, integrated electronics, a user interface, and a hand-held medicament injection pen integrally formed therewith and/or incorporated therein.
(14) FIG. **10** is a perspective view of an integrated system in another embodiment, showing a receiver housing including a receiver, integrated electronics, a user interface, and a hand-held medicament injection pen integrally formed therewith and/or incorporated therein.

(15) FIG. **11** is a perspective view of an integrated system showing an integrated housing including a receiver, integrated electronics, a user interface, and a hand-held medicament injection pen, wherein the housing further includes a cap for the hand-held medicament injection pen.
(16) FIG. **12** is a perspective view of an integrated system showing an integrated housing including a receiver, integrated electronics, a user interface, and a hand-held medicament injection pen, wherein the housing further includes a cap.
(17) FIG. **13** is a block diagram that illustrates integrated electronics in one embodiment.
(18) FIG. **14** is graphical representation of integrated data that can be displayed on an LCD screen, for example, in one embodiment.
(19) FIG. **15** is a flow chart that illustrates the process of validating therapy instructions prior to medicament delivery in one embodiment.
(20) FIG. **16** is a flow chart that illustrates the process of providing adaptive metabolic control using an integrated sensor and hand-held medicament injection pen in one embodiment.
(21) FIG. **17** is a block diagram illustrating an integrated system, in one embodiment, including a continuous glucose sensor and a plurality of hand-held medicament injection pens, in one embodiment.
(22) FIG. **18** is a block diagram illustrating an integrated system, in one embodiment, including a plurality of continuous glucose sensors and a hand-held medicament injection pen, in one embodiment.
(23) FIG. **19** is a block diagram illustrating an integrated system, in one embodiment, including a continuous glucose sensor, a receiver, a basal medicament delivery device and a bolus medicament delivery device, in one embodiment.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

(24) The following description and examples illustrate some exemplary embodiments of the disclosed invention in detail. Those of skill in the art will recognize that there are numerous variations and modifications of this invention that are encompassed by its scope. Accordingly, the description of a certain exemplary embodiment should not be deemed to limit the scope of the present invention.

Definitions

(25) In order to facilitate an understanding of the preferred embodiments, a number of terms are defined below.
(26) The term “algorithm” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a computational process (for example, programs) involved in transforming information from one state to another, for example, by using computer processing.
(27) The term “basal,” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the minimum required rate or other value for something to function. For example, in the case of medicament therapy, the term “basal rate” can refer to a regular (e.g., in accordance with fixed order or procedure, such as regularly scheduled for/at a fixed time), periodic or continuous delivery of low levels of medicament, such as but not limited to throughout a 24-hour period.
(28) The term “basal profile,” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a medicament delivery schedule that includes one or more blocks of time (e.g., time blocks), wherein each block is associated with a maximum medicament delivery rate.
(29) The term “biological sample” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special

or customized meaning), and refers without limitation to sample of a host body, for example blood, interstitial fluid, spinal fluid, saliva, urine, tears, sweat, or the like.
(30) The term “bolus,” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a single dose of medicament, usually given over a short, defined period of time. In one exemplary embodiment, a bolus of medicament is calculated and/or estimated to be sufficient to cover an expected rise in blood glucose, such as the rise that generally occurs during/after a meal.
(31) The term “continuous (or continual) analyte sensing” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the period in which monitoring of analyte concentration is continuously, continually, and or intermittently (regularly or irregularly) performed, for example, about every 5 to 10 minutes.
(32) The phrase “continuous glucose sensing” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the period in which monitoring of plasma glucose concentration is continuously or continually performed, for example, at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes, or longer.
(33) The term “count” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a unit of measurement of a digital signal. For example, a raw data stream or raw data signal measured in counts is directly related to a voltage (for example, converted by an A/D converter), which is directly related to current from the working electrode.
(34) The term “electrochemically reactive surface” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the surface of an electrode where an electrochemical reaction takes place. For example, a working electrode measures hydrogen peroxide produced by the enzyme-catalyzed reaction of the analyte detected, which reacts to create an electric current. Glucose analyte can be detected utilizing glucose oxidase, which produces H.sub.2O.sub.2 as a byproduct. H.sub.2O.sub.2 reacts with the surface of the working electrode, producing two protons (2H.sup.+), two electrons (2e.sup.−) and one molecule of oxygen (O.sub.2), which produces the electronic current being detected.
(35) The term “electronic connection” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to any electronic connection known to those in the art. In one exemplary embodiment, a connection is between the sensing region electrodes and the electronic circuitry of a device that provides electrical communication, such as mechanical (for example, pin and socket) or soldered electronic connections.
(36) The term “host” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to mammals, particularly humans.
(37) The term “host information” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to information related to the host, such as a patient using an integrated system of the preferred embodiments, such as but not limited to a continuous glucose sensor, a medicament delivery device, and/or receiving medicament therapy. In some embodiments, the medicament is insulin or another injectable diabetes medicament, such as but not limited to pramlintide, exenatide, amylin, glucagon, and the like. In some embodiments, host information includes but is not limited to information relating to the host and his/her therapy, such as but not limited to information used to identify the host (e.g., in a clinical setting), such as a

host identification number and/or code, host physical characteristics, host health information (e.g., medical conditions, diseases, illnesses), host exercise information, a therapy protocol, such as but not limited to a medicament therapy protocol assigned to the host, including but not limited to one or more types of medicament the host is to receive and/or target glucose concentration(s), an alarm, an alert and/or an instruction.

(38) The term "integrated," as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to united, bringing together processes or functions.

(39) The term "interrogate," as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to give or send out a signal to (e.g., as a transponder) for triggering an appropriate response to obtain data or information from (a device, database, etc.).

(40) The term "medicament therapy," as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to an identity, an amount and/or schedule of a medicament to be delivered to the host. In some embodiments, the medicament is a diabetes-treating medicament formulated for injection, such as but not limited to insulin, pramlintide, exenatide, amylin, glucagon, derivatives thereof, and the like. In other embodiments, the medicament is one for treating another disease and is formulated for injection.

(41) The terms "operatively connected," "operatively linked," "operably connected," and "operably linked" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to one or more components linked to one or more other components. The terms can refer to a mechanical connection, an electrical connection, or a connection that allows transmission of signals between the components (e.g., including a wireless connection). For example, one or more electrodes can be used to detect the amount of analyte in a sample and to convert that information into a signal; the signal can then be transmitted to a circuit. In such an example, the electrode is "operably linked" to the electronic circuitry.

(42) The terms "processor module" and "processor" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to a computer system, state machine, processor, or the like designed to perform arithmetic or logic operations using logic circuitry that responds to and processes the basic instructions that drive a computer. In some embodiments, the term processor includes storage, e.g., ROM and RAM.

(43) The term "range," as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a sequence, series, or scale between limits (e.g., maximum and minimum values). For example, a range of glucose concentrations can include glucose concentrations from 60 mg/dl to 200 mg/dl. In another example, a range of medicament delivery rates can include rates from about 0.01 U/hr to about 40 U/hr. In some embodiments, a range is a single value.

(44) The terms "sensor," "sensing region" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to the component or region of a device by which an analyte can be quantified.

(45) The terms "smoothing" and "filtering" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to modification of a set of data to

make it smoother and more continuous or to remove or diminish outlying points, for example, by performing a moving average.
(46) The term “single point glucose monitor” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a device that can be used to measure a glucose concentration within a host at a single point in time, for example, a finger stick blood glucose meter. It should be understood that single point glucose monitors can measure multiple samples (for example, blood or interstitial fluid); however only one sample is measured at a time and typically requires some user initiation and/or interaction.
(47) The term “target range,” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a range of glucose concentrations within which a host is to try to maintain his blood sugar. In general, a target range is a range of glucose concentrations considered to be euglycemic. Euglycemic glucose concentrations are discussed in detail in the section entitled “Programming and Processing.”
(48) The term “therapy instruction,” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to an instruction to a medicament delivery device, such as a medicament injection pen or and medicament pump, to deliver a medicament therapy to a host, including but not limited to an amount of medicament to be delivered and/or a time of medicament delivery.
(49) The terms “substantial” and “substantially” as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to a sufficient amount that provides a desired function. In some embodiments, the term “substantially” includes an amount greater than 50 percent, an amount greater than 60 percent, an amount greater than 70 percent, an amount greater than 80 percent, and/or an amount greater than 90 percent. In some embodiments, the integrated electronics are configured to display a representation of medicament delivery on the user interface substantially adjacent to substantially time-corresponding sensor data, wherein “substantially adjacent” refers to a location sufficiently near by or close to the relevant data to create an association, for example.
(50) Overview
(51) FIG. **1** is a block diagram of an integrated system **10** of the preferred embodiments, including a continuous glucose sensor **12**, a receiver **14** for processing and displaying sensor data, a medicament delivery device **16**, and optionally a single point glucose-monitoring device **18**. The integrated diabetes management system **10** of the preferred embodiments provides improved convenience and accuracy thus affording a host **8** with improved convenience, functionality, and safety in the care of their disease.
(52) FIG. **1** shows a continuous glucose sensor **12** that measures a concentration of glucose or a substance indicative of the concentration or presence of the glucose. In some embodiments, the glucose sensor **12** is an invasive, minimally invasive, or non-invasive device, for example a subcutaneous, transdermal, or intravascular device, as described elsewhere herein. In some embodiments, the sensor **12** can analyze a plurality of intermittent biological samples. The glucose sensor can use any method of glucose-measurement, including enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or the like. In alternative embodiments, the sensor **12** can be any sensor capable of determining the level of an analyte in the body, for example oxygen, lactase, insulin, hormones, cholesterol, medicaments, viruses, or the like. The glucose sensor **12** uses any known method to provide an output signal indicative of the concentration of the glucose. The output signal is typically a raw data stream that is used to provide a useful value of the measured glucose concentration to a patient or doctor, for

example.
(53) A receiver **14** is provided that receives and processes the raw data stream, including calibrating, validating, and displaying meaningful glucose values to a host, such as described in more detail below. Although the receiver is shown as wirelessly communicating with the sensor, the receiver can be physically connected to the sensor and/or sensor electronics and/or housed within the medicament delivery device and/or single point monitor, thereby removing the wireless connection. A medicament delivery device **16** is further provided as a part of the integrated system **10**. In some preferred embodiments, the medicament delivery device **16** is a medicament injection pen or jet-type injector for injecting a medicament (e.g., insulin). In some preferred embodiments, the medicament delivery device **16** is a medicament delivery pump, also referred to as an infusion pump, for medicament infusion (e.g., insulin). In some embodiments, both a hand-held medicament injection pen and an infusion pump are used to deliver one or more types of medicament to the host, as described elsewhere herein in greater detail. In some embodiments, an optional single point glucose monitor **18** is further provided as a part of the integrated system **10**, for example a self-monitoring blood glucose meter (SMBG), non-invasive glucose meter, or the like, integrated into a receiver housing and/or a medicament delivery device housing.
(54) Conventionally, each of these devices separately provides valuable information and/or services to diabetic patients. Thus, a typical diabetic patient has numerous individual devices, which they track and consider separately. In some cases, the amount of information provided by these individual devices may require complex understanding of the nuances and implications of each device, for example types and amounts of medicament (e.g., insulin) to deliver. Typically, each individual device is a silo of information that functions as well as the data provided therein, therefore when the devices are able to communicate with each other, enhanced functionality and safety can be realized. For example, when a continuous glucose monitor functions alone (for example, without data other than that which was gathered by the device), sudden changes in glucose level are tracked, but may not be fully understood, predicted, preempted, or otherwise considered in the processing of the sensor data; however, when the continuous glucose sensor is provided with information about time, amount, and type of medicament injections, calories consumed, time or day, meal time, or like, more meaningful, accurate and useful glucose estimation, prediction, and other such processing can be provided, such as described in more detail herein. By integrating these devices, the information from each component can be leveraged to increase the intelligence, benefit provided, convenience, safety, and functionality of the continuous glucose sensor and the other integrated components. Therefore, it would be advantageous to provide a device that aids the diabetic patient in integrating these individual devices in the treatment of his/her disease.
(55) Sensor
(56) The preferred embodiments relate to the use of an analyte sensor **12** that measures a concentration of analyte of interest or a substance indicative of the concentration or presence of the analyte. In some embodiments, the sensor is a continuous device, for example a subcutaneous, transdermal (e.g., transcutaneous), or intravascular device. The analyte sensor can use any method of analyte-sensing, including enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or the like.
(57) The analyte sensor uses any method, including invasive, minimally invasive, and non-invasive sensing techniques, to provide an output signal indicative of the concentration of the analyte of interest. The output signal, which is associated with the analyte concentration of the host, is typically a raw signal that is used to provide a useful value of the analyte of interest to a user, such as a patient or physician, who can be using the device. Accordingly, appropriate smoothing, calibration, and/or evaluation methods can be applied to the signal and/or system as a whole to provide relevant and acceptable estimated analyte data to the user.
(58) FIG. **2**A illustrates the continuous glucose sensor **12**, in one embodiment, an implantable

glucose sensor such as described in U.S. Patent Publication No. 2005-0245799, which is incorporated by reference in its entirety. In this embodiment, a body **13** and a sensing region include the electrodes and a membrane **12***c*. Sensor electronics (not shown) are located within the body **13**. The three electrodes, including but not limited to a working electrode **12***a*, a reference electrode **12***b*, and an auxiliary, counter or second working electrode **12***x*, within the sensing region are operably connected to the sensor electronics and are covered by a sensing membrane **12***c* and an optionally biointerface membrane (not shown), which are described elsewhere herein. The body **13** is preferably formed from epoxy molded around the sensor electronics, however the body can be formed from a variety of materials, including metals, ceramics, plastics, or composites thereof. U.S. Pat. No. 7,134,999, which is incorporated by reference in its entirety, discloses suitable configurations suitable for the body **13**. In one embodiment, the sensing region **12***c* comprises three electrodes including a platinum working electrode **12***a*, a platinum counter electrode **12***x*, and a silver/silver chloride reference electrode **12***b*, for example. However a variety of electrode materials and configurations can be used with the implantable glucose sensor of the preferred embodiments. The top ends of the electrodes are in contact with an electrolyte phase (not shown), which is a free-flowing fluid phase disposed between the sensing membrane and the electrodes. In one embodiment, a counter electrode **12***x* is provided to balance the current generated by the species being measured at the working electrode. In the case of a glucose oxidase based glucose sensor, the species being measured at the working electrode is H.sub.2O.sub.2. Glucose oxidase catalyzes the conversion of oxygen and glucose to hydrogen peroxide and gluconate according to the following reaction:

Glucose+O.sub.2.fwdarw.Gluconate+H.sub.2O.sub.2

(59) The change in H.sub.2O.sub.2 can be monitored to determine glucose concentration because for each glucose molecule metabolized, there is a proportional change in the product H.sub.2O.sub.2. Oxidation of H.sub.2O.sub.2 by the working electrode is balanced by reduction of ambient oxygen, enzyme generated H.sub.2O.sub.2, or other reducible species at the counter electrode. The H.sub.2O.sub.2 produced from the glucose oxidase reaction further reacts at the surface of working electrode and produces two protons (2H.sup.+), two electrons (2e.sup.−), and one oxygen molecule (O.sub.2). In an alternative embodiment, the continuous glucose sensor comprises a continuous glucose sensor such as described with reference to U.S. Pat. No. 6,579,690 to Bonnecaze et al. or U.S. Pat. No. 6,484,046 to Say et al. In another alternative embodiment, the continuous glucose sensor comprises a refillable subcutaneous sensor such as described with reference to U.S. Pat. No. 6,512,939 to Colvin et al. All of the above patents and/or patent applications are incorporated in their entirety herein by reference.

(60) FIG. **2**B illustrates the continuous glucose sensor in another embodiment; the glucose sensor is described in more detail in U.S. Patent Publication No. US-2006-0020187-A1, U.S. Patent Publication No. US-2006-0142651-A1, U.S. Patent Publication No. US-2006-0270923-A1, U.S. Patent Publication No. US-2007-0027370-A1, U.S. Patent Publication No. US-2005-0143635-A1, U.S. Patent Publication No. US-2007-0027385-A1, U.S. Patent Publication No. US-2007-0213611-A1, and U.S. Patent Publication No. US-2008-0083617-A1, which are each incorporated herein by reference in their entirety. FIG. **2**B is a perspective view of an in vivo portion of the continuous glucose sensor **12**, in one embodiment. In this embodiment, the in vivo portion of the sensor includes at least one working electrode **12***a* and a reference electrode **12***b* and a sensing membrane **12***c* (dashed line). In one alternative embodiment, the continuous glucose sensor comprises a glucose sensor such as described in U.S. Pat. No. 6,565,509 to Say et al., U.S. Pat. No. 6,360,888 to McIvor et al. and/or U.S. Pat. No. 6,424,847 to Mastrototaro et al. All of the above patents and/or patent applications are incorporated in their entirety herein by reference.

(61) FIG. **2**C is a cross-section of the sensor shown in FIG. **2**B, taken on line **2**C-**2**C. In preferred embodiments, the membrane **12***c* (e.g., a biointerface and/or sensing membrane) includes at least an enzyme domain **12***f* having an enzyme configured to detect the analyte, such as but not limited

to glucose oxidase (e.g., GOX). In some preferred embodiments, the sensing membrane **12***c* can include one or more additional domains, such as but not limited to an electrode domain **12***d*, an interference domain **12***e*, a resistance domain **12***j*, a cell disruptive domain and/or a cell impermeable domain, for example. Additional sensor and membrane configurations can be found in U.S. Patent Publication No. US-2006-0020187-A1, U.S. Patent Publication No. US-2005-0031689-A1, U.S. Patent Publication No. US-2007-0027370-A1, U.S. Patent Publication No. US-2006-0229512-A1, U.S. Patent Publication No. US-2006-0253012-A1, U.S. Patent Publication No. US-2007-0197890-A1, U.S. Patent Publication No. US-2007-0244379, and U.S. Patent Publication No. US-2007-0235331-A1, each of which is incorporated herein by reference in its entirety.

(62) FIG. **2**D illustrates the continuous glucose sensor in another embodiment, a glucose sensor having first and second working electrodes (e.g., dual-electrode), such as described in U.S. Patent Publication No. US-2007-0027385-A1, U.S. Patent Publication No. US-2007-0213611-A1, and U.S. Patent Publication No. US-2008-0083617-A1, U.S. Pat. No. 7,366,556, and co-pending U.S. patent application Ser. No. 12/111,062, filed Apr. 28, 2008 and entitled "Dual Electrode System for a Continuous Analyte Sensor," each of which are incorporated herein by reference in their entireties. In some preferred embodiments, the dual-electrode continuous glucose sensor includes a first working electrode **12***a*.sub.1 and a second working electrode **12***a*.sub.2, and a reference electrode **12***b*, and a membrane system (not shown), wherein the membrane located over the first working electrode comprises active enzyme and the located over the second working electrode comprises no enzyme or inactive enzyme. Accordingly, a total signal detected by the first working electrode comprises analyte-related (e.g., glucose) and non-analyte-related signal components, while the second working electrode detects a signal comprising only the non-analyte-related signal components. A substantially analyte-only signal can be determined algorithmically, such as, but not limited to, by subtracting the non-analyte-related signal component (detected by the second working electrode) from the total signal (e.g., detected by the first working electrode), thereby providing a substantially "noise-free" analyte signal.

(63) FIG. **2**E illustrates the continuous glucose sensor in yet another embodiment, a continuous glucose sensor configured for implantation into a host's circulatory system, in fluid communication with a host's circulatory system, and/or into an extracorporeal circulatory device. As shown in FIG. **2**E, in some embodiments, the continuous glucose sensor **12** is disposed within a catheter **1201** inserted into a vein **1204** or artery of the host. The catheter **1201** is attached to IV tubing **1203** via a connector **1202**, such as a Leur lock. In the embodiment illustrated in FIG. **2**E, the sensor **12** is exposed to samples of the host's circulatory system (e.g., blood **1205**) by withdrawing a blood sample into the catheter lumen such that the sensing portion of the sensor is exposed to the sample. In some alternative embodiments, the sensor **12** is disposed within the fluid connector or other portion of the IV tubing in fluid communication with the host's circulatory system. In this embodiment, after generation of a signal associated with the concentration of glucose in the blood sample, the sample is expelled from the catheter (e.g., back into the circulatory system) and the sensor is washed and calibrated. Additional embodiments are described in greater detail in co-pending U.S. patent application Ser. No. 11/543,396, filed Oct. 4, 2006 and entitled "Analyte Sensor," co-pending U.S. patent application Ser. No. 12/055,114, filed Mar. 25, 2008 and entitled "Analyte Sensor," and U.S. Patent Publication No. US-2008-0108942-A1. In an alternative embodiment, the continuous glucose sensor comprises an intravascular sensor such as described with reference to U.S. Pat. No. 6,477,395 to Schulman et al. In another alternative embodiment, the continuous glucose sensor comprises an intravascular sensor such as described with reference to U.S. Pat. No. 6,424,847 to Mastrototaro et al. All of the above patents and/or patent applications are incorporated in their entirety herein by reference.

(64) The methods and devices of preferred embodiments can be employed in a continuous glucose sensor that measures a concentration of glucose or a substance indicative of a concentration or a presence of glucose. However, certain methods and devices of preferred embodiments are also

suitable for use in connection with non-continuous (e.g., single point measurement or finger stick) monitors, such as the OneTouch® system manufactured by LifeScan, Inc., or monitors as disclosed in U.S. Pat. Nos. 5,418,142; 5,515,170; 5,526,120; 5,922,530; 5,968,836; and 6,335,203. In some embodiments, the device can analyze a plurality of intermittent biological samples, such as blood, interstitial fluid, or the like. The glucose sensor can use any method of glucose-measurement, including colorimetric, enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or the like. In alternative embodiments, the sensor can be any sensor capable of determining the level of an analyte in the body, for example oxygen, lactase, hormones, cholesterol, medicaments, viruses, or the like.

(65) Although a few exemplary embodiments of continuous glucose sensors are illustrated and described herein, it should be understood that the disclosed embodiments are applicable to any device capable of single analyte, substantially continual or continuous measurement of a concentration of analyte of interest and providing an output signal that represents the concentration of that analyte.

(66) Medicament Delivery Device

(67) Some preferred embodiments provide an integrated system **10**, which includes a medicament delivery device **16** for administering a medicament to a host **8**. An integrated medicament delivery device can be designed for bolus injection, continuous injection, inhalation, transdermal absorption, other method for administering medicament, or any combinations thereof. The term medicament includes any substance used in therapy for a host **8** using the system **10**, for example, insulin, pramlintide, exenatide, amylin, glucagon, derivatives thereof, and the like. PCT International Publication No. WO02/43566 describes glucose, glucagon, and vitamins A, C, or D that can be used with the preferred embodiments. U.S. Pat. Nos. 6,051,551 and 6,024,090 describe types of insulin suitable for inhalation that can be used with the preferred embodiments. U.S. Pat. Nos. 5,234,906, 6,319,893, and European Pat. No. 760677 describe various derivatives of glucagon that can be used with the preferred embodiments. U.S. Pat. No. 6,653,332 describes a combination therapy that can be used with the preferred embodiments. U.S. Pat. No. 6,471,689 and PCT International Publication No. WO81/01794 describe insulins useful for delivery pumps that can be used with the preferred embodiments. U.S. Pat. No. 5,226,895 describes a method of providing more than one type of insulin that can be used with the preferred embodiments. All of the above patents and publications are incorporated herein by reference in their entirety and can be useful as the medicament(s) in the preferred embodiments.

(68) In some embodiments, the medicament delivery device is configured for injection and/or infusion of the medicament. For example, in some embodiments, a medicament delivery device is an infusion pump, such as but not limited to a bedside or a portable infusion pump. In one embodiment, the infusion is a portable medicament pump, as described elsewhere herein. In one preferred embodiment, the medicament delivery device **16** is a medicament pump designed for basal and/or bolus infusion of medicament. The medicament pump of the preferred embodiments includes any portable or bedside (e.g., non-portable) infusion devices, such as is appreciated by one skilled in the art. A few examples of medicament infusion devices (e.g., pumps) that can be used with the preferred embodiments include U.S. Pat. Nos. 5,389,078, 6,471,689, 6,656,148, 6,749,587, 6,999,854, 7,060,059, 7,109,878, 7,267,665, 7,291,133, 7,311,691, 7,374,556 7,303,549, PCT International Publication No. WO 81/01794, European Patent No. 1281351 and co-pending U.S. patent application Ser. No. 12/055,114, filed Mar. 25, 3008 and entitled “Analyte Sensor,” all of which are incorporated herein by reference in their entirety.

(69) In some embodiments, a medicament delivery device **16** is a hand-held medicament injection pen, such as but not limited to a syringe, medicament injection pen or a pneumatic injection device. In some embodiments, the hand-held medicament injection pen is configured for single-use (e.g., disposed of after use). In other embodiments, the hand-held medicament injection pen is a multi-use injection device having single-use, disposable parts. For example, a medicament injection pen

can be configured to use single-use, disposable needles that are thrown away after one use. In one exemplary embodiment, the medicament injection pen is configured for use with a cartridge of a plurality of single-use, disposable needles, such that each used needle can be changed and/or removed, such as but not limited to by ejecting a used needle and installing an unused (e.g., sterile) needle. In still other embodiments, the hand-held medicament injection pen is a multi-use device configured to sequentially deliver (e.g., aseptically) medicament doses to each of a plurality of hosts. For example, in one embodiment, the hand-held medicament injection pen is a pneumatic injection device.

(70) In one preferred embodiment, the integrated medicament delivery device **16** is a hand-held medicament injection pen (e.g., insulin pen) designed for bolus injection. The hand-held medicament injection pen of the preferred embodiments includes any pen-type injector, such as is appreciated by one skilled in the art. A few examples of a hand-held medicament injection pens that can be used with the preferred embodiments include U.S. Pat. Nos. 4,865,591, 5,104,380, 5,226,895, 5,308,340, 5,383,865, 5,536,249, 6,192,891, 7,169,132, 7,195,616, 7,291,132, U.S. Patent Publication No. US-2001-0051792-A1, U.S. Patent Publication No. US-2007-0061674-A1 and U.S. Patent Publication No. US-2008-0015511-A1, each of which is incorporated herein by reference in their entirety.

(71) In some embodiments, a medicament delivery device (e.g., hand-held medicament injection pen) is provided, which includes a processor and a wired or wireless connection to a receiver, which are described in more detail elsewhere herein. In some embodiments, the device includes programming that receives instructions from the receiver **14** regarding type and amount of medicament to administer. In some embodiments, wherein the medicament delivery device is an injection device (e.g., a pen) that includes more than one type of medicament, the receiver provides the necessary instructions to determine which type or types of medicament to administer, and can provide instructions necessary for mixing the one or more medicaments. In some embodiments, the receiver provides the glucose trend information (for example, concentration, rate-of-change, acceleration, or other user input information) and the injection device includes programming necessary to determine appropriate medicament delivery. In some embodiments, the receiver, user interface, and/or integrated electronics are incorporated into and/or integral with the pen. However, any of the electronics (including hardware, firmware and/or software/programming) associated with the receiver, medicament delivery device and/or optional single point monitor can be located in any one or a combination of the receiver, medicament delivery device and/or optional single point monitor.

(72) In some embodiments, the receiver and/or hand-held medicament injection pen is configured to calculate medicament usage and/or a remaining on-board medicament amount. In some embodiments, the integrated electronics (e.g., in the receiver and/or medicament delivery device) are configured to receive sensor data and calculate an amount of time remaining with the current medicament on-board the delivery device (e.g., the amount of medicament within the medicament device's reservoir/cartridge) based on historic, current, estimated, and/or predicted glucose data. In some embodiments, integrated electronics include electronics associated with a receiver and a pen, which can be configured for two-way communication there between, such as described in more detail elsewhere herein.

(73) In some embodiments, the pen includes programming to send information regarding the amount, type, and time of medicament delivery administered to the receiver **14** for processing. The receiver **14** can use this information received from the pen, in combination with the continuous glucose data obtained from the sensor, to monitor and determine the host's glucose patterns, such as to measure his response to each medicament delivery. Knowing the host's individual response to each type and amount of medicament delivery can be useful in adjusting or optimizing the host's therapy. It is noted that individual metabolic profiles (for example, medicament sensitivity) are variable from host to host and time to time. While not wishing to be bound by theory, it is believed

that once the receiver has learned (or as the receiver continuously learns) the individual's metabolic patterns, including glucose trends and associated medicament deliveries, the receiver can be programmed to adjust and optimize the therapy recommendations for the host's individual physiology to maintain their glucose levels within a desired target range. In some embodiments, the receiver (including user interface and integrated electronics) is integral with and/or incorporated into the pen.

(74) In some embodiments, the receiver includes algorithms that use parameters provided by the continuous glucose sensor, such as glucose concentration, rate-of-change of the glucose concentration, and acceleration of the glucose concentration to more particularly determine the type, amount, and time of medicament administration, can be applied to the integrated system **10**, such as described herein. However, the integrated system additionally provides convenience by automation (for example, data transfer through operable connection) and reduced opportunity for human error than may be experienced with the conventional therapy.

(75) In some embodiments, integrated electronics, which are described in more detail elsewhere herein, include programming that requires at least one of the receiver **14**, the single point glucose monitor **18**, and the hand-held medicament injection pen **16** to be validated or confirmed by another of the components to provide a fail safe accuracy check; in these embodiments, the validation includes algorithms programmed into any one or more of the components. In some embodiments, the integrated electronics include programming that requires at least one of the receiver **14** and the hand-held medicament injection pen **16** (e.g., hand-held medicament injection pen such as a pen) to be validated or confirmed by a human (for example, to confirm the amount and/or type of medicament). In these embodiments, validation provides a means by which the receiver can be used adjunctively, when the host or doctor would like to have more control over the host's therapy decisions, for example. See FIGS. **15** and **16** for exemplary processes that can be implemented herein.

(76) In some embodiments, the hand-held medicament injection pen **16** includes a motor configured for electronic control of at least a portion of the hand-held medicament injection pen. In some embodiments, a motor is configured to automatically set an amount of medicament to be delivered to the host, such as but not limited to a medicament bolus amount, for example, using a step motor. In some embodiments, a motor is configured to control a rate of medicament injection into the host. In some embodiments, the integrated electronics (e.g., the receiver), described in more detail elsewhere herein, are configured to remotely control at least one motor, such as those described above. In some embodiments, the integrated electronics are configured to provide a recommended therapy amount (e.g., medicament bolus amount), which can be communicated to the hand-held medicament injection pen (or which can be integral with the pen); in some such embodiments, the integrated electronics and/or hand-held medicament injection pen electronics are configured to automatically set the bolus amount using the motor (e.g., a step motor), however, in some embodiments, a validation step can be required. In some embodiments, the integrated electronics and/or the hand-held medicament injection pen electronics are configured to automatically inject the medicament at a controlled speed and/or rate. Preferably, the system is configured to inject the medicament at an optimum rate to reduce tissue damage and optimize the medicament absorption, which are believed to enable the effectiveness of the medicament to be more consistent over time. In some embodiments, actuation (or control) of setting a bolus amount(s) and/or injection of the medicament is controlled by a receiver operably connected to the hand-held medicament injection pen, for example by actuation (or selection) of a button, a user selectable menu item, or on a touch screen. In alternative embodiments, actuation (or control) of setting a bolus amount(s) and/or injection of the medicament is controlled by the hand-held medicament injection pen, for example by actuation (or selection) of a button, a user selectable menu item, or on a touch screen.

(77) Although much of this description and the exemplary embodiments are drawn to an integrated

hand-held medicament injection pen, the integration concepts described herein are applicable to a variety of other medicament devices, including inhalation devices, transdermal patches, and the like.

(78) Receiver

(79) The preferred embodiments provide an integrated system **10**, which includes a receiver **14** that receives and processes the raw data stream from the continuous glucose sensor **12**. The receiver can perform all or some of the following operations: a calibration, converting sensor data, updating the calibration, evaluating received reference and sensor data, evaluating the calibration for the analyte sensor, validating received reference and sensor data, displaying a meaningful glucose value to a user, calculating therapy recommendations, validating recommended therapy, adaptive programming for learning individual metabolic patterns, and prediction of glucose values, for example. Some complementary systems and methods associated with the receiver are described in more detail with reference to co-pending U.S. Patent Publication No. US-2005-0027463-A1, which is incorporated herein by reference in its entirety.

(80) In some embodiments, the receiver **14** is a PDA- or pager-sized housing, for example, and comprises a user interface **96** that has a plurality of buttons **108** and a liquid crystal display (LCD) screen, which can include a backlight. In some embodiments, the receiver can take other forms, for example a hand-held medicament injection pen case, a hand-held medicament injection pen kit, a hand-held medicament injection pen housing, a medicament delivery device housing and/or receiver, a computer, a server, a cell phone, a personal digital assistant (PDA), or other such device capable of receiving and processing the data such as described herein. Additionally or alternatively, the user interface can include a keyboard, a speaker, a scroll wheel, and/or a vibrator such as described with reference to FIG. **13**. The receiver **14** comprises systems (for example, electronics) necessary to receive, process, and display sensor data from the glucose sensor **12**, such as described in more detail with reference to FIG. **13**. The receiver **14** processes data from the continuous glucose sensor **12** and additionally processes data associated with at least one of the hand-held medicament injection pen **16**, a single point glucose meter **16**, and a host **8** (user).

(81) In some embodiments, the receiver is integral with (physically connected to) the sensor. In some embodiments, the receiver **14** is integrally formed with a medicament delivery device **16** and/or a single point glucose monitor **18**. In some embodiments, the receiver **14**, the medicament delivery device **16** and/or a single point glucose monitor **18** are detachably connected, so that one or more of the components can be individually detached and attached at the user's convenience. In some embodiments, the receiver **14**, the medicament delivery device **16**, and/or a single point glucose monitor **18** are separate from, detachably connectable to, or integral with each other; and one or more of the components are operably connected through a wired or wireless connection, allowing data transfer and thus integration between the components. In some embodiments, the receiver **14** and the medicament delivery device **16** (e.g., a hand-held medicament injection pen) each comprise mutually engaging electrical contacts, which are configured to allow communication between the hand-held medicament injection pen and the receiver. In a further embodiment, the integrated system is configured to initiate communication between the receiver and the hand-held medicament injection pen, in response to engagement of the electrical contacts. Upon engagement of the electrical contacts, the system is configured to communicate medicament delivery data between the receiver and the hand-held medicament injection pen.

(82) In some embodiments, the receiver **14** includes a housing and a user interface **196** located on the receiver housing. In some embodiments, a hand-held medicament injection pen is provided and includes a housing, wherein the user interface **196** is located on the hand-held medicament injection pen housing. In some embodiments, a housing is provided, wherein the housing is configured to receive a hand-held medicament injection pen and wherein the housing includes a user interface **196**. In some embodiments, a hand-held medicament injection pen kit is provided, wherein the hand-held medicament injection pen kit is configured to receive the hand-held

medicament injection pen (and can be configured to receive other accessories, such as medicament cartridges, needles, and the like), wherein the user interface **196** is located on the hand-held medicament injection pen kit. In some embodiments, a receiver, integrated electronics, and a hand-held medicament injection pen are integrally formed into one housing.

(83) In some alternative embodiments, a flexible LED screen is provided as a user interface (or a component thereof), wherein the flexible LED screen is physically located on at least one of the receiver and the hand-held medicament injection pen and/or operably connected to at least one of the receiver and the hand-held medicament injection pen, and wherein the integrated electronics are configured to display sensor data on the flexible LED screen.

(84) In some alternative embodiments, an image projection system is provided, wherein the integrated electronics are configured to project data onto a surface (e.g., wall, skin, and the like) as a user interface (or a component thereof). For example, the image projection system can be provided on the receiver, hand-held medicament injection pen, and/or any housing associated therewith, wherein the image projection system is configured to project an image such as alphanumeric data, icons, pictures, and the like, similar to that conventionally seen on an LCD screen, for example. In use, the image can be projected automatically or in response to actuation by a user, wherein the image includes data such as glucose concentration and/or glucose trend, therapy recommendations, event markers, and the like.

(85) Single Point Glucose Monitor

(86) In some embodiments, the integrated system is configured and arrange for operable communication with a single point glucose monitor **18**, such as but not limited to a meter for measuring glucose within a biological sample, including a sensing region that has a sensing membrane impregnated with an enzyme, similar to the sensing membrane described with reference to U.S. Pat. Nos. 4,994,167 and 4,757,022, which are incorporated herein in their entirety by reference. In some embodiments, the single point glucose monitor includes a conventional finger stick device. However, in alternative embodiments, the single point glucose monitor can use other measurement techniques including enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, and the like. In some embodiments, the single point glucose monitor is configured for wired or wireless communication with a component of the integrated system (e.g., automatic and/or semi-automatic communication), such as but not limited to the receiver. However, in other embodiments, the single point glucose monitor is not configured for operable communication with the integrated system, such that the host must manually input the single point glucose monitor data (e.g., into the receiver). It is noted that the meter is optional in that a separate meter can be used and the glucose data downloaded or input by a user into the receiver.

(87) Integrated System Design

(88) In preferred embodiments, an integrated system **10** includes a receiver **14** (e.g., including user interface and integrated electronics), a medicament delivery device **16**, and optionally a single point glucose meter **18**, wherein the integrated electronics are configured to process and display continuous glucose data from a continuous glucose sensor **12**, including trend graphs, glucose concentration, rate of change information (e.g., directional arrow(s)), high and low glucose alarms, and/or the like, on the user interface. In some embodiments, the integrated electronics are configured to process and display information from the medicament delivery device (e.g., hand-held medicament injection pen). The user interface and integrated electronics can be included in and/or on the hand-held medicament injection pen, a hand-held medicament injection pen kit, the receiver, housings associated therewith, and/or combinations thereof.

(89) In some embodiments, an integrated hand-held medicament injection pen kit is provided, including for example, a case configured to hold a hand-held medicament injection pen, one or more medicament cartridges, one or more needles, etc., as is appreciated by one skilled in the art. In some embodiments, the integrated hand-held medicament injection pen kit additionally includes

a user interface (e.g., an LCD screen), for example on an outside (or an inside) of the case, configured to display continuous glucose data such as described elsewhere herein. In these embodiments, the kit includes electronics, operatively connected to the user interface, including programming configured to perform all or some of the following operations: calibrating and displaying the continuous glucose sensor data, calculating therapy recommendations (e.g., using a bolus-type calculator), validating (e.g., by a user) recommended therapy, and adaptive algorithms configured for learning individual metabolic patterns (e.g., response to therapies administered by the pen), for example.

(90) FIG. **3** is a perspective view of an integrated system **20** in one embodiment, showing an LCD screen **106** on a hand-held medicament injection pen housing **22**. In this exemplary embodiment, the hand-held medicament injection pen **20** includes a hand-held medicament injection pen housing **22**, a receiver, integrated electronics, and an LCD screen **106**, all of which are integrally formed therewith and/or incorporated therein. The hand-held medicament injection pen housing **22** further includes a port **24** configured to receive medicament cartridges and/or needles, and which an end cap can cover. The LCD screen **106** is configured to display data from the continuous glucose sensor and/or the hand-held medicament injection pen, as described in more detail elsewhere herein. An ergonomic handhold includes indentations **26** configured to allow a user's fingers to rest or hold during actuation of the hand-held medicament injection pen via insertion button **28**, for example. While not shown, in some embodiments, sensor and/or medicament delivery electronics can be located partially or wholly with the receiver, with the sensor and/or with the medicament delivery device(s). In some embodiments, the electronics are distributed between the receiver, the sensor and/or the medicament delivery device(s).

(91) In one exemplary embodiment the integrated system **10** is configured and arranged for monitoring and treating diabetes, and includes a medicament delivery device **16** configured and arranged for injecting an amount of medicament into a host **8** and an integrated receiver **14** configured and arranged to receive sensor data from a continuous glucose sensor **12**, wherein the sensor data is indicative of a glucose concentration of the host in vivo, wherein the integrated receiver comprises electronics configured and arranged to process the sensor data. In some embodiments, the electronics are further configured to calculate an amount of medicament therapy (e.g., a deliverable medicament dose, such as but not limited to a bolus dose to be delivered to the host) and/or a time of medicament therapy delivery. As is appreciated by one skilled in the art, the integrated electronics can be located entirely within the receiver **14**, or one or more portions of the electronics can be located with the continuous glucose sensor **12** and/or the medicament delivery device **16** or combinations thereof. Similarly, in some embodiments, the receiver **14** (including integrated electronics) is a separate unit from the sensor **12** and/or hand-held medicament injection pen **16**, while in other embodiments, the receiver (in part or in whole) can be integrated with sensor and/or hand-held medicament injection pen, as is described in greater detail herein. For example, in some embodiments, the integrated receiver includes a housing and the hand-held medicament injection pen is integrally formed with the housing.

(92) In another exemplary embodiment, an integrated system **10** for monitoring and treating diabetes is provided, the system comprising a receiver **14** configured and arranged to receive sensor data from an operably connected continuous glucose sensor **12**, wherein the continuous glucose sensor is configured and arranged to generate sensor data associated with a glucose concentration of a host; integrated electronics configured to process the sensor data and to generate a medicament therapy (e.g., insulin therapy, pramlintide therapy, exenatide therapy, combinations thereof), and an integrated hand-held medicament injection pen **16** for injecting an amount of the corresponding medicament into the host based at least in part on the medicament therapy. The medicament therapy includes but is not limited to a medicament identity, an amount of medicament therapy and/or a time of medicament therapy delivery. In some further embodiments, the receiver and the hand-held medicament injection pen are integrally formed. However, in some other further

embodiments, the receiver and hand-held medicament injection pen are detachably connectable, as described elsewhere herein.

(93) In a further embodiment of a detachably connectable hand-held medicament injection pen **16** (e.g., an insulin, pramlintide or exenatide pen) and receiver **14** housing, the system **10** is configured to initiate communication between the hand-held medicament injection pen and the receiver in response to (detachable) connection of the hand-held medicament injection pen and the housing. For example, in some embodiments, the hand-held medicament injection pen and the housing can include mutually engaging contacts (e.g., electrical contacts) that mate (e.g., make an electrical connection) when the hand-held medicament injection pen is connected to the housing and initiate communication between the receiver and the hand-held medicament injection pen. Upon initiation of communication, the receiver and the hand-held medicament injection pen can transmit data. For example, an amount of medicament therapy (e.g., calculated by the integrated electronics), such as but not limited to a bolus medicament dose (e.g., an amount and type of medicament to be delivered), and a time of medicament therapy can be communicated to the hand-held medicament injection pen, such that the medicament therapy can be delivered to (e.g., injected into) the host. Similarly, the hand-held medicament injection pen can communicate information to the receiver, such as but not limited the amount of medicament delivered to the host, the time the medicament was delivered, the amount of medicament remaining in the hand-held medicament injection pen to be used, the type of medicament contained in the hand-held medicament injection pen, and the like. In some embodiments, wireless communication between the hand-held medicament injection pen and the receiver can be initiated by engagement of the contacts or by host actuation of a switch, button, or the like. In some embodiments, communication between the hand-held medicament injection pen and the receiver is initiated after connection by actuation of a switch, button or the like, such as by the host or by attachment of the two devices. For example, in one embodiment, when the hand-held medicament injection pen is inserted into the receiver housing, an external surface of the hand-held medicament injection pen comes into an adjacent parallel orientation with respect to an internal surface of the receiver housing, which results in depression of a communication actuation button on the interior of the receiver housing. One skilled in the art can appreciate alternative configurations.

(94) In a further embodiment, the integrated system includes a user interface **196**, which is configured an arranged for input of host information and/or output of sensor data and/or medicament delivery data, such as, for example, the LCD screens **106** illustrated in FIGS. **3-12**. For example, the user interface can include a keyboard **198**, buttons **108** and/or a touch screen for input of host information, selection from menus, and the like. The host information includes any information related to the host and his/her medicament therapy, such as but not limited to a host identification (e.g., host ID code/number), physical characteristics of the host, a type of medicament to be injected into the host, a target blood glucose range/level, a protocol for the medicament therapy assigned to the host, an alert, an alarm, and the like. For example, in an embodiment useful in a clinical setting, a caretaker (e.g., nurse, doctor, physician's assistant) can enter a host's ID number and glucose concentration via the user interface, which enables the integrated electronics to calculate a deliverable medicament dose (e.g., according to the medicament therapy protocol assigned to that host ID number), which in turn enables the nurse to deliver an appropriate bolus medicament dose to the host at the bedside. In some embodiments, when the nurse is within a communication distance of the host and his/her implanted continuous glucose sensor, the receiver is configured to interrogate the sensor for the host information and/or sensor data associated with the host's glucose concentration.

(95) In preferred embodiments, the integrated system is configured and arranged to require validation prior to injection an amount of medicament into the host. For example, in some embodiments, the integrated system can prompt the user (e.g., a caretaker, such as a nurse or doctor, or the host himself) to validate (e.g., verify) via the user interface (e.g., via the speaker **100**,

vibrator **102** or screen) the host ID, the host's assigned medicament therapy protocol and/or they type of medicament on board the hand-held medicament injection pen. Additionally, the integrated system can display information to the nurse, such as the host ID, sensor data received from the continuous glucose sensor, processed sensor data, medicament delivery data (e.g., data related to a medicament therapy to be delivered to the host), and the like.

(96) FIG. **4** is a perspective view of an integrated system **32** in another embodiment, showing an LCD screen **106** on a hand-held medicament injection pen housing **36**. In this exemplary embodiment, the hand-held medicament injection pen housing **36** includes a hand-held medicament injection pen, a receiver, integrated electronics, and an LCD screen, all of which are integrally formed therewith and/or incorporated therein. The hand-held medicament injection pen housing **36** further includes a port **38** configured to received medicament cartridges and/or needles, and which an end cap can cover. The LCD screen **106** is configured to display data from the continuous glucose sensor and/or the hand-held medicament injection pen, as described in more detail elsewhere herein. An ergonomic handhold includes a thumb hold **40** configured to allow a user's thumb to rest or hold during actuation of the hand-held medicament injection pen via insertion button **42**, for example. Additionally, a scroll wheel **44** (also referred to as a jog wheel, thumb wheel, jog encoder, or rotary encoder) is provided that allows for scrolling through menus, data (e.g., numbers), and/or options, for example, and selection of the menus, data and/or options. In one such embodiment, the scroll wheel enables the user to view a variety of menu driven screens or options for initiating a sensor, displaying glucose data, displaying therapy recommendations, modifying therapy recommendations, and the like, by scrolling up or down on the wheel; additionally, the scroll wheel enables the user to select from the screens or options by depressing the scroll wheel. It is believed that incorporation of a scroll wheel into the integrated system enables a more compact system design with good ergonomics, usability, and reliability. In some embodiments, one or more buttons and/or toggles are included (alternatively or in addition to a scroll wheel) for moving through menus, data, options and the like.

(97) FIG. **5** is a perspective view of an integrated system **46** in another embodiment, showing a housing **48** configured to receive a hand-held medicament injection pen **50** wherein the housing includes an LCD screen **106** thereon. In this exemplary embodiment, the housing **48** includes a receiver, integrated electronics, and an LCD screen **106** integrally formed therewith and/or incorporated therein. Additionally, the housing includes an opening **54** configured to receive the hand-held medicament injection pen **50**. The illustrated hand-held medicament injection pen shows a dial **56** for setting the medicament bolus amount, a screen **58** for viewing the medicament bolus amount (e.g., from about 0 to about 70 units of medicament in some embodiments) while turning the dial **56**, a medicament cartridge holder/receptacle **60** and a needle **62**; however, any known hand-held medicament injection pen configured can be used, as is appreciated by one skilled in the art, and as described in more detail elsewhere herein. In some embodiments, the integrated system includes a receptacle configured and arranged to receive and medicament cartridge, thereby medicament can be delivered to the host. In some embodiments, wherein the pen and the housing are separate, the receptacle **60** is included in the hand-held medicament injection pen, as illustrated in FIG. **5**. However, in embodiments wherein the pen and the housing are integrally formed, the receptacle can be integrally formed with the housing. The integrated system is configured such that the hand-held medicament injection pen is at least partially received, and can be substantially fully received by the housing **48**. In some embodiments, an end cap **64** is provided to protect the end of the hand-held medicament injection pen and/or for with a storage compartment for storing hand-held medicament injection pen accessories (e.g., needles, medicament cartridges, and the like). The illustrated housing **48** includes an LCD screen **106** and a scroll wheel **44**, which are described in more detail elsewhere herein.

(98) In some embodiments, such as the embodiment illustrated in FIG. **5**, the hand-held medicament injection pen is detachably connectable to the receiver. In some embodiments, wherein

integrated system **46** includes a housing configured to receive the hand-held medicament injection pen, mutually engaging contacts are provided on the hand-held medicament injection pen and on the housing (e.g., receiver, case, etc), such that when the pen is received by (detachably connected to) the housing (e.g., in a predetermined position), direct communication between the pen and the housing (e.g., receiver and/or integrated electronics housed therein) can occur. In some embodiments, the integrated system is configured to detect when the pen is received by the housing and subsequently upload and/or download information there between. In some embodiments, the integrated system is configured to initiate communication between the hand-held medicament injection pen and the housing (e.g., receiver and/or integrated electronics) in response to mutual engagement of the electrical contacts. In some embodiments, the integrated system is configured communicate data (e.g., recommended medicament bolus amount, actual amount of medicament delivered, and time of medicament delivery, glucose data, and the like) between the hand-held medicament injection pen and the housing (e.g., receiver and/or integrated electronics) in response to engagement of the electrical contacts.

(99) FIG. **6** is a perspective view of an integrated system **46** in yet another embodiment, wherein the integrated receiver **14** includes a housing **48** configured to receive a hand-held medicament injection pen **50** wherein the housing includes an LCD screen **106** thereon. In this exemplary embodiment, the housing **48** includes a receiver, integrated electronics, and an LCD screen **106** integrally formed therewith and/or incorporated therein. The illustrated hand-held medicament injection pen **50** shows a screen **58** for viewing the medicament bolus amount, which can be selected using actuation button **44** located on the housing. Actuation button **44** can also be used to toggle/scroll through menus on LCD screen **106**. In some embodiments, the hand-held medicament injection pen includes contacts that mate with contacts of the housing, such that the integrated electronics can automatically set a bolus dose, such as a calculated medicament therapy, that can then be manually delivered by the host. Accordingly, in some embodiments, the hand-held medicament injection pen **16** is detachably connectable to the housing. For example, the hand-held medicament injection pen can be connected to the housing and then removed/separated from the housing. For example, in some embodiments, the hand-held medicament injection pen is disposable and a first hand-held medicament injection pen is removed and thrown away, followed by connection of a second (e.g., new, unused) hand-held medicament injection pen. In another example, the hand-held medicament injection pen is not disposable, but uses disposable cartridges of medicament received in a receptacle. Accordingly, in this example, the hand-held medicament injection pen can be disconnected from the housing, for medicament cartridge replacement, followed by reconnection of the pen to the housing.

(100) FIG. **7** is a perspective view of an integrated system **46***a* in yet another embodiment, in which the integrated receiver **14** includes a housing **48***a*, such as but not limited to a hand-held medicament injection pen kit, configured to receive a hand-held medicament injection pen **50**, wherein the receiver housing includes an LCD screen **106** and an actuation button **44** thereon. In this exemplary embodiment, the system is configured and arranged as a hand-held medicament injection pen kit having a two-part housing configured to open in a clam-shell manner, with a hinge at one edge. While the device illustrated in FIG. **7** includes top and bottom portions connected by a hinge structure, the device can include more than two portions or the portions can be in different orientations from that depicted in FIG. **7**. For example, in some embodiments, the housing has three hingeably-connected portions (e.g., top, middle and bottom). In other embodiments, the portions could open from side to side or from front to back, or any combination thereof. In still other embodiments, a portion of the housing is removably connected (e.g., a battery compartment cover) or is configured to slide/pop out of the housing, such as a drawer.

(101) In the illustrated embodiment (FIG. **7**), the receiver housing is configured with a top portion including a user interface **196** (e.g., the LCD screen **106** (e.g., for display of sensor data and/or the medicament therapy) and an actuation button **44**) located thereon, and a bottom portion configured

with compartments **50***a* and **60***a* configured to hold (e.g., store) the hand-held medicament injection pen **50** as well as one or more accessories (e.g., medicament cartridges, needles, alcohol wipes, etc.). In some embodiments, display a representation of medicament delivery on the user interface, wherein the representation of medicament delivery is substantially adjacent to substantially time-corresponding sensor data, such at that described elsewhere with reference to FIG. **14**. In some embodiments, the user interface includes a flexible LED screen operably connected to at least one of the receiver and the hand-held medicament injection pen, such as, for example, a fold-out or unrolling flexible screen that can be folded up and/or rolled up for storage when not in use. Accordingly, the integrated electronics are configured to display continuous glucose sensor data on the flexible LED screen. In other embodiments, the user interface includes an image projection system configured to project continuous glucose sensor data onto a surface, such as but not limited to a wall, a table top, a book, and the like.

(102) In some embodiments, such as the illustrated embodiment FIG. **7**, the hand-held medicament injection pen is detachably connectable to the receiver housing. For example, the hand-held medicament injection pen and the recess for receiving the hand-held medicament injection pen can include mutually engaging electrical contacts that engage when the hand-held medicament injection pen is put away in the housing. Similarly to the hand-held medicament injection pen, in some embodiments, the receiver is connected to the housing (either detachably or non-detachably). However, in preferred embodiments, the receiver (e.g., including integrated electronics) is integrally formed with the housing. In some embodiments, the system is configured to initiate communication between the hand-held medicament injection pen and the receiver in response to engagement of the mutually engaging electrical contacts (e.g., when the pen is put away in the housing), such that data/information (e.g., the medicament therapy) can be communicated between the receiver and hand-held medicament injection pen. The housing includes the receiver and integrated electronics, as well as a connector **48***b*, for connection of a power cable (e.g., to re-charge an included battery) and/or a data cable (e.g., for connection to a single-point glucose monitor for calibration and/or for connection to a computer, such as for data transfer and/or battery charging). In some embodiments, the hand-held medicament injection pen (e.g., motorized) and the interior of the housing comprise mutually engaging contacts, whereby, when the pen is installed in the housing and the pen and housing contacts are engaged, the integrated electronics can set a bolus dose (on the pen) to be delivered to the host.

(103) FIG. **8** is a perspective view of an integrated system **66** in another embodiment, showing a hand-held medicament injection pen housing **68**, a receiver, integrated electronics, a user interface and a hand-held medicament injection pen integrally formed and/or incorporated therein. The hand-held medicament injection pen housing **68** further includes a port **70** configured to received medicament cartridges and/or needles, and which an end cap can cover. The LCD screen **106** is configured to display data from the continuous glucose sensor and/or the hand-held medicament injection pen, as described in more detail elsewhere herein. An ergonomic handhold includes an indentation **72** configured to allow a user's index finger to rest or hold during actuation of the hand-held medicament injection pen via an insertion button **74**, for example.

(104) FIG. **9** is a perspective view of an integrated system **76** in another embodiment, showing a receiver housing **78** including a receiver, integrated electronics, a user interface and a hand-held medicament injection pen integrally formed therewith and/or incorporated therein. An actuation button **80** (e.g., for actuation of the hand-held medicament injection pen) is incorporated into the integrated receiver housing; the receiver housing further includes a port on an opposing side (e.g., to the actuation button, not shown in FIG. **9**) configured to receive medicament cartridges and/or needles, and which an end cap can cover. In some embodiments, the hand-held medicament injection pen is integrally formed with and/or incorporated into the receiver housing; however, alternative embodiments include an opening in the receiver housing configured to receive a hand-held medicament injection pen similar to that illustrated in FIG. **5** (e.g., such that is detachably

connectable thereto). The LCD screen **106** is configured to display data from the continuous glucose sensor and/or the hand-held medicament injection pen, as described in more detail elsewhere herein. The illustrated housing further includes a scroll wheel **44**, which is described in more detail elsewhere herein. It is believed that the illustrated configuration of FIG. **9** enables a low profile device, wherein a user can wear or carry the integrated system discretely.

(105) FIG. **10** is a perspective view of an integrated system **82** in another embodiment, showing a receiver housing **84** including a receiver, integrated electronics, a user interface, and a hand-held medicament injection pen integrally formed therewith and/or incorporated therein. The illustrated embodiment of FIG. **10** is substantially similar to FIG. **9**; however the integrated hand-held medicament injection pen is rotated 90 degrees within the design of the housing.

(106) FIG. **11** is a perspective view of an integrated system **80** showing an integrated housing **88** including a receiver, integrated electronics, a user interface, and a hand-held medicament injection pen, wherein the housing further includes a cap for the hand-held medicament injection pen. This illustrated embodiment is similar to that of FIGS. **6** and **7**, however further includes a cap **90** configured to protect the end of the hand-held medicament injection pen and/or for with a storage compartment for storing hand-held medicament injection pen accessories (e.g., needles, medicament cartridges, and the like).

(107) FIG. **12** is a perspective view of an integrated system **92** showing an integrated housing **94** including a receiver, integrated electronics, a user interface, and a hand-held medicament injection pen, wherein the housing further includes a cap for the hand-held medicament injection pen. This illustrated embodiment is similar to that of FIG. **11**, however includes a hinged end cap **96** and can enable a design with a reduced volume/size to encourage patient acceptance and/or use.

(108) Integrated Electronics

(109) FIG. **13** is a block diagram that illustrates integrated system electronics in one embodiment. One embodiment is described wherein the processor within the receiver performs much of the processing, however it is understood that all or some of the programming and processing described herein can be accomplished within the continuous glucose sensor, the receiver, a single point glucose monitor, and/or the delivery device, or any combination thereof. Similarly, displays, alarms and other user interface functions can be incorporated into any of the individual components of the integrated delivery device.

(110) In some embodiments, the receiver includes a housing with integrated electronics located within the receiver housing. In some embodiments, a hand-held medicament injection pen comprises a housing, and wherein the integrated electronics are located within the hand-held medicament injection pen housing. In some embodiments, a housing is configured to receive a hand-held medicament injection pen, wherein the housing includes integrated electronics therein. In some embodiments, a hand-held medicament injection pen kit is provided, wherein the hand-held medicament injection pen kit is configured to receive the hand-held medicament injection pen (and can be configured to receive other accessories, such as medicament cartridges, needles, and the like), wherein the integrated electronics are located within the hand-held medicament injection pen kit. In some embodiments, a receiver, integrated electronics and hand-held medicament injection pen are integrally formed into one housing.

(111) A quartz crystal **176** is operably connected to an RF transceiver **178** that together function to receive and synchronize data streams via an antenna **180** (for example, transmission **140**). Once received, a processor module **182** processes the signals, such as described below. However other methods of wired or wireless communication can be substituted for the RF communication described herein.

(112) The processor (or processor module) **182** is the central control unit that performs the processing, such as storing data, analyzing a continuous glucose sensor data stream, analyzing single point glucose values, accuracy checking, checking clinical acceptability, calibrating sensor data, downloading data, recommending therapy instructions, calculating medicament delivery

amount, type and time, learning individual metabolic patterns, and controlling the user interface, by providing prompts, messages, warnings and alarms, and the like. The processor (or processor module) can include hardware and software that performs the processing described herein, including for example, read only memory (ROM), such as flash memory, provides permanent or semi-permanent storage of data, storing data such as sensor ID, receiver ID, and programming to process data streams (for example, programming for performing estimation and other algorithms described elsewhere herein), and random access memory (RAM) stores the system's cache memory and is helpful in data processing.

(113) In some embodiments, the processor **182** monitors the continuous glucose sensor data stream **140** to determine a preferable time for capturing glucose concentration values, using the single point glucose monitor electronics **116** for calibration of the continuous sensor data stream. For example, when sensor glucose data (for example, observed from the data stream) changes too rapidly, a single point glucose monitor reading may not be sufficiently reliable for calibration during unstable glucose changes in the host; in contrast, when sensor glucose data are relatively stable (for example, relatively low rate of change), a single point glucose monitor reading can be taken for a reliable calibration. In some additional embodiments, the processor can prompt the user via the user interface to obtain a single point glucose value for calibration at predetermined intervals. In some additional embodiments, the user interface can prompt the user to obtain a single point glucose monitor value for calibration based upon certain events, such as meals, exercise, large excursions in glucose levels, faulty or interrupted data readings, and the like. In some embodiments, certain acceptability parameters can be set for reference values received from the single point glucose monitor. For example, in one embodiment, the receiver only accepts reference glucose data between about 40 and about 400 mg/dL.

(114) In some embodiments, the processor **182** monitors the continuous glucose sensor data to determine a preferable time for medicament delivery, including type, amount, and time. In some embodiments, the processor is programmed to detect impending clinical risk and can request data input, a reference glucose value from the single point glucose monitor, and the like, in order to confirm a therapy recommendation. In some embodiments, the processor is programmed to process continuous glucose data and medicament therapies, to adaptively adjust to an individual's metabolic patterns. In some embodiments, the processor is programmed to project glucose trends based on data from the integrated system (for example, medicament delivery information, user input, and the like). In some embodiments, the processor is programmed to calibrate the continuous glucose sensor based on the integrated single point glucose monitor **18**. Numerous other programming can be incorporated into the processor, as is appreciated by one skilled in the art, as is described in cited patents and patent applications here, and as is described with reference to flowcharts of FIGS. **15** and **16**.

(115) A battery **192** is operably connected to the processor **182** and provides power for the receiver. In one embodiment, the battery is a standard AAA alkaline battery, however any appropriately sized and powered battery can be used. In some embodiments, a plurality of batteries can be used to power the system. In some embodiments, a power port (not shown) is provided permit recharging of rechargeable batteries. A quartz crystal **194** is operably connected to the processor **182** and maintains system time for the computer system as a whole.

(116) A PC communication (com) port **190** can be provided to enable communication with systems, for example, a serial communications port, allows for communicating with another computer system (for example, PC, PDA, server, or the like). In one exemplary embodiment, the receiver is configured to download historical data to a physician's PC for retrospective analysis by the physician. The PC communication port **190** can also be used to interface with other medical devices, for example pacemakers, implanted analyte sensor patches, infusion devices, telemetry devices, and the like.

(117) A user interface **196** includes a keyboard **198**, a speaker **100**, a vibrator **102**, a backlight **104**,

a liquid crystal display (LCD) **106**, one or more buttons **108**, and/or a scroll wheel **44** (shown in FIG. **4**, for example). The components that comprise the user interface **196** provide controls to interact with the user. The keyboard **198** can allow, for example, input of user information about himself/herself, such as mealtime, exercise, medicament administration, and reference glucose values. The speaker **100** can provide, for example, audible signals or alerts for conditions such as present and/or predicted hyper- and hypoglycemic conditions. The vibrator **102** can provide, for example, tactile signals or alerts for reasons such as described with reference to the speaker, above. The backlight **104** can be provided, for example, to aid the user in reading the LCD in low light conditions. The LCD **106** can be provided, for example, to provide the user with visual data output. In some embodiments, the LCD is a touch-activated screen. The buttons **108** and/or scroll wheel **44** (see FIGS. **4** and **6**, for example) can provide for toggle, menu selection, option selection, mode selection, and reset, for example. In some alternative embodiments, a microphone can be provided to allow for voice-activated control.

(118) The user interface **196**, which is operably connected to the processor **182**, serves to provide data input and output for both the continuous glucose sensor, the hand-held medicament injection pen, and/or for the single point glucose monitor. Data output includes a numeric estimated analyte value, an indication of directional trend of analyte concentration, a graphical representation of the measured analyte data over a period of time, alarms/alerts, therapy recommendations, actual therapy administered, event markers, and the like. In some embodiments, the integrated electronics are configured to display a representation of a target glucose value or target glucose range on the user interface. Some additional data representations are disclosed in Published U.S. Patent Application No. 2005-0203360, which is incorporated herein by reference in its entirety

(119) FIG. **14** is a graphical representation of integrated data that can be displayed on an LCD screen **106**, for example, in one embodiment. In this embodiment, the integrated electronics are configured to display a representation of a value of the sensor data (illustrated by bars in this illustration) above or below the target glucose value (illustrated by a line at “145” (mg/dL) in FIG. **14**) or target glucose range (not shown) on the user interface. In the illustrated embodiment, the x-axis represents time and the y-axis represents glucose concentration in mg/dL. Glucose concentration is graphed over time according to its value as compared to a target (e.g., above and/or below the target). For example, if a target glucose concentration is set at 145 mg/dL and the actual glucose concentration is 180 mg/dL, then the bar value represents 35 mg/dL (180 mg/dL−145 mg/dL) above the target glucose concentration for that glucose measurement. While FIG. **14** shows the glucose concentration as a series of black bars, the data can be shown using a variety of symbols. For example, in one embodiment, the bars are colored, with green bars above the target and red bars below the target. In another embodiment using colored bars, the bars are colored as a gradient, wherein the bars within the target range are green, changing to yellow and then red as the host's glucose concentration is farther and farther away from the target range. In another embodiment, dots, circles, squares and the like are used instead of bars. In still another embodiment, stars, hearts, a thumbs-up graphic, and/or smiley-faces (colored and/or black and white) can be added to the graph to denote periods of time during which the host was within the target. In a further embodiment, the stars, hearts, a thumbs-up graphic, and/or smiley-faces can blink or flash as an award for staying within the target. In still another embodiment, instead of using colors, portions of the graph are made to blink/flash. For example, in one embodiment, a series of dots plot out the host's glucose concentration, with the most recent concentration blinking.

(120) In some embodiments, the integrated electronics are configured to display a representation of medicament delivery on the user interface adjacent to substantially time-corresponding sensor data, which is illustrated as “10 U” and “7 U” in FIG. **14**, representing the units of medicament delivered in a bolus. In these embodiments, the representation of medicament delivery is located substantially adjacent to a glucose value measured at substantially the same time as the medicament delivery. It is believed that by providing a representation of medicament delivery on the user adjacent to

substantially time-corresponding sensor data, a user can see the affect of the therapy (e.g., medicament bolus) on their glucose concentration and/or achievement of target glucose concentration.

(121) In some embodiments, the integrated electronics are configured to display glucose data on the user interface for 1 hour, 3 hours, 6 hours, 9 hours, 1 day, 3 days, 5 days, 7 days, 1 month, 3 months, year-to-date, 1 year, 2 years, 5 years, and the like for example, which provides the user with actual, averaged or estimated glucose values over that time period. In some embodiments, the integrated electronics are configured to display glucose trend data (e.g., charts or graphs) on the user interface, including a graphical representation of glucose values as they change over time. In some embodiments, the integrated electronics are configured to display comparison data for two periods (e.g., charts or graphs) on the user interface, including a trend-related finding between two specific periods of time. In some embodiments, the integrated electronics are configured to display modal day data (e.g., charts or graphs) on the user interface, including glucose summary data based on mealtimes. In some embodiments, the integrated electronics are configured to display modal week data (e.g., charts or graphs) on the user interface, including glucose summary data based on days of the week. In some embodiments, the integrated electronics are configured to display medicament dosage and effects data (e.g., charts or graphs) on the user interface, including medicament regimen information and changes in base medicament pattern. In some embodiments, the integrated electronics are configured to display hypoglycemia and hyperglycemia episode data (e.g., charts or graphs) on the user interface, including information regarding very low and very high glucose readings and/or glucose readings outside of a target range (which can be defined by the user in some embodiments). In some embodiments, the integrated electronics are configured to display rapid swings data (e.g., charts or graphs) on the user interface, including incidents of rapid swings between low and high blood glucose levels, which levels can be pre-programmed or settable by a user, for example.

(122) In some embodiments, prompts or messages can be displayed on the user interface to convey information to the user, such as malfunction, outlier values, missed data transmissions, or the like, for the continuous glucose sensor. Additionally, prompts can be displayed to guide the user through calibration of the continuous glucose sensor. Even more, calibrated sensor glucose data can be displayed, which is described in more detail with reference to co-pending U.S. Patent Publication No. US-2005-0027463-A1 and U.S. Patent Publication No. US-2005-0203360-A1, each of which is incorporated herein by reference in their entirety.

(123) In some embodiments, prompts or messages about the hand-held medicament injection pen can be displayed on the user interface to inform or confirm to the user type, amount, and time of medicament delivery. In some embodiments, the user interface provides historical data and analytes pattern information about the medicament delivery, and the host's metabolic response to that delivery, which may be useful to a patient or doctor in determining the level of effect of various medicaments.

(124) Referring again to FIG. **13**, electronics **110** associated with the delivery device **16** are operably connected to the processor **182** and include a processor **112** for processing data associated with the delivery device **16** and include at least a wired or wireless connection **114** for transmission of data between the processor **182** of the receiver **14** and the processor module **112** of the delivery device **16**. In some embodiments, the delivery device electronics **110** are at least partially or fully incorporated into the integrated electronics, such that electronics **110** may not be required. Other electronics associated with any of the delivery devices cited herein, or other known delivery devices, can be implemented with the delivery device electronics **110** described herein, as is appreciated by one skilled in the art.

(125) In some embodiments, the processor module **112** comprises programming for processing the delivery information in combination with the continuous sensor information. In some alternative embodiments, the processor **182** comprises programming for processing the delivery information in

combination with the continuous sensor information. In some embodiments, both processors **182** and **112** mutually process information related to each component.
(126) In some embodiments, the hand-held medicament injection pen **16** further includes a user interface (not shown), which can include a display and/or buttons, for example. U.S. Pat. Nos. 6,192,891, 5,536,249, and 6,471,689 describe some examples of incorporation of a user interface into a hand-held medicament injection pen, as is appreciated by one skilled in the art.
(127) Electronics **116** associated with the optional single point glucose monitor **18** are operably connected to the processor module **120** and include a potentiostat **118**, in one embodiment, that measures a current flow produced at the working electrode when a biological sample is placed on the sensing membrane, such as described above.
(128) Algorithms
(129) FIG. **15** is a flow chart that illustrates the process **230** of validating therapy instructions prior to medicament delivery, in one embodiment. In some embodiments, the system is configured with programming that provides for validation of therapy recommendations. In some embodiments, the therapy recommendations include a suggestion, on the user interface, of time, amount, and type of medicament to delivery. In some embodiments, therapy instructions include calculating a time, an amount, and/or a type of medicament delivery to administer, and optionally transmitting those instructions to the delivery device. In some embodiments, therapy instructions include that portion of a closed loop system wherein the determination and delivery of medicament is accomplished, as is appreciated by one skilled in the art.
(130) In some embodiments, the therapy recommendations are displayed on a user interface (e.g., of an integrated housing) by representative icons, such as a syringe, a medicament pen, a medicament pump, an apple, orange juice, candy bar, or any icon representative of eating, drinking, or administering therapy, for example. Additionally or alternatively, the therapy recommendations can be preset alphanumeric messages, for example, “3.0 Units,” “consume carbohydrates,” “inject medicament” or “no therapy required”, and can include brand names, amounts, times, acronyms, codes and the like. In response to the recommendation of therapy displayed on the user interface, the user can confirm, modify, and/or cancel the recommended therapy, after which, the integrated hand-held medicament injection pen is configured to administer the appropriate therapy.
(131) Although computing and processing of data is increasingly complex and reliable, there are circumstances in which the therapy recommendations necessitate human intervention. Some examples include when a user is about to alter his/her metabolic state, for example due to a behavior such as exercise, meal, pending manual medicament delivery, and the like. In such examples, the therapy recommendations determined by the programming may not have considered present or upcoming behavior, which can change the recommended therapy. Numerous such circumstances can occur, such that a validation can be advantageous in order to ensure that therapy recommendations are appropriately administered.
(132) At block **232**, a sensor data receiving module, also referred to as the sensor data module, receives sensor data (e.g., a data stream), including one or more time-spaced sensor data points, from a sensor via the receiver, which can be in wired or wireless communication with the sensor. The sensor data point(s) can be raw or smoothed, such as described in U.S. Patent Publication No. US-2005-0043598-A1, which is incorporated herein by reference in its entirety.
(133) At block **234**, a medicament calculation module, which is a part of a processor module, calculates a recommended medicament therapy based on the received sensor data. A variety of algorithms can be used to calculate a recommended therapy as is appreciated by one skilled in the art.
(134) At block **236**, a validation module, which is a part of the processor module, optionally validates the recommended therapy. The validation can include a request, from the user or another component of the integrated system **10**, for additional data to ensure safe and accurate medicament recommendation or delivery. In some embodiments, the validation module requests and/or

considers additional input, such as time of day, meals, sleep, calories, exercise, sickness, or the like. In some embodiments, the validation module is configured to request this information from the user. In some embodiments, the validation module is responsive to a user inputting such information.

(135) In some embodiments, when the integrated system **10** is in a fully automated mode, the validation module is triggered when a potential risk is evaluated. For example, when a clinically risky discrepancy is evaluated, when the acceleration of the glucose value is changing or is low (indicative of a significant change in glucose trend), when it is near a normal meal, exercise or sleep time, when a medicament delivery is expected based on an individual's dosing patterns, and/or a variety of other such situations, wherein outside influences (meal time, exercise, regular medicament delivery, or the like) may require additional consideration in the therapy instructions. These conditions for triggering the validation module can be pre-programmed and/or can be learned over time, for example, as the processor module monitors and patterns an individual's behavior patterns.

(136) In some embodiments, the system can be programmed to request additional information from the user regarding outside influences unknown to the integrated system prior to validation. For example, exercise, food or medicament intake, rest, and the like can be input into the receiver for incorporation into a parameter of the programming (algorithms) that processes the therapy recommendations.

(137) At block **238**, the receiver confirms and sends (for example, displays, transmits and/or delivers) the therapy recommendations. In some embodiments, the receiver can simply confirm and display the recommended therapy, for example. In some embodiments, the receiver can confirm, transmit, and optionally deliver instructions, to the delivery device, regarding the recommended therapy, for example. In some embodiments, the receiver can confirm and ensure the delivery of the recommended therapy, for example. In some embodiments, a glucose value measured by the single point glucose monitor is used to validate the therapy recommendation. It is noted that these examples are not meant to be limiting and there are a variety of methods by which the receiver can confirm, display, transmit, and/or deliver the recommended therapy, within the scope of the preferred embodiments.

(138) FIG. **16** is a flow chart **240** that illustrates the process of providing adaptive metabolic control using an integrated system, in one embodiment. In this embodiment, the integrated system is programmed to learn the patterns of the individual's metabolisms, including metabolic response to medicament delivery.

(139) In some embodiments, the system is configured with programming that provides therapy recommendations based on at least one of the following: glucose concentration, glucose trend information (e.g., rate of change, acceleration, etc), predicted glucose values, food intake (e.g., carbohydrates), exercise, illness, sleep, time of day, and the like. In one such example, the system is configured to request carbohydrate and exercise information, from the user, which is used in combination with data from the continuous glucose sensor to calculate a recommended dose of medicament for injection (e.g., with a hand-held medicament injection pen). In some embodiments, when the user's glucose concentration falls outside of a target range (or is predicted to fall outside of a target range), a recommended therapy is displayed on the user interface (e.g., of an integrated pen as described above), wherein the user has an opportunity to validate the therapy recommendation prior to injection of medicament. After the user has injected the medicament, the amount (and type, etc) of medicament, which is stored in the integrated system, is analyzed, in combination with the user's metabolic response (i.e., continuous glucose data) over a predetermine time period (e.g., minutes to hours after injection), to determine whether the amount (and/or type) of medicament administered affected a desired change (e.g., glucose concentration within a target range). Preferably, the system's programming is configured to process the medicament delivery information and the continuous glucose sensor information, to adaptively adjust therapy

recommendations to an individual's metabolic patterns. Namely, with each medicament injection and/or over multiple medicament injections, the system is configured to adaptively learn how a user responds to various therapies and to adaptively adjust the calculation of therapy recommendations accordingly.

(140) At block **242**, a medicament data receiving module, which can be programmed within the receiver **14** and/or medicament delivery device **16**, receives medicament delivery data, including time, amount, and/or type. In some embodiments, the user is prompted to input medicament delivery information into the user interface. In some embodiments, the medicament delivery dev ice **16** sends the medicament delivery data to the medicament data-receiving module.

(141) At block **244**, a sensor data receiving module, also referred to as the sensor data module, receives sensor data (e.g., a data stream), including one or more time-spaced sensor data points, from a sensor via the receiver, which can be in wired or wireless communication with the sensor.

(142) At block **246**, the processor module, which can be programmed into the receiver **14** and/or the delivery device **16**, is programmed to monitor the sensor data from the sensor data module **242** and medicament delivery data from the medicament delivery module **244** to determine an individual's metabolic profile, including their response to various times, amounts, and/or types of medicaments. The processor module can use any pattern recognition-type algorithm, as is appreciated by one skilled in the art, to quantify the individual's metabolic profile.

(143) At block **248**, a medicament calculation module, which is a part of a processor module, calculates the recommended medicament based on the sensor glucose data, medicament delivery data, and/or the host's individual's metabolic profile. In some embodiments, the recommended therapy is validated such as described with reference to FIG. **15**, above. In some embodiments, the recommended therapy is manually, semi-automatically, or automatically delivered to the host.

(144) At block **250**, the process of monitoring and evaluation a host's metabolic profile is repeated with each receipt of new medicament delivery data, wherein the processor monitors the sensor data and the associated medicament delivery data to determine the individual's metabolic response, in order to adaptively adjust to newly determined metabolic profile or patterns, if necessary. This process can be continuous throughout the life of the integrated system, can be initiated based on conditions met by the continuous glucose sensor, can be triggered by a patient or doctor, and/or can be provided during a start-up or learning phase.

(145) While not wishing to be bound by theory, it is believed that by adaptively adjusting the medicament delivery based on an individual's metabolic profile, including response to medicaments, improved long-term patient care and overall health can be achieved.

(146) Integrated Systems for Clinical Settings

(147) FIG. **17** is a block diagram illustrating an integrated diabetes monitoring and treatment system for use in a clinical setting, in one embodiment. The integrated system includes a continuous glucose sensor **12** configured to continuously detect a signal associated with a glucose concentration of a host, a processor module **182** configured and arranged to process the signal to generate sensor data and a therapy instruction, wherein the therapy instruction comprises a deliverable medicament dose in some embodiments, and a communication module **1700** configured and arranged to communicate the therapy instruction between the processor module and a medicament delivery device **16**, such as one or more hand-held medicament injection pens. Although much of the description is related to hand-held medicament injection pens, the preferred embodiments can be applied to any such medicament delivery device configured for bolus therapy, such as medicament inhalers, and/or the like. In one exemplary embodiment, the glucose sensor is implanted in a host. In some embodiments, a processor module **182** associated with the sensor, processes the sensor data to calculate and medicament therapy (e.g., a medicament dose to be delivered to the host) and a communication module **1700** communicates the medicament therapy instruction to the hand-held medicament injection pen **16**, such as but not limited to via wireless communication. In some embodiments, the processor continually calculates a deliverable

medicament dose that can be transmitted to a hand-held medicament injection pen within range of the communication module. In other embodiments, the processor module calculates the medicament therapy in response to interrogation by a hand-held medicament injection pen, such as via wireless communication. For example, a caretaker can use a hand-held medicament injection pen **16** to interrogate the patient's continuous glucose sensor **12**, to receive the medicament therapy instruction (e.g., identification of the host and a deliverable medicament dose calculated by the processor module **182**; communicated to the hand-held medicament injection pen by the communication module **1700**). In some preferred embodiments, the continuous glucose sensor includes the processor module configured to determine a medicament therapy instruction. However, in some embodiments, the system is configured such that at least a portion of the processor module is disposed within the hand-held medicament injection pen, such that the medicament device performs at least some of the calculations to generate the medicament therapy instruction. In some embodiments, the continuous glucose sensor includes only the minimal electronics necessary to collect the sensor data and (optionally) process the collected data into a data packet that is then communicated to the hand-held medicament injection pen, wherein the hand-held medicament injection pen includes a processor module and processes the data received to generate the medicament therapy instruction. Various intermediate configurations can be appreciated by one skilled in the art.

(148) After receiving the medicament therapy instruction, the caretaker can deliver the medicament dose to the patient, simply by actuating the medicament injection pen. As shown in FIG. **17**, the continuous glucose sensor **12** is configured and arranged to communicate with a plurality of hand-held medicament injection pens (**16***n*), such that in a clinical setting, such as a hospital, each caretaker can carry a hand-held medicament injection pen and use that hand-held medicament injection pen to deliver medicament to the patient (host) as a part of the normal course of patient care, similar to the practice of measuring the patient's temperature, pulse, blood pressure, respiration, pO.sub.2, urine output, and the like, at regular intervals as determined by hospital protocol.

(149) In preferred embodiments, the processor module **182** includes an input module configured for the input of host information and/or a therapy instruction. Preferably, the device is configured and arranged to be programmed (e.g., operated) by an external programmer, such as a caretaker. Such information can be input into the device when the continuous glucose sensor **12** is implanted in the host. For example, in some embodiments, the input module is configured to receive information from a user interface, a hand-held medicament injection pen, an infusion pump, a patient monitor, a single-point glucose monitor, a receiver, and the like. In some embodiments, the information can be input via a user interface incorporated into the continuous glucose sensor or via the hand-held medicament injection pen, which can include a user interface. In other embodiments, the information can be input via a tertiary device having a user interface and configured for communication with the communication module, such as but not limited to a computer, patient monitor, PDA and the like.

(150) In preferred embodiments, host information that can be input via an input module associated with the continuous glucose sensor and/or the hand-held medicament injection pen, wherein the host information includes but is not limited to a host ID, such as a unique identifying code assigned to a patient, host physical characteristics, a type of medicament to be delivered to the host, a therapy protocol assigned to the host, and the like. A therapy instruction includes but is not limited to selection of a therapy protocol and/or portions thereof, including but not limited to a target host blood glucose concentration and/or range of concentrations, selection of an alert to be sounded if the host meets a predetermined criterion, and the like. In preferred embodiments, the therapy instruction comprises at least one of a type of medicament, a medicament dose, and a delivery time. The integrated electronics are further configured and arranged to process host information and/or a therapy instruction. For example, the integrated electronics can process the continuous glucose

sensor data in the context of a selected protocol, such that medicament therapies are calculated to maintain the host within a target blood glucose concentration range (e.g., 100-140 mg/dl blood glucose), for example. In preferred embodiments, the device includes a display module configured and arranged for display of the host information, sensor data, the therapy instruction, the deliverable medicament dose, an alert and/or an alarm.

(151) In some embodiments, the system is configured for communication with a data repository system and/or device (e.g., portable and/or remotely located) configured to receive host information, sensor data, the therapy instruction, the deliverable medicament dose, an alert, an alarm, a predictive alarm, and the like. For example, in some embodiments, the communication module is configured to transmit information related to the host and his/her treatment to a data repository that records and tracks the host's condition and/or enters the data into the host's patient chart. For example, the data can be electronically entered into the host's patient chart remotely, such as in medical records. In another embodiment, the information can be monitored remotely by the patient's physician using a data repository device integrated into a display device, such as a personal computer, cell phone, PDA and the like, which enables the physician to receive predictive alarms of upcoming problems/events or alarms/alerts related to the host's current physical state. Similarly, when the physician visits the host, he can use a portable data repository to collect pertinent data from the continuous glucose sensor. In one exemplary embodiment, the continuous glucose sensor is configured to communicate data and information related to the medicament therapy to a separate and/or remote data repository, for example, wherein the sensor is configured to transmit this information to a remote monitor carried by the physician or at the nurse's station, or to a remote location (e.g., medical records) for storage and/or monitoring. In another exemplary embodiment, the hand-held medicament injection pen (e.g., insulin pen) is configured to communicate data received from the continuous glucose sensor (e.g., via the communication module) and information related to medicament therapy delivered to the host to the separate and/or remote data repository, for example, by transmitting this information to a remote monitor carried by the physician or at the nurse's station, or to a remote location (e.g., medical records) for storage and/or monitoring.

(152) As shown in FIG. **17**, the integrated system includes a hand-held medicament injection pen **16**, configured to communicate with the continuous glucose sensor **12** (e.g., and vice versa) and to deliver a medicament to the host. In some embodiments, the system is configured to communicate with a plurality of hand-held medicament injection pens **16***n*. For example, in one embodiment, the system is configured such that a host wearing a continuous glucose sensor can be monitored and/or treated by a plurality of caretakers, each of whom carries a hand-held medicament injection pen. For example, the host's sensor is configured to communicate with a first caretaker's hand-held medicament injection pen, then a second caretaker's hand-held medicament injection pen, and so on. As a non-limiting example, for a host in the hospital, at the initiation of each work shift, a new nurse can check the host's glucose level (e.g., via communication between the host's sensor and the nurse's hand-held medicament injection pen, as described herein) and deliver insulin, if needed. Accordingly, the continuous glucose sensor and the hand-held medicament injection pen(s) can communicate with each other when operably connected, to allow wired and/or wireless communication therebetween.

(153) FIG. **18** is a block diagram illustrating a medicament delivery device for monitoring and treating diabetes in one or more host, such as but not limited to in a clinical setting, in another embodiment. Although much of the description is related to hand-held medicament injection pens, the preferred embodiments can be applied to any such medicament delivery device configured for bolus therapy, such as medicament inhalers, and/or the like. The medicament delivery device **16** includes a communication module **1700** configured to interrogate an operably connected continuous glucose sensor **12** and to receive sensor data (e.g., a signal associated with a glucose concentration of a host) therefrom, a processor module **182** configured to process the sensor data

and calculate a medicament therapy, and a hand-held medicament injection pen (e.g., configured to receive a cartridge of medicament for injection) configured and arranged to deliver medicament based at least in part on the medicament therapy. In some embodiments, the system is configured for use with a continuous glucose sensor configured and arranged for transcutaneous implantation in the host, such as for use in the general wards, in which case the signal generated by the glucose sensor can be measured in the interstitial fluid, for example. In other embodiments, the system is configured for use with a continuous glucose sensor configured and arranged for implantation in the host's circulatory system (e.g., via an artery or vein) or in an extracorporeal blood circulation device, in which case the signal generated by the glucose sensor is associated with a glucose concentration of a sample of the host's circulatory system.

(154) In one embodiment, the communication module **1700**, which can be integrally formed with the hand-held medicament injection pen or in wired or wireless communication therewith or detachably connected to the hand-held medicament injection pen, is configured to receive information from an operably connected continuous glucose sensor when the hand-held medicament injection pen interrogates it. The hand-held medicament injection pen and the continuous glucose sensor can be operably connected using any method known in the art, such as but not limited to by wired and/or wireless communication. In one embodiment, the caretaker can simply hold the hand-held medicament injection pen within a predetermined communication range, such that the hand-held medicament injection pen and continuous glucose sensor can communicate with each other by wireless communication, such as RF, IR, Bluetooth, and the like. In another embodiment, the system is configured such that the hand-held medicament injection pen can communicate with the sensor via inductive coupling communication when the caretaker holds the pen adjacent to the sensor or touches the pen to the sensor. A variety of alternative useful communication methodologies are appreciated by one skilled in the art.

(155) In some embodiments, the hand-held medicament injection pen **16** includes a processor module **182** that includes programming for calculating the medicament therapy based at least in part on the sensor data, as described elsewhere herein. For example, the programming directs use of algorithms for calculating an amount of medicament to be delivered to the host, based at least in part on the sensor data received from the host's continuous glucose sensor. In preferred embodiments, the processor module calculates dosing information (e.g., a type of medicament to be delivered, an amount of medicament to be delivered and a time of delivery, and/or the like) using one or more algorithms described elsewhere herein. While the embodiment shown in FIG. **18** depicts the processor module **182** disposed within the hand-held medicament injection pen, in some embodiments, some or all of the processor electronics and/or functions can reside within the continuous analyte sensor(s) **12***n*. For example, in some embodiments, the electronics/components/modules (e.g., processor module, communication module, and the like) of receiver **14**, as depicted in FIG. **18**, can be distributed among other integrated system components, such as but not limited to the continuous analyte senor **12** and the hand-held medicament injection pen.

(156) In some embodiments, the processor module **182** is configured for validation of the dosing information. For example, the processor module can request validation of a calculated medicament dose and/or identification of the host prior to injection of the dose into the host. In some embodiments, the system is configured to disallow/prevent injection unless at least the dose (e.g., medicament identity, amount of medicament to be delivered and/or time of delivery) and/or host information has been validated. For example, the hand-held medicament injection pen can interrogate a first continuous glucose sensor, calculate a medicament dose and request validation prior to allowing the caretaker to inject the calculated dose into the host. The caretaker can move on to a second host and repeat the process. Accordingly, accidental injection (e.g., of one host's medicament dose into another host) can be avoided.

(157) Preferably, the hand-held medicament injection pen includes a user interface, such as that

described with reference to FIG. **13**, configured and arranged for input and/or display of at least some medical information, wherein medical information comprises at least one of host information, received sensor data, processed sensor data, the calculated medicament therapy, a delivered medicament therapy, an instruction, an alert, an alarm and a failsafe. Host information includes at least one of a host ID, type of medicament to be received, a target glucose level and/or range, predicted hypoglycemia/hypoglycemia, a therapy protocol, an alert, and an alarm. In some embodiments, the user interface is detachably connected to the hand-held medicament injection pen, such as via mutually engaging contacts that allow communication therebetween then the user interface is connected with the hand-held medicament injection pen. However, in other embodiments, the user interface (in part or in its entirety) is integrally formed with the hand-held medicament injection pen.

(158) In some embodiments, the hand-held medicament injection pen includes a communication module **1700** configured to communicate treatment information (e.g., host information, continuous glucose information, the therapy protocol, dosing information, medicament type, medicament delivered and time of medicament delivery) to a central monitor. A central monitor can be a device configured to receive information communicated from one or more hand-held medicament injection pens, such as a computerized device including a user interface for display of received information and optionally for communicating commands/instructions back to one or more hand-held medicament injection pens. In some embodiments, a central monitor can include one or more intermediate receiving devices, located about the hospital ward or at the nurses' station, and configured to receive the communicated information wirelessly, and then to relay the communicated information to the central monitor via a wired and/or wireless connection. In some embodiments, the system can be configured such that when a caretaker moves within a range of the intermediate receiving device and/or the central monitor itself, the receiving device/central monitor recognizes the hand-held medicament injection pen and triggers the pen to download information related to treatment of the host(s). Alternatively, recognition of the receiving device/central monitor by the hand-held medicament injection pen triggers the information download. The central monitor can be located in a centralized location, such as at the nurses' station or in medical records, or in a more private remote location, such as in the physician's office or in a nurse supervisor's office. Location of the central monitor at a location remote from the glucose sensor(s) and/or hand-held medicament injection pen enables remote monitoring of hand-held medicament injection pen use (e.g., how, when & where it is used) and/or function (e.g., if it is functioning properly).

(159) In some embodiments, at least a portion of the system is configured provide adaptive metabolic control of the host's glucose, as described with reference to FIG. **16**. Accordingly, the processor module is configured to receive sensor data and medicament therapy data (e.g., information related to medicament delivery to the host) and to monitor the sensor data for the host's metabolic response to the delivered medicament therapy. Accordingly, the system can calculate new medicament therapy based on the host's metabolic response to the medicament deliver. For example, if the host is highly sensitive to insulin, the system can intelligently monitor the host's response to an insulin dose and recalculate new medicament doses to take the host's insulin sensitivity into account. For example, in this particular circumstance, the processor module can calculate a small insulin dose, such that the host's glucose is maintained within the target range and hypoglycemia can be avoided. In another example, a host may be very insensitive to insulin. In the case of this insulin insensitive host, the system can monitor the lack of glucose concentration decreases upon insulin therapy delivery, and re-calculate future insulin doses (e.g., increase the volume of insulin delivered in a bolus dose and/or increase a basal delivery rate), such that this host's glucose can be maintained in the target range.

(160) Integrated Systems for Ambulatory Use

(161) FIG. **19** is a block diagram illustrating an integrated system (monitoring and treating diabetes) for ambulatory use, in one embodiment. Such a system can be used by an ambulatory

host to accurately monitor and treat his diabetes in real-time, by continuously monitoring his blood glucose level and infusing/injecting medicament with a basal medicament delivery device (e.g., a medicament pump) and a bolus medicament delivery device (e.g., a hand-held medicament injection pen) based at least in part on the data generated by the continuous glucose sensor, in either an open-loop, closed-loop or semi-closed-loop manner. In this embodiment, the integrated system includes a receiver **14** configured and arranged to receive continuous glucose sensor data from an operably connected continuous glucose sensor **12** implanted in a host, a processor module configured to process the continuous glucose sensor data and to provide medicament dosing information based at least in part on the continuous glucose sensor data, and a communication module configured and arranged to communicate the medicament dosing information with the medicament delivery devices **16***a* and **16***b*. Although a separate receiver is illustrated in FIG. **19**, the receiver **14**, including the processor module and/or communication module, can be located with the continuous glucose sensor, the basal medicament delivery device, the bolus medicament delivery device and/or combinations thereof, eliminating a need for a separately housed receiver.

(162) In some embodiments, the basal medicament delivery device **16***a* is a medicament pump **16***a*, and the medicament dosing information comprises a basal dose of medicament. Accordingly, the processor module comprises programming to calculate the basal dose based at least in part on the continuous glucose sensor data. The receiver is configured to communicate the basal dose to the medicament pump, which, in turn, is configured to infuse the basal medicament dose into the host. Since the glucose sensor is a continuous glucose sensor, the system can be configured to continually recalculate the basal medicament dose and readjust the dose according to the host's needs, as indicated by the sensor data generated by the continuous glucose sensor. This enables adaptive metabolic control **240**, as described with reference to FIG. **16**, and optimized, real-time patient care.

(163) In some preferred embodiments, the bolus medicament delivery device **16***b* is a hand-held medicament injection pen **16***b* and the medicament dosing information comprises a bolus medicament dose. Accordingly, the processor module comprises programming to calculate a bolus dose of medicament based at least in part on the continuous glucose sensor data. In some embodiments, the hand-held medicament injection pen is configured to infuse the same medicament as the medicament pump, while in other embodiments, the hand-held medicament injection pen is configured to infuse a medicament other than the medicament infused by the medicament pump, as is described in greater detail below. In some embodiments, the hand-held medicament injection pen includes a motor. The motor can be configured to automatically set the amount of medicament based at least in part on the medicament dosing information. For example the medicament dosing information can include an instruction for the hand-held medicament injection pen to automatically portion out a bolus medicament dose, which can be manually delivered by the host. In a further embodiment, the medicament is not delivered manually (e.g., by the host actuating a plunger to inject the medicament), rather the medicament is delivered semi-automatically, such that the host can hold the pen against the injection site (e.g., as if to inject the medicament) and actuate the pen to inject the medicament automatically. In this embodiment, the motor of the hand-held medicament injection pen can be configured to control a rate of medicament injection into the host and the medicament dosing information comprises an instruction for the hand-held medicament injection pen to deliver the bolus dose at a programmed rate. For example, it is known that the activity of injected medicament is dependent, in part, on the rate of injection. The hand-held medicament injection pen can be configured to inject the medicament at a rate selected to optimize the medicament's activity. Accordingly, the host's management of his blood sugar can be optimized and more consistent.

(164) In some embodiments, the integrated system is configured for use with at least two hand-held medicament injection pens, such as both a medicament pump **16***a* and a hand-held medicament injection pen **16***b*. While the host may choose to use a single type of medicament in both devices,

the convenient use of multiple modes of medicament delivery is enabled by this embodiment. For example, a first medicament delivery pump can be configured to deliver a first type of medicament, a second hand-held medicament injection pen can be configured to deliver a second type of medicament, and so on. In one exemplary embodiment, a medicament pump **16***a* is configured to deliver a long-acting medicament while a hand-held medicament injection pen **16***b* is configured to deliver a short-acting medicament. In a second exemplary embodiment, a medicament pump **16***a* is configured to deliver the short-acting medicament while a hand-held medicament injection pen **16***b* is configured to deliver the long-acting medicament. In a third exemplary embodiment, the two medicament delivery devices are configured to deliver the same type of medicament. For example, a basal medicament delivery device **16***a* can be configured to frequently deliver small doses (e.g., basal doses) of a short-acting insulin while a bolus medicament delivery device **16***b* can be configured to deliver a large dose (e.g., a bolus) of the short-acting insulin. Additional configurations are contemplated in the preferred embodiments. Regardless, of the type of medicament delivered and the delivery device used, the processor module includes programming to calculate the dose of that particular medicament in response to the continuous glucose sensor data, such that the host can be maintained within a target blood glucose range.

(165) In preferred embodiments, the communication module is configured and arranged for wireless communication with the integrated hand-held medicament injection pen(s) **16***a*/**16***b*, as described elsewhere herein. In some embodiments, the communication module comprises a transceiver configured and arranged to interrogate and/or provide medicament dosing information to the integrated hand-held medicament injection pen, however, other modes of wireless communication can be used. Preferably, the communication module is configured and arranged to enable communicate between the at least two integrated medicament delivery devices, such as but not limited to a medicament pump and a hand-held medicament injection pen. However, the use of additional hand-held medicament injection pens (e.g., a pump and two pens) is contemplated in the preferred embodiments. Preferably, in preferred embodiments, the communication module is configured and arranged to communicate with the at least two integrated medicament delivery devices simultaneously, for example, within substantially the same time period. Accordingly, the processor module calculates both the basal and bolus therapy recommendations for the devices, respectively, considering both the basal and bolus therapies together, and wherein the communication module is configured to communicate with the basal and bolus medicament delivery devices(s), such as to optimize control of the host's blood glucose level, such as maintaining the host's glucose level within a target range. In some embodiments, the communication module is configured to provide notification to the user, relating to injection of the medicament. For example, in some embodiments, the communication module can alert the host (e.g., via the receiver or one of the hand-held medicament injection pens) that a medicament dose is recommended, is being injected and/or has been injected, and optionally require validation of the medicament dose, as described elsewhere herein. For example, in one embodiment, the receiver and/or hand-held medicament injection pen is configured to emit an auditory alert (e.g., beep or buzz) when a bolus medicament dose have been calculated and is ready to be delivered.

(166) In preferred embodiments, the integrated system includes a user interface configured and arranged to display continuous glucose sensor data and/or medicament dosing information. In some embodiments, the user interface is further configured for input of host information and/or medicament delivery device information, wherein the medicament delivery device information is associated with a medicament pump and a hand-held medicament injection pen. As described elsewhere herein, the host information can include at least one of host identity, host physical state, target glucose concentration and type of medicament to be delivered, and the like. Also described elsewhere herein, the medicament delivery information can include at least one of host identity, identification of a functionally connected hand-held medicament injection pen, a type of medicament to be delivered, a medicament delivery profile and/or protocols and a failsafe, and the

like.
(167) In one example, the host can use an integrated system including a continuous glucose sensor **12** (e.g., a sensor as described with reference to FIGS. **2**B-**2**D), a receiver **14**, a medicament infusion pump **16***a* and a hand-held medicament injection pen **16***b*, wherein the receiver is configured and arranged for wireless communication with the sensor, the medicament pump and the hand-held medicament injection pen. The receiver includes a user interface that is configured such that the host can program the system, such as using a toggle button and/or scroll wheel to select instructions on a display integrated into the receiver. In some embodiments, the receiver is integral with or detachably connected to either the medicament pump or the hand-held medicament injection pen (see FIGS. **3**-**12**), such that the host is required to carry only the pump and the pen (e.g., instead of three devices; a receiver, a pump and a pen). In some embodiments, a medicament injection pen kit is provided, as described with reference to FIGS. **6**-**7**. Preferably, the system is configured such that the host can program the medicament pump to deliver basal medicament doses and the hand-held medicament injection pen to deliver bolus medicament doses, all of which are based at least in part on sensor data generated by and received from the continuous glucose sensor, whereby the processor module processes the received sensor data, calculates the medicament doses (basal and/or bolus) and coordinates the delivery of the medicament doses to the host. For example, the processor module can calculate the basal medicament doses and automatically instruct the medicament pump to infuse the basal doses into the host (based at least in part on the continuous glucose sensor data). Substantially simultaneously, the processor module can calculate bolus medicament doses and set the hand-held medicament injection pen to deliver the calculated bolus dose, and then alert the host to inject the bolus dose. Advantageously, the host is afforded greater control and flexibility in managing his blood sugar, which, in turn, enables increased host health and reduced complication of his diabetes.
(168) Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in U.S. Pat. Nos. 4,994,167; 4,757,022; 6,001,067; 6,741,877; 6,702,857; 6,558,321; 6,931,327; 6,862,465; 7,074,307; 7,081,195; 7,108,778; 7,110,803; 7,192,450; 7,226,978; 7,310,544; 7,364,592; and 7,366,556.
(169) Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in U.S. Patent Publication No. US-2005-0143635-A1; U.S. Patent Publication No. US-2005-0181012-A1; U.S. Patent Publication No. US-2005-0177036-A1; U.S. Patent Publication No. US-2005-0124873-A1; U.S. Patent Publication No. US-2005-0115832-A1; U.S. Patent Publication No. US-2005-0245799-A1; U.S. Patent Publication No. US-2005-0245795-A1; U.S. Patent Publication No. US-2005-0242479-A1; U.S. Patent Publication No. US-2005-0182451-A1; U.S. Patent Publication No. US-2005-0056552-A1; U.S. Patent Publication No. US-2005-0192557-A1; U.S. Patent Publication No. US-2005-0154271-A1; U.S. Patent Publication No. US-2004-0199059-A1; U.S. Patent Publication No. US-2005-0054909-A1; U.S. Patent Publication No. US-2005-0051427-A1; U.S. Patent Publication No. US-2003-0032874-A1; U.S. Patent Publication No. US-2005-0103625-A1; U.S. Patent Publication No. US-2005-0203360-A1; U.S. Patent Publication No. US-2005-0090607-A1; U.S. Patent Publication No. US-2005-0187720-A1; U.S. Patent Publication No. US-2005-0161346-A1; U.S. Patent Publication No. US-2006-0015020-A1; U.S. Patent Publication No. US-2005-0043598-A1; U.S. Patent Publication No. US-2005-0033132-A1; U.S. Patent Publication No. US-2005-0031689-A1; U.S. Patent Publication No. US-2004-0186362-A1; U.S. Patent Publication No. US-2005-0027463-A1; U.S. Patent Publication No. US-2005-0027181-A1; U.S. Patent Publication No. US-2005-0027180-A1; U.S. Patent Publication No. US-2006-0020187-A1; U.S. Patent Publication No. US-2006-0036142-A1; U.S. Patent Publication No. US-2006-0020192-A1; U.S. Patent Publication No. US-2006-0036143-A1; U.S. Patent Publication No. US-2006-0036140-A1; U.S. Patent Publication No. US-2006-0019327-A1; U.S. Patent Publication No. US-2006-0020186-A1; U.S. Patent Publication No. US-2006-0036139-A1; U.S. Patent Publication No. US-2006-0020191-A1; U.S. Patent Publication No. US-2006-

0020188-A1; U.S. Patent Publication No. US-2006-0036141-A1; U.S. Patent Publication No. US-2006-0020190-A1; U.S. Patent Publication No. US-2006-0036145-A1; U.S. Patent Publication No. US-2006-0036144-A1; U.S. Patent Publication No. US-2006-0016700-A1; U.S. Patent Publication No. US-2006-0142651-A1; U.S. Patent Publication No. US-2006-0086624-A1; U.S. Patent Publication No. US-2006-0068208-A1; U.S. Patent Publication No. US-2006-0040402-A1; U.S. Patent Publication No. US-2006-0036142-A1; U.S. Patent Publication No. US-2006-0036141-A1; U.S. Patent Publication No. US-2006-0036143-A1; U.S. Patent Publication No. US-2006-0036140-A1; U.S. Patent Publication No. US-2006-0036139-A1; U.S. Patent Publication No. US-2006-0142651-A1; U.S. Patent Publication No. US-2006-0036145-A1; U.S. Patent Publication No. US-2006-0036144-A1; U.S. Patent Publication No. US-2006-0200022-A1; U.S. Patent Publication No. US-2006-0198864-A1; U.S. Patent Publication No. US-2006-0200019-A1; U.S. Patent Publication No. US-2006-0189856-A1; U.S. Patent Publication No. US-2006-0200020-A1; U.S. Patent Publication No. US-2006-0200970-A1; U.S. Patent Publication No. US-2006-0183984-A1; U.S. Patent Publication No. US-2006-0183985-A1; U.S. Patent Publication No. US-2006-0195029-A1; U.S. Patent Publication No. US-2006-0229512-A1; U.S. Patent Publication No. US-2006-0222566-A1; U.S. Patent Publication No. US-2007-0032706-A1; U.S. Patent Publication No. US-2007-0016381-A1; U.S. Patent Publication No. US-2007-0027370-A1; U.S. Patent Publication No. US-2007-0027384-A1; U.S. Patent Publication No. US-2007-0032718-A1; U.S. Patent Publication No. US-2007-0059196-A1; U.S. Patent Publication No. US-2007-0066873-A1; U.S. Patent Publication No. US-2007-0093704-A1; U.S. Patent Publication No. US-2007-0197890-A1; U.S. Patent Publication No. US-2007-0173710-A1; U.S. Patent Publication No. US-2007-0163880-A1; U.S. Patent Publication No. US-2007-0203966-A1; U.S. Patent Publication No. US-2007-0213611-A1; U.S. Patent Publication No. US-2007-0232879-A1; U.S. Patent Publication No. US-2007-0235331-A1; U.S. Patent Publication No. US-2008-0021666-A1; U.S. Patent Publication No. US-2008-0033254-A1; U.S. Patent Publication No. US-2008-0045824-A1; U.S. Patent Publication No. US-2008-0071156-A1; U.S. Patent Publication No. US-2008-0086042-A1; U.S. Patent Publication No. US-2008-0086044-A1; U.S. Patent Publication No. US-2008-0086273-A1; U.S. Patent Publication No. US-2008-0083617-A1; U.S. Patent Publication No. US-2008-0119703-A1; and U.S. Patent Publication No. US-2008-0119706-A1.

(170) Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in U.S. patent application Ser. No. 09/447,227 filed Nov. 22, 1999 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. patent application Ser. No. 11/654,135 filed Jan. 17, 2007 and entitled “POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES”; U.S. patent application Ser. No. 11/654,140 filed Jan. 17, 2007 and entitled “MEMBRANES FOR AN ANALYTE SENSOR”; U.S. patent application Ser. No. 11/543,490 filed Oct. 4, 2006 and entitled “ANALYTE SENSOR”; U.S. patent application Ser. No. 11/691,426 filed Mar. 26, 2007 and entitled “ANALYTE SENSOR”; U.S. patent application Ser. No. 12/037,830 filed Feb. 26, 2008 and entitled “ANALYTE MEASURING DEVICE”; U.S. patent application Ser. No. 12/037,812 filed Feb. 26, 2008 and entitled “ANALYTE MEASURING DEVICE”; U.S. patent application Ser. No. 12/102,654 filed Apr. 14, 2008 and entitled “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. patent application Ser. No. 12/102,729 filed Apr. 14, 2008 and entitled “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. patent application Ser. No. 12/102,745 filed Apr. 14, 2008 and entitled “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. patent application Ser. No. 12/098,359 filed Apr. 4, 2008 and entitled “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. patent application Ser. No. 12/098,353 filed Apr. 4, 2008 and entitled “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. patent application Ser. No. 12/098,627 filed Apr. 7, 2008 and entitled “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. patent application Ser. No. 12/103,594 filed Apr. 15, 2008 and entitled

“BIOINTERFACE WITH MACRO- AND MICRO-ARCHITECTURE”; U.S. patent application Ser. No. 12/111,062 filed Apr. 28, 2008 and entitled “DUAL ELECTRODE SYSTEM FOR A CONTINUOUS ANALYTE SENSOR”; U.S. patent application Ser. No. 12/105,227 filed Apr. 17, 2008 and entitled “TRANSCUTANEOUS MEDICAL DEVICE WITH VARIABLE STIFFNESS”; U.S. patent application Ser. No. 12/101,810 filed Apr. 11, 2008 and entitled “TRANSCUTANEOUS ANALYTE SENSOR”; U.S. patent application Ser. No. 12/101,790 filed Apr. 11, 2008 and entitled “TRANSCUTANEOUS ANALYTE SENSOR”; U.S. patent application Ser. No. 12/101,806 filed Apr. 11, 2008 and entitled “TRANSCUTANEOUS ANALYTE SENSOR”; U.S. patent application Ser. No. 12/113,724 filed May 1, 2008 and entitled “LOW OXYGEN IN VIVO ANALYTE SENSOR”; U.S. patent application Ser. No. 12/113,508 filed May 1, 2008 and entitled “LOW OXYGEN IN VIVO ANALYTE SENSOR”; U.S. patent application Ser. No. 12/055,098 filed Mar. 25, 2008 and entitled “ANALYTE SENSOR”; U.S. patent application Ser. No. 12/054,953 filed Mar. 25, 2008 and entitled “ANALYTE SENSOR”; U.S. patent application Ser. No. 12/055,114 filed Mar. 25, 2008 and entitled “ANALYTE SENSOR”; U.S. patent application Ser. No. 12/055,078 filed Mar. 25, 2008 and entitled “ANALYTE SENSOR”; U.S. patent application Ser. No. 12/055,149 filed Mar. 25, 2008 and entitled “ANALYTE SENSOR”; U.S. patent application Ser. No. 12/055,203 filed Mar. 25, 2008 and entitled “ANALYTE SENSOR”; and U.S. patent application Ser. No. 12/055,227 filed Mar. 25, 2008 and entitled “ANALYTE SENSOR”.

(171) All references cited herein, including but not limited to published and unpublished applications, patents, and literature references, are incorporated herein by reference in their entirety and are hereby made a part of this specification. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.

(172) The term “comprising” as used herein is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.

(173) All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claims in any application claiming priority to the present application, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.

(174) The above description discloses several methods and materials of the present invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this disclosure or practice of the invention disclosed herein. Consequently, it is not intended that this invention be limited to the specific embodiments disclosed herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention.

Claims

1. A method comprising: determining mealtimes of a host; processing glucose sensor data generated using a glucose sensor, the sensor data indicative of a glucose concentration of the host; and displaying a graphical representation of the processed glucose sensor data on a display device, the displaying including graphing or charting glucose data summaries based on the mealtimes of the host.

2. The method of claim 1, wherein the processed glucose sensor data includes averaged glucose values over a time period.
3. The method of claim 2, wherein the time period is one of 1 day, 5 days, 7 days, or 1 month.
4. The method of claim 1, wherein the glucose data summaries are modal day graphs.
5. The method of claim 1, wherein the glucose data summaries include bar charts.
6. The method of claim 1, wherein the glucose data summaries include glucose trend data.
7. The method of claim 1, wherein the processing the glucose sensor data further comprises processing both the glucose sensor data and the mealtimes of the host.
8. The method of claim 1, wherein the glucose sensor data comprises continuous glucose sensor data generated by a continuous glucose sensor.
9. The method of claim 1, wherein the mealtimes of the host are determined based at least in part on user input.
10. The method of claim 9, wherein the user input is received via a user interface displayed by the display device.
11. The method of claim 1, wherein the mealtimes of the host are determined automatically.
12. A system comprising: a glucose sensor; a display device; and at least a memory and a processor to perform operations comprising: determining mealtimes of a host; processing glucose sensor data generated using the glucose sensor, the sensor data indicative of a glucose concentration of the host; and displaying a graphical representation of the processed sensor data on the display device, the displaying including graphing or charting glucose data summaries based on the mealtimes of the host.
13. The system of claim 12, wherein the processed sensor data includes averaged glucose values over a time period.
14. The system of claim 13, wherein the time period is one of 1 day, 5 days, 7 days or 1 month.
15. The system of claim 12, wherein the glucose sensor data comprises continuous glucose sensor data generated by a continuous glucose sensor.
16. The system of claim 12, wherein the mealtimes of the host are determined based at least in part on user input.
17. The system of claim 16, wherein the user input is received via a user interface displayed by the display device.
18. The system of claim 12, wherein the mealtimes of the host are determined automatically.
19. A method comprising: determining mealtimes of a host; processing analyte sensor data generated using an analyte sensor worn by the host; and displaying a graphical representation of the processed analyte sensor data on a display device, the displaying including graphing or charting glucose data summaries based on the mealtimes of the host.
20. The method of claim 19, wherein the analyte sensor data comprises glucose sensor data.